10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-38196

DUPONT DE NEMOURS, INC.

(Exact name of registrant as specified in its charter)

Delaware	81-1224539
State or other jurisdiction of incorporation or organization	(I.R.S. Employer Identification No.)

974 Centre Road	Building 730	Wilmington	Delaware	19805
(Address of Principal Executive Offices)				(Zip Code)

(302) 774-3034

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	DD	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

                                                ☑ Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

                                 ☑ Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	☑	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☑ No

The registrant had 496,788,948 shares of common stock, $0.01 par value, outstanding at November 4, 2022.

DuPont de Nemours, Inc.

QUARTERLY REPORT ON FORM 10-Q

For the quarterly period ended September 30, 2022

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		PAGE
Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Statements of Operations	5
	Consolidated Statements of Comprehensive Income	6
	Condensed Consolidated Balance Sheets	7
	Consolidated Statements of Cash Flows	8
	Consolidated Statements of Equity	9
	Notes to the Consolidated Financial Statements (Unaudited)	11
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	42
	Overview	42
	Results of Operations	44
	Segment Results	47
	Changes in Financial Condition	51
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	55
Item 4.	Controls and Procedures	55
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	56
Item 1A.	Risk Factors	57
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	58
Item 4.	Mine Safety Disclosures	58
Item 5.	Other Information	58
Item 6.	Exhibits	59
SIGNATURES		60

3

DuPont de Nemours, Inc.

DuPontTM and all products, unless otherwise noted, denoted with TM, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

FORWARD-LOOKING STATEMENTS

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the possibility that the Company may fail to realize the anticipated benefits of the $5 billion share repurchase program announced on November 8, 2022 and that the program may be suspended, discontinued or not completed prior to its termination on June 30, 2024; (ii) ability to achieve anticipated tax treatments in connection with mergers, acquisitions, divestitures, (including in connection with the divestiture of the majority of its historic Mobility & Materials segment to Celanese completed on November 1, 2022, and DuPont’s pursuit of plans to divest the Delrin® acetal homopolymer business), and other portfolio changes actions and impact of changes in relevant tax and other laws; (iii) indemnification of certain legacy liabilities; (iv) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (v) failure to timely close on anticipated terms (or at all), realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with mergers, acquisitions, divestitures and other portfolio changes; (vi) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to operational and supply chain impacts or disruptions, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geo-political and weather related events; (vii) ability to offset increases in cost of inputs, including raw materials, energy and logistics; (viii) risks, including ability to achieve, and costs associated with DuPont’s sustainability strategy including the actual conduct of the company’s activities and results thereof, and the development, implementation, achievement or continuation of any goal, program, policy or initiative discussed or expected; and (ix) other risks to DuPont's business, operations; each as further discussed in DuPont’s most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

4

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DuPont de Nemours, Inc.

Consolidated Statements of Operations

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions, except per share amounts (Unaudited)	2022		2021		2022		2021
Net sales	$	3,317	$	3,199	$	9,913	$	9,320
Cost of sales	2,095		2,032		6,354		5,852
Research and development expenses	129		137		413		409
Selling, general and administrative expenses	356		411		1,130		1,201
Amortization of intangibles	146		158		447		410
Restructuring and asset related charges - net	—		1		101		8
Acquisition, integration and separation costs	7		29		28		58
Equity in earnings of nonconsolidated affiliates	16		22		62		65
Sundry income (expense) - net	26		1		123		155
Interest expense	128		115		370		390
Income from continuing operations before income taxes	498		339		1,255		1,212
Provision for income taxes on continuing operations	139		80		299		172
Income from continuing operations, net of tax	359		259		956		1,040
Income from discontinued operations, net of tax	17		145		723		5,249
Net income	376		404		1,679		6,289
Net income attributable to noncontrolling interests	9		13		37		26
Net income available for DuPont common stockholders	$	367	$	391	$	1,642	$	6,263
Per common share data:
Earnings per common share from continuing operations - basic	$	0.69	$	0.48	$	1.81	$	1.86
Earnings per common share from discontinued operations - basic	0.05		0.27		1.44		9.49
Earnings per common share - basic	$	0.73	$	0.75	$	3.25	$	11.35
Earnings per common share from continuing operations - diluted	$	0.69	$	0.48	$	1.80	$	1.86
Earnings per common share from discontinued operations - diluted	0.05		0.27		1.44		9.46
Earnings per common share - diluted	$	0.73	$	0.75	$	3.24	$	11.32
Weighted-average common shares outstanding - basic	499.4		521.5		505.6		551.7
Weighted-average common shares outstanding - diluted	500.4		523.1		506.9		553.1

See Notes to the Consolidated Financial Statements.

5

DuPont de Nemours, Inc.

Consolidated Statements of Comprehensive Income

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions (Unaudited)	2022		2021		2022		2021
Net income	$	376	$	404	$	1,679	$	6,289
Other comprehensive (loss) income, net of tax
Cumulative translation adjustments	(837)		(189)		(1,802)		(554)
Pension and other post-employment benefit plans	29		12		21		23
Derivative instruments	42		20		109		38
Split-off of N&B	—		—		—		258
Total other comprehensive loss	(766)		(157)		(1,672)		(235)
Comprehensive (loss) income	(390)		247		7		6,054
Comprehensive income attributable to noncontrolling interests, net of tax	1		12		9		17
Comprehensive (loss) income attributable to DuPont	$	(391)	$	235	$	(2)	$	6,037

See Notes to the Consolidated Financial Statements.

6

DuPont de Nemours, Inc.

Condensed Consolidated Balance Sheets

In millions, except share amounts (Unaudited)	September 30, 2022		December 31, 2021
Assets
Current Assets
Cash and cash equivalents	$	1,785	$	1,972
Accounts and notes receivable - net	2,257		2,159
Inventories	2,359		2,086
Prepaid and other current assets	216		177
Assets held for sale	—		245
Assets of discontinued operations	7,733		7,664
Total current assets	14,350		14,303
Property, plant and equipment - net of accumulated depreciation (September 30, 2022 - $4,227; December 31, 2021 - $4,142)	5,477		5,753
Other Assets
Goodwill	16,302		16,981
Other intangible assets	5,550		6,222
Restricted cash and cash equivalents	103		53
Investments and noncurrent receivables	779		919
Deferred income tax assets	122		116
Deferred charges and other assets	1,416		1,360
Total other assets	24,272		25,651
Total Assets	$	44,099	$	45,707
Liabilities and Equity
Current Liabilities
Short-term borrowings	$	1,287	$	150
Accounts payable	2,061		2,102
Income taxes payable	284		201
Accrued and other current liabilities	990		1,040
Liabilities related to assets held for sale	—		25
Liabilities of discontinued operations	1,392		1,413
Total current liabilities	6,014		4,931
Long-Term Debt	10,564		10,632
Other Noncurrent Liabilities
Deferred income tax liabilities	464		1,459
Pension and other post-employment benefits - noncurrent	625		762
Other noncurrent obligations	929		873
Total other noncurrent liabilities	2,018		3,094
Total Liabilities	18,596		18,657
Commitments and contingent liabilities
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2022: 496,738,067 shares; 2021: 511,792,785 shares)	5		5
Additional paid-in capital	49,199		49,574
Accumulated deficit	(22,692)		(23,187)
Accumulated other comprehensive (loss) income	(1,603)		41
Total DuPont stockholders' equity	24,909		26,433
Noncontrolling interests	594		617
Total equity	25,503		27,050
Total Liabilities and Equity	$	44,099	$	45,707

See Notes to the Consolidated Financial Statements.

7

DuPont de Nemours, Inc.

Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
In millions (Unaudited)	2022		2021
Operating Activities
Net income	$	1,679	$	6,289
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	906		1,094
Credit for deferred income tax and other tax related items	(977)		(182)
Earnings of nonconsolidated affiliates less than (in excess of) dividends received	10		(41)
Net periodic benefit (credit) cost	(6)		2
Periodic benefit plan contributions	(51)		(62)
Net gain on sales and split-offs of assets, businesses and investments	(73)		(5,117)
Restructuring and asset related charges - net	101		15
Inventory step-up amortization	—		12
Other net loss	39		128
Changes in assets and liabilities, net of effects of acquired and divested companies:
Accounts and notes receivable	(342)		(399)
Inventories	(688)		(515)
Accounts payable	194		379
Other assets and liabilities, net	(78)		57
Cash provided by operating activities	714		1,660
Investing Activities
Capital expenditures	(558)		(707)
Proceeds from sales of property and businesses, net of cash divested	364		285
Acquisitions of property and businesses, net of cash acquired	5		(2,323)
Purchases of investments	(15)		(2,001)
Proceeds from sales and maturities of investments	15		2,001
Other investing activities, net	4		18
Cash used for investing activities	(185)		(2,727)
Financing Activities
Changes in short-term borrowings	1,137		—
Proceeds from credit facility	600		—
Proceeds from issuance of long-term debt transferred to IFF at split-off	—		1,250
Repayment of credit facility	(600)		—
Payments on long-term debt	—		(5,000)
Purchases of common stock	(1,125)		(1,643)
Proceeds from issuance of Company stock	83		110
Employee taxes paid for share-based payment arrangements	(25)		(26)
Distributions to noncontrolling interests	(35)		(34)
Dividends paid to stockholders	(500)		(476)
Cash transferred to IFF and subsequent adjustments	(11)		(100)
Other financing activities, net	(4)		(2)
Cash used for financing activities	(480)		(5,921)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(191)		(49)
Decrease in cash, cash equivalents and restricted cash	(142)		(7,037)
Cash, cash equivalents and restricted cash from continuing operations, beginning of period	2,037		8,733
Cash, cash equivalents and restricted cash from discontinued operations, beginning of period	39		42
Cash, cash equivalents and restricted cash at beginning of period	2,076		8,775
Cash, cash equivalents and restricted cash from continuing operations, end of period	1,896		1,700
Cash, cash equivalents and restricted cash from discontinued operations, end of period	38		38
Cash, cash equivalents and restricted cash at end of period	$	1,934	$	1,738

See Notes to the Consolidated Financial Statements.

8

DuPont de Nemours, Inc.

Consolidated Statements of Equity

For the nine months ended September 30, 2022 and 2021

In millions (Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings  (Accumulated Deficit)		Accumulated Other Comp Loss		Treasury Stock		Non-controlling Interests		Total Equity
Balance at December 31, 2020	$	7	$	50,039	$	(11,586)	$	44	$	—	$	566	$	39,070
Net income	—		—		6,263		—		—		26		6,289
Other comprehensive loss	—		—		—		(226)		—		(9)		(235)
Dividends ($0.90 per common share)	—		(476)		—		—		—		—		(476)
Common stock issued/sold	—		110		—		—		—		—		110
Stock-based compensation	—		30		—		—		—		—		30
Contributions from non-controlling interests	—		—		—		—		—		84		84
Distributions to non-controlling interests	—		—		—		—		—		(34)		(34)
Purchases of treasury stock	—		—		—		—		(1,643)		—		(1,643)
Retirement of treasury stock	—		—		(1,643)		—		1,643		—		—
Split-off of N&B	(2)		—		(15,926)		—		—		(27)		(15,955)
Other	—		(1)		—		—		—		—		(1)
Balance at September 30, 2021	$	5	$	49,702	$	(22,892)	$	(182)	$	—	$	606	$	27,239
Balance at December 31, 2021	$	5	$	49,574	$	(23,187)	$	41	$	—	$	617	$	27,050
Net income	—		—		1,642		—		—		37		1,679
Other comprehensive loss	—		—		—		(1,644)		—		(28)		(1,672)
Dividends ($0.99 per common share)	—		(500)		—		—		—		—		(500)
Common stock issued/sold	—		83		—		—		—		—		83
Stock-based compensation	—		42		—		—		—		—		42
Contributions from non-controlling interests	—		—		—		—		—		2		2
Distributions to non-controlling interests	—		—		—		—		—		(35)		(35)
Purchases of treasury stock	—		—		—		—		(1,125)		—		(1,125)
Retirement of treasury stock	—		—		(1,125)		—		1,125		—		—
Other	—		—		(22)		—		—		1		(21)
Balance at September 30, 2022	$	5	$	49,199	$	(22,692)	$	(1,603)	$	—	$	594	$	25,503

See Notes to the Consolidated Financial Statements.

9

DuPont de Nemours, Inc.

Consolidated Statements of Equity

For the three months ended September 30, 2022 and 2021

In millions (Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings (Accumulated Deficit)		Accumulated Other Comp Loss		Treasury Stock		Non-controlling Interests		Total Equity
Balance at June 30, 2021	$	5	$	49,681	$	(22,783)	$	(26)	$	—	$	587	$	27,464
Net income	—		—		391		—		—		13		404
Other comprehensive loss	—		—		—		(156)		—		(1)		(157)
Common stock issued/sold	—		2		—		—		—		—		2
Stock-based compensation	—		17		—		—		—		—		17
Contributions from non-controlling interests	—		—		—		—		—		17		17
Distributions to non-controlling interests	—		—		—		—		—		(10)		(10)
Purchases of treasury stock	—		—		—		—		(500)		—		(500)
Retirement of treasury stock	—		—		(500)		—		500		—		—
Other	—		2		—		—		—		—		2
Balance at September 30, 2021	$	5	$	49,702	$	(22,892)	$	(182)	$	—	$	606	$	27,239
Balance at June 30, 2022	$	5	$	49,176	$	(22,808)	$	(845)	$	—	$	609	$	26,137
Net income	—		—		367		—		—		9		376
Other comprehensive loss	—		—		—		(758)		—		(8)		(766)
Stock-based compensation	—		23		—		—		—		—		23
Distributions to non-controlling interests	—		—		—		—		—		(15)		(15)
Purchases of treasury stock	—		—		—		—		(250)		—		(250)
Retirement of treasury stock	—		—		(250)		—		250		—		—
Other	—		—		(1)		—		—		(1)		(2)
Balance at September 30, 2022	$	5	$	49,199	$	(22,692)	$	(1,603)	$	—	$	594	$	25,503

See Notes to the Consolidated Financial Statements.

10

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

Note		Page
1	Summary of Significant Accounting Policies	12
2	Recent Accounting Guidance	13
3	Acquisitions	13
4	Divestitures	14
5	Revenue	18
6	Restructuring and Asset Related Charges - Net	19
7	Supplementary Information	20
8	Income Taxes	21
9	Earnings Per Share Calculations	22
10	Accounts and Notes Receivable - Net	23
11	Inventories	23
12	Property, Plant, and Equipment	23
13	Nonconsolidated Affiliates	23
14	Goodwill and Other Intangible Assets	24
15	Short-Term Borrowings, Long-Term Debt and Available Credit Facilities	26
16	Commitments and Contingent Liabilities	28
17	Leases	32
18	Stockholders' Equity	33
19	Pension Plans and Other Post-Employment Benefits	34
20	Stock-Based Compensation	34
21	Financial Instruments	35
22	Fair Value Measurements	37
23	Segments and Geographic Regions	38
24	Subsequent Events	41

11

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

In these notes, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should also be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, collectively referred to as the "2021 Annual Report." The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Mobility & Materials

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). The Company had previously entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese") on February 17, 2022. Refer to Note 4 and Note 24 - Subsequent Events for further information. In addition, on February 18, 2022, the Company announced it is advancing the process to divest its Delrin® acetal homopolymer (H-POM) business, subject to entry into a definitive agreement and satisfaction of customary closing conditions. The Delrin® divestiture together with the M&M Divestiture discussed above (the "M&M Divestitures") represent a strategic shift that will have a major impact on DuPont's operations and results. See Note 4 for more information.

The financial position of DuPont as of September 30, 2022 and December 31, 2021 present the businesses to be divested as part of the M&M Divestiture and the divestiture of Delrin® (the "M&M Businesses") as discontinued operations. The results of operations for the three and nine months ended September 30, 2022 and 2021 present the financial results of the M&M Businesses as discontinued operations. The cash flows and comprehensive income of the M&M Businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of the M&M Businesses. See Note 4 to the interim Consolidated Financial Statements for additional information.

The Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines, previously reported within the historic Mobility & Materials segment, (the "Retained Businesses") are not included in the scope of the M&M Divestitures. Effective with the signing of the Transaction Agreement, the Retained Businesses were realigned to Corporate & Other. The reporting changes have been retrospectively applied for all periods presented.

N&B Transaction

On February 1, 2021, DuPont completed the separation and distribution of the Nutrition & Biosciences business segment (the "N&B Business"), and the merger of Nutrition & Biosciences, Inc. (“N&B”), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF"). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). See Note 4 for more information.

The results of operations of DuPont for the three and nine months ended September 30, 2021 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable periods. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B.

12

NOTE 2 - RECENT ACCOUNTING GUIDANCE

Accounting Guidance Issued But Not Adopted at September 30, 2022

In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (i.e., unearned revenue) acquired in a business combination to be recognized and measured in accordance with ASC 606, Revenue from Contracts with Customers. Historically, the Company has recognized contract assets and contract liabilities at the acquisition date based on fair value estimates in accordance with ASC 805, Business Combinations. ASU 2021-08 is effective for interim and annual periods beginning after December 15, 2022 on a prospective basis, with early adoption permitted.

In September 2022, the FASB issued Accounting Standards Update No. 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50)" ("ASU 2022-04") to enhance transparency about the use of supplier finance programs. The new guidance requires that a buyer in a supplier finance program provides additional qualitative and quantitative disclosures about its program including the nature of the program, activity during the period, changes from period to period, and the potential magnitude of the program. The amendments in ASU 2022-04 are effective for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the amendment on rollforward information which is effective prospectively for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently evaluating the potential impact of ASU 2022-04 to its related disclosures.

NOTE 3 - ACQUISITIONS

Intended Rogers Acquisition

On November 2, 2021, the Company announced that it had entered into a definitive agreement to acquire all the outstanding shares of Rogers Corporation (“Rogers”) for about $5.2 billion (the “Intended Rogers Acquisition”). On November 1, 2022, the Company announced the termination of the agreement, as DuPont and Rogers have been unable to obtain timely clearance from all the required regulators. DuPont paid Rogers a termination fee of $162.5 million in accordance with the agreement on November 2, 2022. Refer to Note 24 - Subsequent Events for additional information.

Laird Performance Materials Acquisition

On July 1, 2021, DuPont completed the acquisition (the "Laird PM Acquisition") of 100% of the ownership interest of Laird Performance Materials (“Laird PM”) from Advent International for aggregate, adjusted cash consideration of approximately $2,404 million. The cash consideration paid included a net upward adjustment of approximately $100 million for acquired cash and net working capital, amongst other items. Laird PM is reported within the Interconnect Solutions business of the Electronics & Industrial segment. The Company accounted for the acquisition in accordance with ASC 805, which requires the assets acquired and liabilities assumed to be recognized on the balance sheet at their fair values as of the acquisition date. There were no material updates to the purchase accounting and the purchase price allocation is considered final. For additional information regarding the acquisition of Laird PM, see Note 3, "Acquisitions," in the 2021 Annual Report.

Acquisition, Integration and Separation Costs

Acquisition, integration and separation costs primarily consist of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees. For the three and nine months ended September 30, 2022 these costs were primarily related to costs associated with the divestiture of the Biomaterials business unit, the prior year acquisition of Laird PM and the Intended Rogers Acquisition. Comparatively, for the three and nine months ended September 30, 2021 these costs were primarily associated with the execution of activities related to strategic initiatives including the divestiture of the Biomaterials business unit in May 2022, the prior year acquisition of Laird PM and the divestitures of the Clean Technologies and Solamet® business units.

These costs are recorded within "Acquisition, integration and separation costs" within the interim Consolidated Statements of Operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Acquisition, integration and separation costs	$	7	$	29	$	28	$	58

13

NOTE 4 - DIVESTITURES

Mobility & Materials Divestiture

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). On February 17, 2022, the Company entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese"). Refer to Note 24 - Subsequent Events for additional information. The Company also announced on February 18, 2022 that its Board of Directors approved the divestiture of the Delrin® acetal homopolymer (H-POM) business, subject to entry into a definitive agreement and satisfaction of customary closing conditions. As of September 30, 2022, the Company anticipates a closing date for the sale of Delrin® within a year.

The Company has determined that the M&M Businesses meet the criteria to be classified as held for sale and that the sale represents a strategic shift that will have a major effect on the Company’s operations and results.

The results of operations of the M&M Businesses are presented as discontinued operations as summarized below:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Net sales	$	988	$	1,072	$	3,100	$	3,062
Cost of sales	771		746		2,357		2,093
Research and development expenses	12		15		41		47
Selling, general and administrative expenses	25		64		110		189
Amortization of intangibles	—		38		28		120
Restructuring and asset related charges - net	—		—		—		5
Acquisition, integration and separation costs	135		—		357		—
Equity in (losses) earnings of nonconsolidated affiliates	(5)		3		(7)		11
Sundry income (expense) - net	7		7		—		15
Income from discontinued operations before income taxes	47		219		200		634
Provision for (benefit from) income taxes on discontinued operations	21		45		(607)		136
Income from discontinued operations, net of tax	26		174		807		498
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	33	$	170	$	812	$	484

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the M&M Businesses:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation and amortization	$	—	$	70	$	45	$	214
Capital expenditures 1	$	22	$	17	$	64	$	41

1.Total capital expenditures are presented on a cash basis.

14

The following table summarizes the major classes of assets and liabilities of the M&M Businesses classified as held for sale presented as discontinued operations at September 30, 2022 and December 31, 2021:

In millions	September 30, 2022		December 31, 2021
Assets
Cash and cash equivalents	$	38	$	39
Accounts and notes receivable - net	624		552
Inventories	1,072		776
Other current assets	45		59
Property, plant and equipment - net	1,193		1,213
Goodwill	2,432		2,597
Other intangible assets	2,127		2,220
Investments and noncurrent receivables	52		62
Deferred income tax assets	21		27
Deferred charges and other assets	129		119
Total assets of discontinued operations	$	7,733	$	7,664
Liabilities
Accounts payable	$	552	$	510
Income taxes payable	41		77
Accrued and other current liabilities	137		157
Deferred income tax liabilities	537		515
Pension and other post employment benefits - noncurrent	55		90
Other noncurrent liabilities	70		64
Total liabilities of discontinued operations	$	1,392	$	1,413

N&B Transaction

On February 1, 2021, DuPont completed the separation and distribution of the N&B Business, and merger of N&B, a subsidiary DuPont formed to hold the N&B Business, with a subsidiary of IFF. The distribution was effected through an exchange offer where, on the terms and subject to the conditions of the Exchange Offer, eligible participating DuPont stockholders had the option to tender all, some or none of their shares of common stock, par value $0.01 per share, of DuPont (the “DuPont Common Stock”) for a number of shares of common stock, par value $0.01 per share, of N&B (the “N&B Common Stock”) and which resulted in all shares of N&B Common Stock being distributed to DuPont stockholders that participated in the Exchange Offer. The consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). The N&B Transaction was subject to IFF shareholder approval, customary regulatory approvals, tax authority rulings including a favorable private letter ruling from the U.S. Internal Revenue Service which confirms the N&B Transaction to be free of U.S. federal income tax, and expiration of the public exchange offer. DuPont does not have an ownership interest in IFF as a result of the N&B Transaction.

In the Exchange Offer, DuPont accepted approximately 197.4 million shares of its common stock in exchange for about 141.7 million shares of N&B Common Stock as of the date of the N&B Transaction. As a result, DuPont reduced its common stock outstanding by 197.4 million shares of DuPont Common Stock. In the N&B Merger, each share of N&B Common Stock was automatically converted into the right to receive one share of IFF common stock, par value $0.125 per share, based on the terms of the N&B Merger Agreement.

15

The results of operations of N&B are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2021
In millions
Net sales	$	507
Cost of sales	354
Research and development expenses	21
Selling, general and administrative expenses	47
Amortization of intangibles	38
Restructuring and asset related charges - net	1
Acquisition, integration and separation costs	172
Sundry income (expense) - net	8
Interest expense	13
Loss from discontinued operations before income taxes	(131)
Benefit from income taxes on discontinued operations	(27)
Loss from discontinued operations, net of tax	(104)
Non-taxable gain on split-off	4,940
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	4,836

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to N&B:

	Nine Months Ended September 30, 2021
In millions
Depreciation and amortization	$	63
Capital expenditures	$	27

In connection with and in accordance with the terms of the N&B Transaction, prior to consummation of the Exchange Offer and the N&B Merger, DuPont received a one-time cash payment of approximately $7.3 billion, (the "Special Cash Payment").

The Company recognized a non-taxable gain of approximately $4,940 million on the N&B Transaction. The gain is recorded in "Income from discontinued operations, net of tax" in the Company's interim Consolidated Statements of Operations for the nine months ended September 30, 2021.

N&B Transaction Agreements

In connection with the N&B Transaction, effective December 15, 2019, the Company, as previously discussed, entered into the following agreements: N&B Separation and Distribution Agreement, N&B Merger Agreement, and N&B Employee Matters Agreement. In connection with the closing of the N&B Transaction, and effective February 1, 2021, the Company entered into the following agreements: N&B IP Cross-License Agreement and N&B Tax Matters Agreement.

Discontinued Operations Activity

The Company recorded income from discontinued operations, net of tax of $17 million and $145 million for the three months ended September 30, 2022 and 2021, respectively, and $723 million and $5,249 million for the nine months ended September 30, 2022 and 2021, respectively.

Discontinued operations activity consists of the following:

Income from discontinued operations, net of tax	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
M&M Divestitures	$	26	$	174	$	807	$	498
N&B Transaction	—		(12)		—		4,836
Other 1	(9)		(17)		(84)		(85)
Income from discontinued operations, net of tax	$	17	$	145	$	723	$	5,249

1.Primarily related to the binding Memorandum of Understanding (“MOU”) between Chemours, Corteva, E. I. du Pont de Nemours and Company ("EID") and the Company. For additional information on these matters, refer to Note 16.

16

Biomaterials

In May 2022, the Company completed the sale of its Biomaterials business unit, which included the Company's equity method investment in DuPont Tate & Lyle Bio Products, to the Huafon Group. Total consideration received related to the sale was approximately $240 million. For the nine months ended September 30, 2022, a pre-tax gain of $26 million ($21 million net of tax) was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations. The results of operations of the Biomaterials business unit are reported in Corporate & Other.

The following table summarizes the carrying value of the major assets and liabilities of the Biomaterials business unit reflected as held for sale at December 31, 2021:

In millions	December 31, 2021
Assets
Accounts and notes receivable - net	$	27
Inventories	48
Investments and noncurrent receivables	158
Property, plant and equipment - net	12
Assets held for sale	$	245
Liabilities
Accounts payable	$	21
Accrued and other current liabilities	3
Other noncurrent obligations	1
Liabilities related to assets held for sale	$	25

17

NOTE 5 - REVENUE

Revenue Recognition

Products

Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to supply manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows.

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Industrial Solutions	$	496	$	474	$	1,499	$	1,412
Interconnect Solutions	446		489		1,371		1,158
Semiconductor Technologies	569		504		1,704		1,517
Electronics & Industrial	$	1,511	$	1,467	$	4,574	$	4,087
Safety Solutions	$	684	$	646	$	2,001	$	1,933
Shelter Solutions	476		414		1,385		1,193
Water Solutions	374		337		1,074		1,011
Water & Protection	$	1,534	$	1,397	$	4,460	$	4,137
Retained Businesses 1	$	272	$	226	$	804	$	721
Other 2	—		109		75		375
Corporate & Other	$	272	$	335	$	879	$	1,096
Total	$	3,317	$	3,199	$	9,913	$	9,320

1. Retained Businesses includes the Auto Adhesives & Fluids, MultibaseTM and Tedlar® businesses.

2. Net sales reflected in Other include activity of previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
U.S. & Canada	$	1,149	$	1,011	$	3,293	$	2,875
EMEA 1	523		562		1,665		1,672
Asia Pacific	1,524		1,529		4,622		4,490
Latin America	121		97		333		283
Total	$	3,317	$	3,199	$	9,913	$	9,320

1.Europe, Middle East and Africa.

Contract Balances

From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivables when the right to consideration becomes unconditional. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue.

Revenue recognized in the first nine months of 2022 and 2021 from amounts included in contract liabilities at the beginning of the period was insignificant.

Contract Balances	September 30, 2022		December 31, 2021
In millions
Accounts and notes receivable - trade 1	$	1,712	$	1,643
Deferred revenue - current 2, 3	$	16	$	25

1.Included in "Accounts and notes receivable - net" in the Condensed Consolidated Balance Sheets.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

3.Noncurrent deferred revenue balances in the current and comparative periods were not material.

18

NOTE 6 - RESTRUCTURING AND ASSET RELATED CHARGES - NET

Charges for restructuring programs and asset related charges, which include asset impairments and other net charges, were zero and $101 million for the three and nine months ended September 30, 2022 and $1 million and $8 million for the three and nine months ended September 30, 2021. These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $21 million at September 30, 2022 and $43 million at December 31, 2021, recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Restructuring activity consists of the following programs:

2021 Restructuring Actions

In October 2021, the Company approved targeted restructuring actions to capture near-term cost reductions (the "2021 Restructuring Actions"). The Company recorded pre-tax restructuring charges of $55 million inception-to-date, consisting of severance and related benefit costs of $33 million and asset related charges of $22 million.

Total liabilities related to the 2021 Restructuring Actions were $17 million at September 30, 2022 and $25 million at December 31, 2021 and recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Actions related to the 2021 Restructuring Program are substantially complete.

2020 Restructuring Program

In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the N&B Transaction (the "2020 Restructuring Program"). The Company recorded pre-tax restructuring charges of $159 million inception-to-date, consisting of severance and related benefit costs of $107 million and asset related charges of $52 million.

Total liabilities related to the 2020 Restructuring Program were $2 million at September 30, 2022 and $11 million at December 31, 2021 and recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Actions related to the 2020 Restructuring Program are substantially complete.

Equity Method Investment Impairment Related Charges

In connection with the M&M Divestitures described in Note 4, in the first quarter of 2022 a portion of an equity method investment was reclassified to “Assets of discontinued operations” within the Condensed Consolidated Balance Sheet. The reclassification served as a triggering event requiring the Company to perform an impairment analysis on the retained portion of the equity method investment held within “Investments and noncurrent receivables” on the Condensed Consolidated Balance Sheet. The fair value of the retained equity method investment was estimated using a discounted cash flow model (a form of the income approach). The Company's assumptions in estimating fair value utilize Level 3 inputs and include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, and terminal growth rates. The Company determined the fair value of the retained equity method investment was below the carrying value and had no expectation the fair value would recover in the short-term due to the current economic environment. As a result, management concluded the impairment was other-than-temporary and, in March 2022, recorded an impairment charge of $94 million reflected in “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2022 related to the Electronics & Industrial segment. No impairment was required to be recorded for the portion of the equity method investment included within “Assets of discontinued operations.”

2022 Restructuring Program

In October 2022, subsequent to quarter end, the Company approved targeted restructuring actions to capture near-term cost reductions and to further simplify certain organizational structures following the M&M Divestitures (the "2022 Restructuring Program"). The Company expects to incur costs of up to $125 million, primarily related to the payment of severance and asset related charges. Restructuring costs will begin in the fourth quarter of 2022 and are expected to be substantially complete by the end of 2023.

19

NOTE 7 - SUPPLEMENTARY INFORMATION

Sundry Income (Expense) - Net	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Non-operating pension and other post-employment benefit ("OPEB") credits	$	7	$	9	$	20	$	22
Interest income	5		1		8		10
Net gain on divestiture and sales of other assets and investments 1, 2	6		8		75		175
Foreign exchange gains (losses), net	5		(19)		9		(35)
Miscellaneous income (expenses) - net 3	3		2		11		(17)
Sundry income (expense) - net	$	26	$	1	$	123	$	155

1. The nine months ended September 30, 2022 primarily reflects income of $26 million related to the gain on sale of the Biomaterials business unit and $37 million related to the sale of a land use right within the Water & Protection segment.

2. The nine months ended September 30, 2021 primarily reflects income of $140 million related to the gain on sale of assets within Corporate & Other and income of $28 million related to the gain on sale of assets within the Electronics & Industrial segment.

3. The nine months ended September 30, 2021 includes an impairment charge of approximately $15 million related to an asset sale.

Cash, Cash Equivalents and Restricted Cash

In connection with the cost sharing arrangement entered into as part of the MOU, the Company is contractually obligated to make deposits into an escrow account to address potential future PFAS costs. At September 30, 2022 and December 31, 2021, the Company had restricted cash of $103 million and $53 million included within non-current “Restricted cash and cash equivalents” in the Condensed Consolidated Balance Sheets, the majority of which is attributable to the MOU cost sharing arrangement. Additional information regarding the MOU and the escrow account can be found in Note 16.

Accrued and Other Current Liabilities

"Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets were $990 million at September 30, 2022 and $1,040 million at December 31, 2021. Accrued payroll, which is a component of "Accrued and other current liabilities," was $326 million at September 30, 2022 and $436 million at December 31, 2021. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at September 30, 2022 and at December 31, 2021.

20

NOTE 8 - INCOME TAXES

Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the third quarter of 2022 was 27.9 percent, compared with an effective tax rate of 23.6 percent for the third quarter of 2021. The effective tax rate differential for the third quarter of 2022 was driven by the cumulative impact of currency fluctuation and the geographic mix of earnings. For the first nine months of 2022, the effective tax rate on continuing operations was 23.8 percent, compared with 14.2 percent for the first nine months of 2021. The effective tax rate for the first nine months of 2021 was principally the result of a $59 million tax benefit related to the step-up in tax basis in the goodwill of the Company's European regional headquarters legal entity.

In connection with the integration of Laird PM, the Company completed certain internal restructurings that were determined to be tax free under the applicable sections of the Internal Revenue Code. If the aforementioned transactions were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax liability.

Certain internal distributions and reorganizations that occurred during 2021 and 2020 in preparation for the N&B Transaction and the external distribution in 2021 qualified as tax-free transactions under the applicable sections of the Internal Revenue Code. If the aforementioned transactions were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax liability. Under the N&B Tax Matters Agreement, the Company would generally be allocated such liability and not be indemnified, unless certain non-qualifying actions are undertaken by N&B or IFF. To the extent that the Company is responsible for any such liability, there could be a material adverse impact on the Company's business, financial condition, results of operations and cash flows in future reporting periods.

As a result of the M&M Businesses meeting the held for sale criteria in the first quarter of 2022, the Company recorded a net tax expense of $12 million and a net tax benefit of $655 million for the three and nine months ended September 30, 2022, respectively, in connection with certain internal restructuring and some of which relied upon legal entity valuations. These restructurings involve legal entities that hold M&M Businesses and are expected to be conveyed to Celanese as part of the M&M Divestiture and legal entities that are expected to remain with DuPont. The aforementioned net tax benefit is included in “Income from discontinued operations, net of tax” in the interim Consolidated Statements of Operations. See Note 4 for additional information on the M&M Divestitures.

21

NOTE 9 - EARNINGS PER SHARE CALCULATIONS

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2022 and 2021:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Income from continuing operations, net of tax	$	359	$	259	$	956	$	1,040
Net income from continuing operations attributable to noncontrolling interests	16		9		42		12
Income from continuing operations attributable to common stockholders	$	343	$	250	$	914	$	1,028
Income from discontinued operations, net of tax	17		145		723		5,249
Net income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to common stockholders	24		141		728		5,235
Net income attributable to common stockholders	$	367	$	391	$	1,642	$	6,263

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.81	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.49
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.25	$	11.35

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.80	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.46
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.24	$	11.32

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2022	2021	2022	2021
Weighted-average common shares - basic	499.4	521.5	505.6	551.7
Plus dilutive effect of equity compensation plans	1.0	1.6	1.3	1.4
Weighted-average common shares - diluted	500.4	523.1	506.9	553.1
Stock options, restricted stock units, and performance-based restricted stock units excluded from EPS calculations 2	4.4	2.4	3.0	2.7

1.Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

2.These outstanding options to purchase shares of common stock, restricted stock units, and performance-based restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

22

NOTE 10 - ACCOUNTS AND NOTES RECEIVABLE - NET

In millions	September 30, 2022		December 31, 2021
Accounts receivable – trade 1	$	1,691	$	1,612
Other 2	566		547
Total accounts and notes receivable - net	$	2,257	$	2,159

1.Accounts receivable – trade is net of allowances of $38 million at September 30, 2022 and $28 million at December 31, 2021. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts.

2.Other includes receivables in relation to value added tax, indemnification assets, general sales tax and other taxes, and other receivables. No individual group represents more than ten percent of total receivables.

NOTE 11 - INVENTORIES

In millions	September 30, 2022		December 31, 2021
Finished goods	$	1,334	$	1,201
Work in process	519		446
Raw materials	392		323
Supplies	114		116
Total inventories	$	2,359	$	2,086

NOTE 12 - PROPERTY, PLANT, AND EQUIPMENT

	Estimated Useful Lives (Years)			September 30, 2022		December 31, 2021
In millions
Land and land improvements	1	-	25	$	394	$	440
Buildings	1	-	50	1,904		1,954
Machinery, equipment, and other	1	-	25	6,462		6,467
Construction in progress				944		1,034
Total property, plant and equipment				$	9,704	$	9,895
Total accumulated depreciation				$	4,227	$	4,142
Total property, plant and equipment - net				$	5,477	$	5,753

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation expense	$	137	$	142	$	414	$	407

NOTE 13 - NONCONSOLIDATED AFFILIATES

The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and noncurrent receivables" in the Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates at September 30, 2022 and December 31, 2021 is $733 million and $817 million, respectively. In the first quarter of 2022, the Company recorded an other-than-temporary impairment on an equity method investment. See Note 6 for more information.

The Company maintained an ownership interest in six nonconsolidated affiliates at September 30, 2022.

Sales to nonconsolidated affiliates represented less than 2 percent of total net sales for the three and nine months ended September 30, 2022 and 2021. Purchases from nonconsolidated affiliates represented less than 3 percent of “Cost of sales” for the three and nine months ended September 30, 2022 and less than 4 percent for the three and nine months ended September 30, 2021.

23

NOTE 14 - GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 were as follows:

In millions	Electronics & Industrial		Water & Protection		Corporate & Other		Total
Balance at December 31, 2021	$	9,583	$	6,801	$	597	$	16,981
Currency Translation Adjustment	(337)		(326)		(16)		(679)
Balance at September 30, 2022	$	9,246	$	6,475	$	581	$	16,302

The Company tests goodwill for impairment annually during the fourth quarter, or more frequently when events or changes in circumstances indicate that fair value is below carrying value.

During the first quarter of 2022, in conjunction with the announcement of the M&M Divestitures, the Company realigned the Retained Businesses, previously within the historic Mobility & Materials segment, to Corporate & Other (the "2022 Realignment"). The announcement of the M&M Divestitures and 2022 Realignment served as triggering events requiring the Company to perform impairment analyses related to goodwill carried by the impacted reporting units as of March 1, 2022. Goodwill impairment analyses were performed for reporting units impacted in the historic Mobility & Materials segment prior to the realignment, and no impairments were identified. As part of the 2022 Realignment, the Company assessed and re-defined certain reporting units effective March 1, 2022, including a reallocation of goodwill on a relative fair value basis, as applicable, to the newly identified reporting units and M&M Divestitures disposal groups. Goodwill impairment analyses were performed for the new reporting units reported within Corporate & Other and no impairments were identified. The fair value of the reporting units and the M&M Divestitures disposal groups were estimated using a combination of a discounted cash flow model and/or market approach. The Company's assumptions in estimating fair value include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, the terminal growth rates, and derived multiples from comparable market transactions.

During the first quarter of 2021, in conjunction with the closing of the N&B Transaction, the Company changed its management and reporting structure (the “2021 Segment Realignment”), which served as a triggering event requiring the Company to perform an impairment analysis related to goodwill carried by certain reporting units as of February 1, 2021, prior to the realignment. As part of the 2021 Segment Realignment, the Company assessed and re-defined certain reporting units effective February 1, 2021, including reallocation of goodwill on a relative fair value basis, as applicable, to reporting units impacted. Goodwill impairment analyses were then performed for reporting units impacted and no impairments were identified. The fair value of each reporting unit tested was estimated using a combination of a discounted cash flow model and market approach. The Company's assumptions in estimating fair value include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, the terminal growth rates, and derived multiples from comparable market transactions.

The Company's analyses used the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs. The Company’s significant assumptions in these analyses include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and tax rates. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate.

24

Other Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2022						December 31, 2021
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	2,331	$	(1,241)	$	1,090	$	2,374	$	(1,124)	$	1,250
Trademarks/tradenames	1,114		(542)		572		1,125		(500)		625
Customer-related	5,416		(2,366)		3,050		5,806		(2,296)		3,510
Other	105		(71)		34		113		(80)		33
Total other intangible assets with finite lives	$	8,966	$	(4,220)	$	4,746	$	9,418	$	(4,000)	$	5,418
Intangible assets with indefinite lives:
Trademarks/tradenames	804		—		804		804		—		804
Total other intangible assets with indefinite lives	804		—		804		804		—		804
Total	$	9,770	$	(4,220)	$	5,550	$	10,222	$	(4,000)	$	6,222

As part of the 2022 Realignment, the Company reallocated its intangible assets with indefinite lives to align with the new segment structure. This served as a triggering event requiring the Company to perform an impairment analysis related to intangible assets with indefinite lives carried by its historic Mobility & Materials segment as of March 1, 2022, prior to the realignment. Subsequent to the realignment, impairment analyses were then performed for the intangible assets with indefinite lives reported in Corporate & Other. No impairments were identified as a result of the analyses described above.

As part of the 2021 Segment Realignment, the Company reallocated its intangible assets with indefinite lives to align with the new segment structure. This served as a triggering event requiring the Company to perform an impairment analysis related to intangible assets with indefinite lives carried by its segments as of February 1, 2021, prior to the realignment. Subsequent to the realignment, the Company realigned intangible assets with indefinite lives as applicable to align the intangible assets with indefinite lives with the new segment structure. Impairment analyses were then performed for the intangible assets with indefinite lives carried by the segments after the realignment. No impairments were identified as a result of the analyses described above.

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2022		December 31, 2021
In millions
Electronics & Industrial	$	3,000	$	3,429
Water & Protection	2,456		2,686
Corporate & Other	94		107
Total	$	5,550	$	6,222

Total estimated amortization expense for the remainder of 2022 and the five succeeding fiscal years is as follows:

Estimated Amortization Expense
In millions
Remainder of 2022	$	139
2023	$	567
2024	$	539
2025	$	498
2026	$	471
2027	$	424

25

NOTE 15 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

The Company's short-term borrowings consist of commercial paper. At September 30, 2022 and December 31, 2021, the Company's short-term borrowings were $1,287 million and $150 million, respectively. The increase in short-term borrowing is due to cash flow needs related to the M&M Divestiture as well as normal operating needs. The weighted-average interest rate on commercial paper was 3.19 percent at September 30, 2022 and 0.34 percent at December 31, 2021.

The following table summarizes the Company's long-term debt:

Long-Term Debt	September 30, 2022				December 31, 2021
In millions	Amount		Weighted Average Rate		Amount		Weighted Average Rate
Promissory notes and debentures 1
Final maturity 2023	$	2,800	4.18	%	$	2,800	3.89	%
Final maturity 2025	1,850		4.49	%	1,850		4.49	%
Final maturity 2026 and thereafter 2	5,975		5.20	%	6,050		5.13	%
Other facilities:
Finance lease obligations	2				2
Less: Unamortized debt discount and issuance costs	63				70
Total	$	10,564			$	10,632

1. Represents senior unsecured notes (the "2018 Senior Notes"), which are senior unsecured obligations of the Company. See Note 24 for additional information.

2. Includes fair value hedging adjustment of $75 million related to the Company's interest rate swap agreements. See Note 21 for additional information.

Principal Payments of long-term debt for the remainder of 2022 and the five succeeding fiscal years are as follows:

Maturities of Long-Term Debt for Next Five Years at September 30, 2022	Total
In millions
Remainder of 2022	$	—
2023	$	2,800
2024	$	—
2025	$	1,850
2026	$	—
2027	$	—

The estimated fair value of the Company's long-term borrowings was determined using Level 2 inputs within the fair value hierarchy, as described in Note 22. Based on quoted market prices for the same or similar issues, or on current rates offered to the Company for debt of the same remaining maturities, the fair value of the Company's long-term borrowings, was $10.21 billion and $12.60 billion at September 30, 2022 and December 31, 2021, respectively.

Available Committed Credit Facilities

The following table summarizes the Company's credit facilities:

Committed and Available Credit Facilities at September 30, 2022
In millions	Effective Date	Committed Credit		Credit Available		Maturity Date	Interest
Revolving Credit Facility, Five-year	April 2022	$	2,500	$	2,488	April 2027	Floating Rate
364-day Revolving Credit Facility	April 2022	1,000		1,000		April 2023	Floating Rate
Total Committed and Available Credit Facilities		$	3,500	$	3,488

In July 2022, the Company drew down $600 million under the 364-day Revolving Credit Facility in order to facilitate certain intercompany internal restructuring steps related to the M&M Divestiture. The Company repaid the borrowing in September 2022.

Intended Rogers Acquisition

In connection with the Intended Rogers Acquisition, on November 22, 2021, the Company entered into a two-year senior unsecured committed term loan agreement in the amount of $5.2 billion. In October 2022, the facility was amended to extend the lending commitments (as amended the "Amended 2021 Term Loan Facility"). On November 1, 2022, the M&M Divestiture closed and therefore based on the terms of the Amended 2021 Term Loan Facility the commitment was terminated. Refer to Note 24 - Subsequent Events for additional information on the Intended Rogers Acquisition.

26

May 2020 Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “May 2020 Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May 2020 Debt Offering”). The consummation of the N&B Transaction triggered the special mandatory redemption feature of the May 2020 Debt Offering. The Company redeemed the May 2020 Notes on May 13, 2021 and funded the redemption with proceeds from the Special Cash Payment.

Term Loan Facilities

On February 1, 2021, the Company terminated its fully drawn $3 billion term loan facilities. The termination triggered the repayment of the aggregate outstanding principal amount of $3 billion, plus accrued and unpaid interest through and including January 31, 2021. The Company funded the repayment with proceeds from the Special Cash Payment.

Revolving Credit Facilities

On April 12, 2022, the Company entered into a new $2.5 billion five-year revolving credit facility (the "2022 Five-Year Revolving Credit Facility"). The 2022 Five-Year Revolving Credit Facility is generally expected to remain undrawn and serve as a backstop to the Company's commercial paper and letter of credit issuance. On April 12, 2022, the Company entered into an updated $1 billion 364-day revolving credit facility (the "2022 $1B Revolving Credit Facility").

Uncommitted Credit Facilities and Outstanding Letters of Credit

Unused bank credit lines on uncommitted credit facilities were approximately $810 million at September 30, 2022. These lines are available to support short-term liquidity needs and general corporate purposes including letters of credit. Outstanding letters of credit were approximately $107 million at September 30, 2022. These letters of credit support commitments made in the ordinary course of business.

Debt Covenants and Default Provisions

The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subject to certain limitations. The 2018 Senior Notes also contain customary default provisions. The 2021 Term Loan Facility, the Five-Year Revolving Credit Facility and the 2022 $1B Revolving Credit Facility contain a financial covenant requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2022, the Company was in compliance with this financial covenant. There were no material changes to the debt covenants and default provisions at September 30, 2022.

27

NOTE 16 - COMMITMENTS AND CONTINGENT LIABILITIES

Litigation, Environmental Matters, and Indemnifications

The Company and certain subsidiaries are involved in various lawsuits, claims and environmental actions that have arisen in the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, as well as possible obligations to investigate and mitigate the effects on the environment of the disposal or release of certain substances at various sites. In addition, in connection with divestitures and the related transactions, the Company from time to time has indemnified and has been indemnified by third parties against certain liabilities that may arise in connection with, among other things, business activities prior to the completion of the respective transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. The Company records liabilities for ongoing and indemnification matters when the information available indicates that it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated.

As of September 30, 2022, the Company has recorded indemnification assets of $18 million within "Accounts and notes receivable - net" and $229 million within "Deferred charges and other assets" and indemnification liabilities of $122 million within "Accrued and other current liabilities" and $221 million within "Other noncurrent obligations" within the Condensed Consolidated Balance Sheets.

The Company’s accruals discussed below for indemnification liabilities related to the binding Memorandum of Understanding (“MOU”) between Chemours, Corteva, EID and the Company and to the DowDuPont ("DWDP") Separation and Distribution Agreement and the Letter Agreement between the Company and Corteva (together the “Agreements”), are included in the balances above.

PFAS Stray Liabilities: Future Eligible PFAS Costs

On July 1, 2015, EID, a Corteva subsidiary since June 1, 2019, completed the separation of EID’s Performance Chemicals segment through the spin-off of Chemours to holders of EID common stock (the “Chemours Separation”). On June 1, 2019, the Company completed the separation of its agriculture business through the spin-off of Corteva, Inc. (“Corteva”), including Corteva’s subsidiary EID.

On January 22, 2021, the Company, Corteva, EID and Chemours entered into the MOU pursuant to which the parties have agreed to release certain claims that had been raised by Chemours including any claims arising out of or resulting from the process and manner in which EID structured or conducted the Chemours Separation, and any other claims that challenge the Chemours Separation or the assumption of Chemours Liabilities (as defined in the Chemours Separation Agreement) by Chemours and the allocation thereof, subject in each case to certain exceptions set forth in the MOU. In connection with the MOU, the confidential arbitration process regarding certain claims by Chemours was terminated in February 2021. The parties have further agreed not to bring any future, additional claims regarding the Chemours Separation Agreement or the MOU outside of arbitration.

Pursuant to the MOU, the parties have agreed to share certain costs associated with potential future liabilities related to alleged historical releases of certain PFAS out of pre-July 1, 2015 conduct (“eligible PFAS costs”) until the earlier to occur of (i) December 31, 2040, (ii) the day on which the aggregate amount of Qualified Spend, as defined in the MOU, is equal to $4 billion or (iii) a termination in accordance with the terms of the MOU. PFAS refers to per- or polyfluoroalkyl substances, which include perfluorooctanoic acids and its ammonium salts (“PFOA”).

The parties have agreed that, during the term of this sharing arrangement, Qualified Spend up to $4 billion will be borne 50 percent by Chemours and 50 percent, up to a cap of $2 billion, by the Company and Corteva. The Company and Corteva will split their 50 percent of Qualified Spend in accordance with the Agreements. After the term of this arrangement, Chemours’ indemnification obligations under the Chemours Separation Agreement would continue unchanged, subject in each case to certain exceptions set forth in the MOU.

In order to support and manage any potential future eligible PFAS costs, the parties also agreed to establish an escrow account. The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50 percent of the deposits and DuPont and Corteva together will make 50 percent of the deposits necessary to restore the balance of the escrow account to $700 million. Such payments will be made in a series of

28

consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU. At September 30, 2022 and December 31, 2021, DuPont's escrow deposits of $100 million and $50 million, respectively, are reflected in "Restricted cash and cash equivalents" on the Condensed Consolidated Balance Sheet.

Under the Agreements, Divested Operations and Businesses ("DDOB") liabilities of EID not allocated to or retained by Corteva or the Company are categorized as relating to either (i) PFAS Stray Liabilities, if they arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS; or (ii) Non-PFAS Stray Liabilities, (and together with PFAS Stray Liabilities, the “EID Stray Liabilities”).

The Agreements provide that the Company and Corteva will each bear specified amounts plus an additional $200 million of Indemnifiable Losses, described below, in relation to certain EID Stray Liabilities. The Agreements further provide that the Company and Corteva will each bear 50 percent, $150 million each, of the first $300 million of total Indemnifiable Losses related to PFAS Stray Liabilities. When the companies meet their respective $150 million threshold, Indemnifiable Losses related to PFAS Stray Liabilities will be borne 71 percent by DuPont and 29 percent by Corteva.

Indemnifiable Losses up to $150 million incurred for PFAS Stray Liabilities are credited against each company’s $200 million threshold. Whenever Corteva or DuPont meets its $200 million threshold, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. Thereafter, DuPont will bear 71 percent and Corteva will bear 29 percent of Indemnifiable Losses related to Non-PFAS Stray Liabilities.

Indemnifiable Losses, as defined in the DWDP Separation and Distribution Agreement, include, among other things, attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense of EID Stray Liabilities.

In connection with the MOU and the Agreements, the Company has recognized the following indemnification liabilities related to eligible PFAS costs:

Indemnified Liabilities Related to the MOU
In millions	Sept 30, 2022		Dec 31, 2021		Balance Sheet Classification
Current indemnified liabilities	$	55	$	37	Accrued and other current liabilities
Long-term indemnified liabilities	$	129	$	89	Other noncurrent obligations
Total indemnified liabilities accrued under the MOU 1, 2	$	184	$	126

1.As of September 30, 2022 and December 31, 2021, total indemnified liabilities accrued include $168 million and $112 million, respectively, related to Chemours environmental remediation activities at their site in Fayetteville, North Carolina under the Consent Order between Chemours and the North Carolina Department of Environmental Quality (the "NC DEQ").

2.In addition to the above, as of December 31, 2021, the Company had recognized a liability of $12.5 million related to the settlement agreement between Chemours, Corteva and DuPont and Delaware's Attorney General, discussed below.

Future charges associated with the MOU would be recognized over the term of the agreement as a component of income from discontinued operations to the extent liabilities become probable and estimable.

In 2004, EID settled a West Virginia state court class action, Leach v. E. I. du Pont de Nemours and Company, which alleged that PFOA from EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Members of the Leach class have standing to pursue personal injury claims for six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. Since the 2017 settlement about 100 additional cases alleging personal injury, including kidney and testicular cancer claims, were filed or noticed and pending in the Ohio MDL.

On January 21, 2021, EID and Chemours entered into settlement agreements with plaintiffs’ counsel representing the Ohio MDL plaintiffs providing for a settlement of cases and claims in the Ohio MDL, except as noted below (the “Settlement”). The total settlement amount was $83 million in cash with each of the Company and EID contributing $27 million and Chemours contributing $29 million. At June 30, 2021 the Company had paid in full its $27 million contribution. The Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by the Company, Corteva, EID or Chemours. In connection with the Settlement, in April 2021 the plaintiffs filed a motion to terminate

29

the Ohio MDL. The case captioned “Abbott v. E. I. du Pont de Nemours and Company” is a personal injury action that is not included in the Settlement of the Ohio MDL. DuPont was not named party in the Leach case or the Ohio MDL and is not a named party in the Abbott case.

As of September 30, 2022, there are various cases alleging damages due to PFAS which are discussed below. Such actions often include additional claims based on allegations that the transfer by EID of certain PFAS liabilities to Chemours resulted in a fraudulent conveyance or voidable transaction. With the exception of the fraudulent conveyance claims, which are excluded from the MOU, legal fees, expenses, costs, and any potential liabilities for eligible PFAS costs presented by the following matters will be shared as defined in the MOU between Chemours, EID, Corteva and DuPont.

Beginning in April 2019, several dozen lawsuits alleging water contamination from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against EID and Chemours, in addition to 3M and other AFFF manufacturers. The majority of these lawsuits were consolidated in a multi-district litigation docket in federal court in South Carolina (the “SC MDL”). Since then, the SC MDL has grown and contains approximately 3,130 cases. Most of the actions in the SC MDL name DuPont as a defendant due to the fraudulent transfer claims related to the Chemours Separation and the DowDuPont separations. Generally, the SC MDL contains multiple types of lawsuits including, but not limited to, approximately 2,840 personal injury cases, state attorneys general natural resource damages cases, and water provider contamination cases. Three of the water provider contamination cases have been selected by the court as bellwether cases. The court has encouraged all parties to discuss resolution of the water provider category of cases. Consistent with the court’s instruction and under the mutual obligations of the MOU, Chemours, Corteva/EID and DuPont, together, are engaged with plaintiffs’ counsel on these cases. DuPont has never made or sold AFFF, perfluorooctanesulfonic acid ("PFOS") or PFOS containing products.

There are also state attorneys general lawsuits against DuPont, outside of the SC MDL. These also claim environmental contamination by certain PFAS compounds but distinct from AFFF. Generally, the states raise common law tort claims and seek economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup contamination from certain PFAS compounds, and to abate the alleged nuisance. Most of these actions include fraudulent transfer claims related to the Chemours Separation and the DowDuPont separations.

In July 2021, Chemours, Corteva (for itself and EID) and DuPont reached a resolution with the State of Delaware that avoids litigation and addresses potential natural resources damages from known historical and current releases by the companies in or affecting Delaware. The resolution releases these potential state claims arising from the environmental impacts of various chemicals, including PFAS, across all current and historical locations. Consistent with the MOU, Chemours will bear 50 percent or $25 million of the $50 million settlement and Corteva and DuPont will each bear $12.5 million. The Company paid its portion of the settlement in January 2022. The settlement also calls for a potential Supplemental Payment to Delaware up to a total of $25 million funded 50 percent by Chemours and 50 percent by Corteva and DuPont, jointly, under certain circumstances which are not deemed probable.

In April 2021, DuPont de Nemours (Nederland) B.V., and the Dutch entities of Chemours and Corteva, received a civil summons filed before the Court of Rotterdam, the Netherlands, on behalf of four municipalities neighboring the Chemours Dordrecht facility. The municipalities are seeking liability declarations relating to the Dordrecht site’s current and historical PFAS operations and emissions.

In addition to the above matters, the Company is a named party in various other legal matters that make claims related to PFAS, for which the costs of litigation and future liabilities, if any, are eligible PFAS costs under the MOU and Indemnification Losses under the Agreements. These matters include lawsuits filed by water districts and private water companies in New Jersey and California generally alleging contamination of water systems.

There are pending cases that make claims related to PFAS that have been filed against Chemours and Corteva/EID in which the Company is not a named party, but for which the costs of litigation and future liabilities, if any, are or may be eligible PFAS costs under the MOU and Indemnification Losses under the Agreements.

While Management believes it has appropriately estimated the liability associated with eligible PFAS matters and Indemnifiable Losses as of the date of this report, it is reasonably possible that the Company could incur additional eligible PFAS costs and Indemnifiable Losses in excess of the amounts accrued. These additional costs could have a significant effect on the Company’s financial condition and/or cash flows in the period in which they occur; however, costs qualifying as Qualified Spend are limited by the terms of the MOU.

30

Other Litigation Matters

In addition to the matters described above, the Company is party to claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. As of September 30, 2022, the Company has liabilities of $23 million associated with these other litigation matters. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company. In accordance with its accounting policy for litigation matters, the Company will expense litigation defense costs as incurred, which could be significant to the Company’s financial condition and/or cash flows in the period.

Environmental Matters

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At September 30, 2022, the Company had accrued obligations of $260 million for probable environmental remediation and restoration costs. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the Condensed Consolidated Balance Sheets. It is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

In June of 2022, the EPA announced updated health advisories for various PFAS compounds in drinking water. Chemours received notice from the NC DEQ that its obligations under the Consent Order could be enlarged as a result of EPA’s announcement. In the second quarter of 2022, the Company recorded an incremental liability related to its indemnification obligations under the MOU. The increase primarily relates to incremental costs associated with activities at Chemours' site in Fayetteville, North Carolina under the Consent Order with the NC DEQ.

The accrued environmental obligations include the following:

Environmental Accrued Obligations
In millions	Sept 30, 2022		Dec 31, 2021		Potential exposure above the amount accrued 1
Environmental remediation liabilities not subject to indemnity	$	39	$	43	$	105
Environmental remediation indemnified liabilities:
Indemnifications related to Dow and Corteva 2	48		46		63
MOU related obligations (discussed above) 3	172		116		84
Other Environmental Indemnifications	1		—		2
Total environmental related liabilities	$	260	$	205	$	254

1.The environmental accrual represents management’s best estimate of the costs for remediation and restoration with respect to environmental matters, although it is reasonably possible that the ultimate cost with respect to these particular matters could range above the amount accrued.

2.Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify Dow and Corteva for certain Non-PFAS clean-up responsibilities and associated remediation costs.

3.The MOU related obligations include the Company's estimate of its liability under the MOU for remediation activities based on the current regulatory environment.

31

NOTE 17 - LEASES

The lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Operating lease costs	$	27	$	27	$	82	$	80

Operating cash flows from operating leases, excluding those related to the M&M Divestitures, were $82 million and $80 million for the nine months ended September 30, 2022 and 2021, respectively.

New operating lease assets and liabilities entered into during the nine months ended September 30, 2022 and 2021 were $75 million and $64 million, respectively. Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2022		December 31, 2021
Operating Leases
Operating lease right-of-use assets 1	$	386	$	422
Current operating lease liabilities 2	84		92
Noncurrent operating lease liabilities 3	301		337
Total operating lease liabilities	$	385	$	429

1.Included in "Deferred charges and other assets" in the Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the Condensed Consolidated Balance Sheet.

Operating lease right-of-use ("ROU") assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide the lessor’s implicit rate, the Company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments.

Lease Term and Discount Rate for Operating Leases	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (years)	8.07		8.50
Weighted average discount rate	2.33	%	2.01	%

Maturities of lease liabilities were as follows:

Maturity of Lease Liabilities at September 30, 2022	Operating Leases
In millions
Remainder of 2022	$	25
2023	89
2024	75
2025	53
2026	36
2027 and thereafter	153
Total lease payments	$	431
Less: Interest	46
Present value of lease liabilities	$	385

The Company has leases in which it is the lessor, with the largest being a result of the N&B transaction. In connection with the N&B Transaction, DuPont entered into leasing agreements with IFF, whereby DuPont is leasing certain properties, including office spaces and R&D laboratories to IFF. These leases are classified as operating leases and lessor income and related expenses are not significant to the Company's Condensed Consolidated Balance Sheet or interim Consolidated Statement of Operations. Lease agreements where the Company is the lessor have final expirations through 2036.

32

NOTE 18 - STOCKHOLDERS' EQUITY

Share Repurchase Program

In February 2022, the Company's Board of Directors authorized a $1.0 billion share buyback program which expires on March 31, 2023, (the "2022 Share Buyback Program"). During the third quarter, the Company repurchased and retired 4.3 million shares for $250 million under this program. As of September 30, 2022, the Company repurchased and retired a total of 11.9 million shares for $750 million under the 2022 Share Buyback Program. Refer to Note 24 - Subsequent Events for additional information on the share repurchase programs.

In the first quarter of 2021, the Company's Board of Directors authorized a $1.5 billion share buyback program, which expired on June 30, 2022 ("2021 Share Buyback Program"). At the expiry of the 2021 Share Buyback Program, the Company had repurchased and retired a total of 19.6 million shares for $1.5 billion.

On June 1, 2019, the Company's Board of Directors approved a $2 billion share buyback program ("2019 Share Buyback Program"), which expired on June 1, 2021. At the expiry of the 2019 Share Buyback Program, the Company had repurchased and retired a total of 29.9 million shares at a cost of $2 billion.

Accumulated Other Comprehensive Loss

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2022 and 2021:

Accumulated Other Comprehensive Loss	Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2021
Balance at January 1, 2021	$	470	$	(425)	$	(1)	$	44
Other comprehensive (loss) income before reclassifications	(545)		20		38		(487)
Amounts reclassified from accumulated other comprehensive loss	—		3		—		3
Split-off of N&B reclassification adjustment	184		73		1		258
Net other comprehensive (loss) income	$	(361)	$	96	$	39	$	(226)
Balance at September 30, 2021	$	109	$	(329)	$	38	$	(182)
2022
Balance at January 1, 2022	$	(88)	$	73	$	56	$	41
Other comprehensive (loss) income before reclassifications	(1,774)		24		109		(1,641)
Amounts reclassified from accumulated other comprehensive loss	—		(3)		—		(3)
Net other comprehensive (loss) income	$	(1,774)	$	21	$	109	$	(1,644)
Balance at September 30, 2022	$	(1,862)	$	94	$	165	$	(1,603)

The tax effects on the net activity related to each component of other comprehensive (loss) income were not significant for the three and nine months ended September 30, 2022 and 2021.

A summary of the reclassifications out of AOCL for the three and nine months ended September 30, 2022 and 2021 is provided as follows:

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2022		2021		2022		2021
Cumulative translation adjustments	$	—	$	—	$	—	$	184	See (1) below
Pension and other post-employment benefit plans	$	(2)	$	2	$	(4)	$	110	See (1) below
Tax expense (benefit)	—		(5)		1		(34)		See (1) below
After tax	$	(2)	$	(3)	$	(3)	$	76
Derivative instruments	$	—	$	—	$	—	$	1	See (1) below
Total reclassifications for the period, after tax	$	(2)	$	(3)	$	(3)	$	261

1. The activity for the three and nine months ended September 30, 2022 is classified within the "Sundry income (expense) - net". The activity for the three and nine months ended September 30, 2021 is classified almost entirely within "Income from discontinued operations, net of tax" as part of the N&B Transaction, with a portion classified within "Sundry income (expense) - net" and "(Benefit from) provision for income taxes on continuing operations" as part of continuing operations.

33

NOTE 19 - PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS

A summary of the Company's pension plans and other post-employment benefits can be found in Note 19 to the Consolidated Financial Statements included in the Company’s 2021 Annual Report.

The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post-employment benefits:

Net Periodic Benefit (Credit) Cost for All Plans	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Service cost 1	$	9	$	13	$	32	$	42
Interest cost 2	14		11		41		32
Expected return on plan assets 3	(24)		(26)		(76)		(80)
Amortization of prior service credit 4	(1)		(2)		(4)		(4)
Amortization of unrecognized net loss 5	1		3		2		10
Curtailment/settlement 6	(2)		(1)		(1)		2
Net periodic benefit (credit) cost - total	$	(3)	$	(2)	$	(6)	$	2
Less: Net periodic benefit credit - discontinued operations	(2)		(2)		(7)		(4)
Net periodic benefit cost - continuing operations	$	(1)	$	—	$	1	$	6

1. The service cost from continuing operations was $6 million and $21 million for the three and nine months ended September 30, 2022, respectively, compared with $9 million and $28 million for the three and nine months ended September 30, 2021, respectively.

2. The interest cost from continuing operations was $13 million and $37 million for the three and nine months ended September 30, 2022, respectively, compared with $10 million and $29 million for the three and nine months ended September 30, 2021, respectively.

3. The expected return on plan assets from continuing operations was $19 million and $57 million for the three and nine months ended September 30, 2022, respectively, compared with $19 million and $59 million for the three and nine months ended September 30, 2021.

4. The amortization of prior service credit from continuing operations was zero and $2 million for the three and nine months ended September 30, 2022, respectively, compared with a gain of $2 million and $4 million for the three and nine months ended September 30, 2021, respectively.

5. The amortization of unrecognized net loss from continuing operations was $1 million and $3 million or the three and nine months ended September 30, 2022, respectively, compared with a net loss of $3 million and $10 million for the three and nine months ended September 30, 2021, respectively.

6. The curtailment and settlement gain from continuing operations was $2 million and $1 million for the three and nine months ended September 30, 2022, respectively, a gain of $1 million for the three months ended September 30, 2021, and a loss of $2 million for the nine months ended September 30, 2021.

The continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations.

DuPont expects to make additional contributions in the aggregate of approximately $35 million by year-end 2022.

NOTE 20 - STOCK-BASED COMPENSATION

A summary of the Company's stock-based compensation plans can be found in Note 20 to the Consolidated Financial Statements included in the Company's 2021 Annual Report. In the second quarter of 2020, the stockholders of DuPont approved the DuPont 2020 Equity and Incentive Plan (the "2020 Plan") which allows the Company to grant options, share appreciation rights, restricted shares, restricted stock units ("RSUs"), share bonuses, other share-based awards, cash awards, or any combination of the foregoing. Under the 2020 Plan, a maximum of 17 million shares of common stock are available for award as of September 30, 2022.

DuPont recognized share-based compensation expense of $20 million and $15 million for the three months ended September 30, 2022 and 2021, respectively, and $58 million and $49 million for the nine months ended September 30, 2022 and 2021, respectively. The income tax benefits related to stock-based compensation arrangements were $4 million and $3 million for the three months ended September 30, 2022 and 2021, respectively, and $12 million and $10 million for the nine months ended September 30, 2022 and 2021, respectively.

In the first quarter of 2022, the Company granted 0.7 million RSUs, 0.5 million stock options and 0.3 million performance-based stock units ("PSUs"). The weighted-average fair values per share associated with the grants were $75.12 per RSU, $17.41 per stock option and $81.55 per PSU. The stock options had a weighted-average exercise price per share of $75.05. There was minimal activity in the second and third quarters of 2022.

34

NOTE 21 - FINANCIAL INSTRUMENTS

The following table summarizes the fair value of financial instruments at September 30, 2022 and December 31, 2021:

Fair Value of Financial Instruments	September 30, 2022								December 31, 2021
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	427	$	—	$	—	$	427	$	841	$	—	$	—	$	841
Restricted cash equivalents 1	$	111	$	—	$	—	$	111	$	65	$	—	$	—	$	65
Total cash and restricted cash equivalents	$	538	$	—	$	—	$	538	$	906	$	—	$	—	$	906
Long-term debt including debt due within one year	$	(10,639)	$	497	$	(64)	$	(10,206)	$	(10,632)	$	—	$	(1,963)	$	(12,595)
Derivatives relating to:
Net investment hedge 2	—		211		—		211		—		74		—		74
Foreign currency 3, 4	—		39		(50)		(11)		—		5		(10)		(5)
Interest rate swap agreements 5	—		—		(75)		(75)		—		—		—		—
Total derivatives	$	—	$	250	$	(125)	$	125	$	—	$	79	$	(10)	$	69

1.At September 30, 2022 there was $8 million of restricted cash classified as "Prepaid and other current assets" and $103 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheets. At December 31, 2021 there was $12 million of restricted cash classified as "Prepaid and other current assets" and $53 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheet. See Note 7 for more information on restricted cash.

2.Classified as "Deferred charges and other assets" in the Condensed Consolidated Balance Sheets.

3.Classified as "Prepaid and other current assets" and "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

4.Presented net of cash collateral where master netting arrangements allow.

5.Classified as "Other noncurrent obligations" in the Condensed Consolidated Balance Sheets.

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps.

The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly monitored and reported to management.

The notional amounts of the Company's derivative instruments were as follows:

Notional Amounts	September 30, 2022		December 31, 2021
In millions
Derivatives designated as hedging instruments:
Net investment hedge	$	1,000	$	1,000
Interest rate swap agreements	$	1,000	$	—
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(407)	$	(625)

1.Presented net of contracts bought and sold.

35

Derivatives Designated in Hedging Relationships

Net Foreign Investment Hedge

In the second quarter of 2021, the Company entered into fixed-for-fixed cross currency swaps with an aggregate notional amount totaling $1 billion to hedge the variability of exchange rate impacts between the U.S. dollar and euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $1 billion at an interest rate of 4.73% for €819 million at a weighted average interest rate of 3.26%. The cross-currency swap is designated as a net investment hedge and expires on November 15, 2028.

The Company has made an accounting policy election to account for the net investment hedge using the spot method. The Company has also elected to amortize the excluded components in interest expense in the related quarterly accounting period that such interest is accrued. The cross-currency swap is marked to market at each reporting date and any unrealized gains or losses are included in unrealized currency translation adjustments within AOCL, net of amounts associated with excluded components which are recognized in interest expense in the interim Consolidated Statements of Operations.

Interest Rate Swap Agreements

In the second quarter of 2022, the Company entered into fixed-to-floating interest rate swap agreements with an aggregate notional principal amount totaling $1 billion to hedge changes in the fair value of the Company’s long-term debt due to interest rate change movements. These swaps converted $1 billion of the Company’s $1.65 billion principal amount of fixed rate notes due 2038 into floating rate debt for the portion of their terms through 2032 with an interest rate based on the Secured Overnight Financing Rate ("SOFR"). Under the terms of the agreements, the Company agrees to exchange, at specified intervals, fixed for floating interest amounts based on the agreed upon notional principal amount. The interest rate swaps are designated as fair value hedges and expire on November 15, 2032.

The interest rate swaps are carried at fair value. Fair value hedge accounting has been applied and thus, changes in the fair value of these swaps and changes in the fair value of the related hedged portion of long-term debt will be presented and will net to zero in Sundry income (expense) – net in the interim Consolidated Statements of Operations.

Derivatives not Designated in Hedging Relationships

Foreign Currency Contracts

The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues.

Effect of Derivative Instruments

Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a loss of $24 million and $11 million for the three months ended September 30, 2022 and 2021, respectively. There was a loss of $73 million and $38 million for the nine months ended September 30, 2022 and 2021, respectively. The income statement effects of other derivatives were immaterial.

36

NOTE 22 - FAIR VALUE MEASUREMENTS

Fair Value Measurements on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2022	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	538
Derivatives relating to: 2
Net investment hedge	211
Foreign currency contracts 3	80
Total assets at fair value	$	829
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	10,206
Derivatives relating to: 2
Interest rate swap agreements	75
Foreign currency contracts 3	91
Total liabilities at fair value	$	10,372

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts for foreign currency contracts were $41 million for both assets and liabilities as of September 30, 2022.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Fair value includes fair value hedging adjustments related to the Company's interest rate swap agreements.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2021	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	906
Derivatives relating to: 2
Net investment hedge	74
Foreign currency contracts 3	11
Total assets at fair value	$	991
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	12,595
Derivatives relating to: 2
Foreign currency contracts 3	16
Total liabilities at fair value	$	12,611

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $6 million for both assets and liabilities as of December 31, 2021.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Fair Value Measurements on a Nonrecurring Basis

In the first quarter of 2022, the Company recorded an other-than-temporary impairment, classified as Level 3 measurements, on an equity method investment. See Note 6 for further discussion of these fair value measurements.

37

NOTE 23 - SEGMENTS AND GEOGRAPHIC REGIONS

Effective February 2022, the revenues and certain expenses of the M&M Businesses are classified as discontinued operations in the current and historical periods. In addition, the Retained Businesses previously reported in the historic Mobility & Materials segment are reported in Corporate & Other. These reporting changes have been retrospectively applied for all periods presented.

The historic Mobility & Material segment costs that are classified as discontinued operations include only direct operating expenses incurred by the M&M Businesses which the Company will cease to incur upon the close of the M&M Divestitures. Indirect costs, such as those related to corporate and shared service functions previously allocated to the M&M Businesses, do not meet the criteria for discontinued operations and remain reported within continuing operations. A portion of these indirect costs include costs related to activities the Company will continue to undertake post-closing of the M&M Divestiture, and for which it will be reimbursed (“Future Reimbursable Indirect Costs”). Future Reimbursable Indirect Costs are reported within continuing operations but are excluded from operating EBITDA as defined below. The remaining portion of these indirect costs is not subject to future reimbursement (“Stranded Costs”). Stranded Costs are reported within continuing operations in Corporate & Other and are included within Operating EBITDA.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

The reporting changes have been retrospectively reflected in the segment results for all periods presented.

Segment Information	Electronics. & Industrial		Water & Protection		Corporate & Other 1		Total
In millions
Three Months Ended September 30, 2022
Net sales	$	1,511	$	1,534	$	272	$	3,317
Operating EBITDA 2	$	473	$	382	$	1	$	856
Equity in earnings of nonconsolidated affiliates	$	7	$	9	$	—	$	16
Three Months Ended September 30, 2021
Net sales	$	1,467	$	1,397	$	335	$	3,199
Operating EBITDA 2	$	475	$	353	$	(11)	$	817
Equity in earnings of nonconsolidated affiliates	$	13	$	7	$	2	$	22
Nine Months Ended September 30, 2022
Net sales	$	4,574	$	4,460	$	879	$	9,913
Operating EBITDA 2	$	1,429	$	1,071	$	3	$	2,503
Equity in earnings of nonconsolidated affiliates	$	26	$	31	$	5	$	62
Nine Months Ended September 30, 2021
Net sales	$	4,087	$	4,137	$	1,096	$	9,320
Operating EBITDA 2	$	1,335	$	1,060	$	5	$	2,400
Equity in earnings of nonconsolidated affiliates	$	32	$	27	$	6	$	65

1.Corporate & Other includes activities of the Retained Businesses and previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

2.A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA is provided below.

38

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2022 and 2021		Three Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	359	$	259
+	Provision for income taxes on continuing operations	139		80
Income from continuing operations before income taxes		$	498	$	339
+	Depreciation and amortization	283		300
-	Interest income 1	5		1
+	Interest expense	127		115
-	Non-operating pension/OPEB benefit 1	7		9
-	Foreign exchange gains (losses), net 1	5		(19)
+	Future reimbursable indirect costs	14		15
-	Significant items	49		(39)
Operating EBITDA		$	856	$	817

1.Included in "Sundry income (expense) - net."

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2022 and 2021		Nine Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	956	$	1,040
+	Provision for income taxes on continuing operations	299		172
Income from continuing operations before income taxes		$	1,255	$	1,212
+	Depreciation and amortization	861		817
-	Interest income 1	8		10
+	Interest expense	365		390
-	Non-operating pension/OPEB benefit 1	20		22
-	Foreign exchange gains (losses), net 1	9		(35)
+	Future reimbursable indirect costs	45		46
-	Significant items	(14)		68
Operating EBITDA		$	2,503	$	2,400

1.Included in "Sundry income (expense) - net."

The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(7)	$	(7)
Gain on divestiture 2	—		—		5		5
Intended Rogers Acquisition financing fees 3	—		—		(1)		(1)
Employee Retention Credit 4	20		20		12		52
Total	$	20	$	20	$	9	$	49

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Reflected in "Sundry income (expense) - net."

3. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

4. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

39

Significant Items by Segment for the Three Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(29)	$	(29)
Restructuring and asset related charges - net 2	—		—		(1)		(1)
Gain on divestiture 3	—		—		3		3
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	(27)	$	(39)

1. Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

Significant Items by Segment for the Nine Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(28)	$	(28)
Restructuring and asset related charges - net 2	(1)		(3)		(3)		(7)
Asset impairment charges 3	(94)		—		—		(94)
Gain on divestiture 4	—		37		31		68
Intended Rogers Acquisition financing fees 5	—		—		(5)		(5)
Employee Retention Credit 6	20		20		12		52
Total	$	(75)	$	54	$	7	$	(14)

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Includes restructuring actions and asset related charges. See Note 6 for additional information.

3. Relates to an impairment of an equity method investment. See Note 6 for additional information.

4. Reflected in "Sundry income (expense) - net."

5. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

6. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

Significant Items by Segment for the Nine Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(58)	$	(58)
Restructuring and asset related charges - net 2	(2)		—		(6)		(8)
Gain on divestiture 3	2		—		144		146
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	80	$	68

1.Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

40

NOTE 24 - SUBSEQUENT EVENTS

Closing of the M&M Divestiture and the Use of Proceeds

On November 1, 2022, DuPont completed the divestiture of the majority of its historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Business”), to Celanese for a purchase price of $11.0 billion in cash. Preliminary cash received, as adjusted for preliminary and other adjustments, was $11.0 billion including approximately $0.5 billion of cash transferred with the M&M Business for which DuPont was reimbursed.

Use of Net Proceeds

On November 7, 2022, DuPont’s Board of Directors approved a new share repurchase program authorizing the repurchase and retirement of up to $5 billion of common stock. The new repurchase authorization of up to $5 billion is in addition to the $250 million remaining under the Company’s existing share repurchase program which was approved in February 2022. The Company intends to enter accelerated share repurchase agreements (the “ASR Agreements”) imminently, for the repurchase of an aggregate of approximately $3.25 billion of common stock with $250 million of such repurchases under the existing program and the remaining $3 billion under the new program. Any additional repurchases under the new share repurchase program will be made from time to time on the open market at prevailing market prices or in privately negotiated transactions off the market, which may include additional accelerated share repurchase agreements. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The new repurchase program terminates on June 30, 2024, unless extended or shortened by the Board of Directors.

The Company is in the process of notifying holders of the 2018 Senior Notes of the Company's intent to exercise its right to redeem fixed-rate long term debt of $2.5 billion due 2023 in full together with unpaid interest. The Company expects to complete the redemption by the end of 2022 with proceeds from the M&M Transaction.

Intended Rogers Acquisition

On November 1, 2022, the Company announced the termination of the previously announced agreement to acquire the outstanding shares of Rogers Corporation, as DuPont and Rogers have been unable to obtain timely clearance from all the required regulators. DuPont paid Rogers a termination fee of $162.5 million in accordance with the agreement on November 2, 2022, which will be recognized as a charge in the fourth quarter of 2022.

41

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to, and should be read in conjunction with, the interim Consolidated Financial Statements and related notes to enhance the understanding of the Company’s operations and present business environment. Components of management’s discussion and analysis of financial condition and results of operations include:

•Overview

•Result of Operations

•Segment Results

•Changes in Financial Condition

OVERVIEW

DuPont is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life by applying diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, building and construction, healthcare and worker safety.

As of September 30, 2022, the Company has $2.0 billion of working capital and approximately $1.8 billion in cash and cash equivalents. The Company expects its cash and cash equivalents, cash generated from operations, and ability to access the debt capital markets to provide sufficient liquidity and financial flexibility to meet the liquidity requirements associated with its continuing operations.

Outlined below are recent developments and material historical transactions impacting this Quarterly Report on Form 10-Q.

Mobility & Materials Divestitures

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). On February 17, 2022, the Company entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese"). Refer to Note 24 - Subsequent Events for further information. The Company also announced on February 18, 2022 that its Board of Directors approved of the divestiture of the Delrin® acetal homopolymer (H-POM) business (the "Delrin® Divestiture"), subject to entry into a definitive agreement and satisfaction of closing conditions. The Delrin® Divestiture together with the M&M Divestiture discussed above (the "M&M Divestitures") represent a strategic shift that will have a major impact on DuPont's operations and results.

The financial position of DuPont as of September 30, 2022 and December 31, 2021 present the businesses to be divested as part of the M&M Divestiture and the Delrin® Divestiture (the "M&M Businesses") as assets and liabilities held for sale, presented as discontinued operations. The results of operations for the three and nine months ended September 30, 2022 and 2021 present the financial results of the M&M Businesses as discontinued operations. The cash flows and comprehensive income of the M&M Businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of the M&M Businesses. See Note 4 to the interim Consolidated Financial Statements for additional information.

The Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines, previously reported within the historic Mobility & Materials segment, (the "Retained Businesses") are not included in the scope of the M&M Divestitures. Effective with the signing of the Transaction Agreement, the Retained Businesses were realigned to Corporate & Other. The reporting changes have been retrospectively applied for all periods presented.

42

Recent Developments

Macroeconomic Conditions

Certain macroeconomic factors, including the inflationary cost environment and supply chain disruptions, along with the novel coronavirus (“COVID-19”) and its variants, continue to adversely impact the global economy, including certain suppliers of the Company’s key raw materials. As a result of COVID-19, the Company qualified for a tax credit of payroll taxes under the Employee Retention Credit (“ERC”) pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act and American Rescue Plan Act. In the third quarter of 2022, the Company recorded approximately $59 million of benefit to the ERC for full year 2020 and Q1 2021 payroll taxes previously paid. The benefit was recorded as an offset to the Cost of Sales, Research and Development Expenses ("R&D") and Selling, General and Administrative Expenses ("SG&A"), with a portion, approximately $7 million, of the benefit relating to discontinued operations. The Company anticipates receiving a refund of the credit in 2023.

Within the third quarter of 2022, while end-market demand remained strong, the Company experienced rising costs of raw materials, logistic and energy due to inflationary pressures, rising interest rates and foreign currency impacts, particularly in EMEA. At this time, the Company is not able to predict the extent to which these macroeconomic events may impact its consolidated results of operations or financial condition. In addition, the Company is assessing the recently announced US regulations covering the export of semiconductor materials into China and is monitoring developments to determine the potential impact of these regulations to the Semiconductor business.

The Inflation Reduction Act of 2022 ("IRA") was signed into law on August 16, 2022. The IRA introduces a new 15% corporate minimum tax, based on adjusted financial statement income of certain large corporations. Applicable corporations would be allowed to claim a credit for the minimum tax paid against regular tax in future years. While this tax law change does not have an immediate effect, the Company will continue to evaluate its impact as further information becomes available. The Inflation Reduction Act also includes an excise tax that would impose a 1% surcharge on stock repurchases, effective January 1, 2023.

Russia, Belarus, Ukraine

With respect to the war in the Ukraine, the Company’s business and operational environment is impacted by, among other things, responsive governmental actions including sanctions imposed by the U.S. and other governments. In the second quarter of 2022, the Company exited substantially all business operations in Russia, the net sales from which are less than one percent of DuPont’s consolidated net sales in 2021. The Company does not have operations in the Ukraine. DuPont has experienced supply chain challenges and increased logistics, raw material and energy costs due in part to the negative impact on the global economy from the ongoing war in Ukraine. The extent to which the conflict may continue to impact DuPont in future periods will depend on future developments, including the severity and duration of the conflict, its impact on regional and global economic conditions, and the extent of supply chain disruptions. DuPont will continue to monitor the conflict and assess the related sanctions and other effects and may take further actions if necessary.

Dividends

On June 30, 2022, the Company announced that its Board declared a third quarter dividend of $0.33 per share paid on September 15, 2022, to shareholders of record on July 29, 2022.

On October 19, 2022, the Company announced that its Board declared a fourth quarter dividend of $0.33 per share payable on December 15, 2022, to shareholders of record on November 30, 2022.

Laird Acquisition

On July 1, 2021, the Company completed the acquisition of Laird Performance Materials ("Laird PM") from Advent International. The Company paid for the acquisition from existing cash balances. See Note 3 to the interim Consolidated Financial Statements and “Liquidity and Capital Resources” for more information.

N&B Transaction

On February 1, 2021, the Company completed the divestiture of the Nutrition & Biosciences (“N&B”) business to International Flavors & Fragrance Inc. (“IFF”). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”).

43

The results of operations of DuPont for the three and nine months ended September 30, 2021 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable periods. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B. See Note 4 to the interim Consolidated Financial Statements for additional information on the N&B Transaction.

RESULTS OF OPERATIONS

Summary of Sales Results	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Net sales	$	3,317	$	3,199	$	9,913	$	9,320

The following table summarizes sales variances by segment and geographic region from the prior year:

Sales Variances by Segment and Geographic Region
Percentage change from prior year	Three Months Ended September 30, 2022										Nine Months Ended September 30, 2022
	Local Price & Product Mix		Currency		Volume		Portfolio & Other		Total		Local Price & Product Mix		Currency		Volume		Portfolio & Other		Total
Electronics & Industrial	3	%	(4)	%	4	%	—	%	3	%	2	%	(3)	%	6	%	7	%	12	%
Water & Protection	13		(5)		2		—		10		12		(3)		(1)		—		8
Corporate & Other 1	10		(4)		5		(30)		(19)		10		(3)		—		(27)		(20)
Total	8	%	(4)	%	3	%	(3)	%	4	%	7	%	(3)	%	2	%	—	%	6	%
U.S. & Canada	12	%	—	%	7	%	(5)	%	14	%	12	%	—	%	5	%	(2)	%	15	%
EMEA 2	9		(10)		(3)		(4)		(8)		9		(8)		(1)		(1)		(1)
Asia Pacific	5		(5)		2		(2)		—		3		(3)		2		1		3
Latin America	12		—		15		(2)		25		9		—		8		1		18
Total	8	%	(4)	%	3	%	(3)	%	4	%	7	%	(3)	%	2	%	—	%	6	%

1.Corporate & Other includes activities of the Retained Businesses and previously divested businesses Biomaterials, Clean Technologies and Solamet®.

2.Europe, Middle East and Africa.

The Company reported net sales for the three months ended September 30, 2022 of $3.3 billion, up 4 percent from $3.2 billion for the three months ended September 30, 2021, due to an 8 percent increase in local price and product mix, a 3 percent increase in volume, partially offset by a 3 percent decrease in portfolio actions and a 4 percent unfavorable currency impact. Local price and product mix increased across all operating segments, including within Water & Protection (up 13 percent), Electronics & Industrial (up 3 percent) and Corporate & Other (up 10 percent). Local price and product mix increased across all regions. Volume also increased across each segment with Electronics & Industrial (up 4 percent), Water & Protection (up 2 percent) and Corporate & Other (up 5 percent). Portfolio and other changes declined 3 percent driven by Corporate & Other (down 30 percent) due to the sale of the Biomaterials and Clean Technologies businesses. Currency was down 4 percent compared with the same period last year, primarily driven by the weakening of the euro against the U.S. dollar in EMEA (down 10 percent).

Net sales for the nine months ended September 30, 2022 were $9.9 billion, up 6 percent from $9.3 billion for the nine months ended September 30, 2021, due to a 7 percent increase in local price and product mix, a 2 percent increase in volume, partially offset by a 3 percent unfavorable currency impact. Local price and product mix increased across all operating segments, including within Water & Protection (up 12 percent), Electronics & Industrial (up 2 percent) and Corporate & Other (up 10 percent). Local price and product mix increased across all regions. Volume increase was driven by Electronics & Industrial (up 6 percent), partially offset by Water & Protection (down 1 percent), and Corporate & Other was flat. Portfolio and other in total was flat, however, the addition of Laird PM in Electronics & Industrial (up 7 percent) was offset by declines within Corporate & Other (down 27 percent) due to the sale of the Biomaterials, Clean Technologies and Solamet® businesses. Currency was down 3 percent compared with the same period last year, primarily driven by the weakening of the euro against the U.S. dollar in EMEA (down 8 percent).

44

Cost of Sales

Cost of sales was $2.1 billion for the three months ended September 30, 2022, up from $2.0 billion for the three months ended September 30, 2021. Cost of sales increased for the three months ended September 30, 2022 primarily due to increased sales volume, higher raw materials costs and higher logistics and energy costs, partially offset by a payroll tax credit recognized under the ERC of the CARES Act.

Cost of sales as a percentage of net sales for the three months ended September 30, 2022 was 63 percent compared with 64 percent for the three months ended September 30, 2021.

For the nine months ended September 30, 2022, cost of sales was $6.4 billion, up from $5.9 billion for the nine months ended September 30, 2021. Cost of sales increased for the nine months ended September 30, 2022 primarily due to increased sales volume, currency impacts, and higher raw materials and higher logistics and energy costs, partially offset by a payroll tax credit recognized under the ERC of the CARES Act.

Cost of sales as a percentage of net sales for the nine months ended September 30, 2022 was 64 percent compared with 63 percent for the nine months ended September 30, 2021.

Research and Development Expenses ("R&D")

R&D expenses totaled $129 million in the third quarter of 2022, down from $137 million in the third quarter of 2021. This slight decrease was due to a payroll tax credit recognized under the ERC of the CARES Act. R&D as a percentage of net sales was consistent period over period at 4 percent for the three months ended September 30, 2022 and 2021.

For the first nine months of 2022, R&D expenses totaled $413 million up from $409 million in the first nine months of 2021. R&D as a percentage of net sales was consistent period over period at 4 percent for the nine months ended September 30, 2022 and 2021.

Selling, General and Administrative Expenses ("SG&A")

SG&A expenses were $356 million in the third quarter of 2022, down from $411 million in the third quarter of 2021. SG&A as a percentage of net sales was 11 percent and 13 percent for the three months ended September 30, 2022 and 2021, respectively. The decline for the three months ended September 30, 2022 as compared with the same period of the prior year was primarily due to currency fluctuations, lower personnel related expenses and a payroll tax credit recognized under the ERC of the CARES Act.

For the first nine months of 2022, SG&A expenses totaled $1,130 million, down from $1,201 million in the first nine months of 2021. SG&A as a percentage of net sales was 11 percent and 13 percent for the nine months ended September 30, 2022 and 2021, respectively. The decline for the nine months ended September 30, 2022 as compared with the same period of the prior year was primarily due to currency fluctuations, lower personnel related expenses and a payroll tax credit recognized under the ERC of the CARES Act.

Amortization of Intangibles

Amortization of intangibles was $146 million in the third quarter of 2022, down from $158 million in the third quarter of 2021. The decrease for the three months ended September 30, 2022 as compared with the same period of the prior year was primarily due to currency fluctuations.

In the first nine months of 2022, amortization of intangibles was $447 million, up from $410 million in the same period of the prior year. The increase for the nine months ended September 30, 2022 as compared with the same period of the prior year was primarily due to the amortization of the intangible assets acquired in the July 1, 2021 Laird PM acquisition.

Restructuring and Asset Related Charges - Net

Restructuring and asset related charges - net were zero in the third quarter of 2022, down from $1 million in the third quarter of 2021. The activity in the third quarter of 2021 is related to the 2020 Restructuring Program.

In the first nine months of 2022, restructuring and asset related charges - net were $101 million, up from $8 million in the same period last year. The activity for the nine months of 2022 includes a $94 million impairment charge related to an equity method investment. The activity for the nine months of 2021 is primarily related to the 2020 Restructuring Program.

See Note 6 to the interim Consolidated Financial Statements for additional information.

45

Acquisition, Integration and Separation Costs

Acquisition, integration and separation costs were $7 million in the third quarter of 2022, down from $29 million in the third quarter of 2021. In the first nine months of 2022, acquisition, integration and separation costs were $28 million, down from $58 million in the same period of the prior year. Acquisition, integration and separation costs primarily consist of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees. For the three and nine months ended September 30, 2022 these costs were primarily related to the divestiture of the Biomaterials business unit, the 2021 acquisition of Laird PM and the Intended Rogers Acquisition. Comparatively, for the three and nine months ended September 30, 2021 these costs were primarily associated with the acquisition of Laird PM and the divestitures of the Biomaterials, Clean Technologies and Solamet® business units. See Note 3 to the interim Consolidated Financial Statements for additional information.

Separation costs associated with the M&M Divestitures are reported within "Income from discontinued operations, net of tax" in the interim Consolidated Statements of Operations. See Note 4 to the interim Consolidated Financial Statements for additional information.

Equity in Earnings of Nonconsolidated Affiliates

The Company's share of the earnings of nonconsolidated affiliates was $16 million in the third quarter of 2022, down from $22 million in the third quarter of 2021. In the first nine months of 2022, the Company's share of the earnings of nonconsolidated affiliates was $62 million, down from $65 million in the first nine months of 2021. The decrease is primarily due to lower equity earnings across the portfolio in the third quarter of 2022.

Sundry Income (Expense) - Net

Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post-employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the third quarter of 2022 was income of $26 million compared with income of $1 million in the third quarter of 2021. The third quarter of 2022 primarily included income related to non-operating pension and other post-employment benefit credits of $7 million, interest income of $5 million, a $6 million adjustment to gain on prior divestitures and foreign currency exchange gains of $5 million. The third quarter of 2021 primarily included benefits related to non-operating pension and other post-employment benefit credits of $9 million, and adjustments to previous gains on divestiture and sales of other assets of $8 million, partially offset by foreign currency exchange losses of $19 million.

In the first nine months of 2022, sundry income (expense) - net was income of $123 million compared with income of $155 million. The first nine months of 2022 primarily included benefits related to income related to non-operating pension and other post-employment benefit credits of $20 million, miscellaneous income of $11 million, foreign currency exchange gains of $9 million and net gain on the sale of the Biomaterials division of $26 million and $37 million related to the sale of a land use right within the Water & Protection segment. The first nine months of 2021 included benefits related to the sale of assets within Corporate & Other and the Electronics & Industrial segment of $140 million and $28 million, respectively, and income related to non-operating pension and other post-employment benefit credits of $22 million, partially offset by miscellaneous expenses of $17 million and foreign currency exchange losses of $35 million.

Interest Expense

Interest expense was $128 million and $115 million for the three months ended September 30, 2022 and 2021, respectively. Interest expense was $370 million and $390 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in interest expense for the three months ended September 30, 2022 compared to the same period of the prior year primarily relates to increased commercial paper borrowing and intra-quarter borrowing on the 364-day Revolving Credit Facility. The decrease in interest expense nine months ended September 30, 2022 compared to the same period of the prior year primarily relates to the reduction in long-term debt following the N&B Transaction, specifically the early repayment of the $3.0 billion Term Loan Facilities in February 2021 and the redemption of the May 2020 Notes completed in May 2021. Refer to Note 15 to the interim Consolidated Financial Statements for additional information.

46

Provision for Income Taxes on Continuing Operations

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate on continuing operations for the third quarter of 2022 was 27.9 percent, compared with an effective tax rate of 23.6 percent for the third quarter of 2021. The effective tax rate differential for the third quarter of 2022 was driven by the cumulative impact of currency fluctuation and the geographic mix of earnings. The effective tax rate differential for the second quarter of 2021 included a $12 million tax benefit relating to the impact of changes in tax law enacted during the quarter. For the first nine months of 2022, the effective tax rate on continuing operations was 23.8 percent, compared with 14.2 percent for the first nine months of 2021. The effective tax rate for the third quarter and for the first nine months of 2021 was principally the result of a $59 million tax benefit related to the step-up in tax basis in the goodwill of the Company's European regional headquarters legal entity.

SEGMENT RESULTS

Effective February 2022, the revenues and certain expenses of the M&M Businesses were classified as discontinued operations in the current and historical periods. The Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines within the historic Mobility & Materials segment (the "Retained Businesses") are not in the scope of the M&M Divestitures. Effective with the signing of the Transaction Agreement, the Retained Businesses were realigned to Corporate & Other. The reporting changes have been retrospectively reflected for all periods presented.

The Mobility & Material Businesses costs that are classified as discontinued operations include only direct operating expenses incurred by the M&M Businesses which the Company will cease to incur upon the close of the M&M Divestitures. Indirect costs, such as those related to corporate and shared service functions previously allocated to the M&M Businesses, do not meet the criteria for discontinued operations and remain reported within continuing operations. A portion of these indirect costs include costs related to activities the Company will continue to undertake post-closing of the M&M Divestiture, and for which it will be reimbursed (“Future Reimbursable Indirect Costs”). Future Reimbursable Indirect Costs are reported within continuing operations but are excluded from operating EBITDA as defined below. The remaining portion of these indirect costs are not subject to future reimbursement (“Stranded Costs”). Stranded Costs are reported within continuing operations in Corporate & Other and are included within Operating EBITDA.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, and adjusted for significant items. Reconciliations of these measures can be found in Note 23 to the interim Consolidated Financial Statements.

47

ELECTRONICS & INDUSTRIAL

The Electronics & Industrial segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication and packaging of semiconductors and integrated circuits and provides innovative solutions for thermal management and electromagnetic shielding as well as metallization processes for metal finishing, decorative, and industrial applications. Electronics & Industrial is a leading provider of platemaking systems and photopolymer plates for the packaging graphics industry, digital printing inks and cutting-edge materials for the manufacturing of displays for organic light emitting diode. In addition, the segment produces innovative engineering polymer solutions, high performance parts, medical silicones and specialty lubricants.

Electronics & Industrial	Three Months Ended				Nine Months Ended
In millions	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021
Net sales	$	1,511	$	1,467	$	4,574	$	4,087
Operating EBITDA	$	473	$	475	$	1,429	$	1,335
Equity earnings	$	7	$	13	$	26	$	32

Electronics & Industrial	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2022		September 30, 2022
Change in Net Sales from Prior Period due to:
Local price & product mix	3	%	2	%
Currency	(4)		(3)
Volume	4		6
Portfolio & other	—		7
Total	3	%	12	%

Electronics & Industrial net sales were $1,511 million for the three months ended September 30, 2022, up 3 percent from $1,467 million for the three months ended September 30, 2021. Net sales increased due to a 4 percent increase in volume and a 3 percent increase in local price, partially offset by 4 percent unfavorable currency impact. Volume growth was led by Semiconductor Technologies which was driven by continued transition to more advanced node technologies and high performance computing, including cloud and data centers. Volume gains in Industrial Solutions were driven by growth in electronics applications, healthcare and aerospace markets. Within Interconnect Solutions, volume gains in industrial-end markets and for applications requiring electromagnetic shieldingg and thermal management were more than offset by declines in smartphones, consumer electronics and automotive markets.

Operating EBITDA was $473 million for the three months ended September 30, 2022, which remained flat compared with $475 million for the three months ended September 30, 2021. Volume growth and price gains were offset by higher raw materials logistic and energy costs and lower equity earnings.

Electronics & Industrial net sales were $4,574 million for the nine months ended September 30, 2022, up 12 percent from $4,087 million for the nine months ended September 30, 2021. Net sales increased due to a 7 percent increase in portfolio, a 6 percent increase in volume and a 2 percent increase in local price, partially offset by 3 percent unfavorable currency impact. The portfolio impact reflects the July 1, 2021 acquisition of Laird PM. Volume growth was led by Semiconductor Technologies which was driven by transition to more advanced node technologies, growth in high performance computing and 5G communications. Within Industrial Solutions, volume gains were driven by higher demand in healthcare and industrial-end markets as well as continued strength in electronics applications. Within Interconnect Solutions, volume gains driven by Laird acquisition and higher demand in industrial films, were more than offset by weakness in consumer electronics, smartphones, and automotive.

Operating EBITDA was $1,429 million for the nine months ended September 30, 2022, up 7 percent compared with $1,335 million for the nine months ended September 30, 2021 driven by strong volume growth and price gains, the acquisition of Laird PM, partially offset by higher raw materials and logistics costs and higher plant start up costs.

48

WATER & PROTECTION

The Water & Protection segment is a leading provider of engineered products and integrated systems for a number of industries including worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.

Water & Protection	Three Months Ended				Nine Months Ended
In millions	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021
Net sales	$	1,534	$	1,397	$	4,460	$	4,137
Operating EBITDA	$	382	$	353	$	1,071	$	1,060
Equity earnings	$	9	$	7	$	31	$	27

Water & Protection	Three Months Ended		Nine Months Ended
Percentage change from prior year	September 30, 2022		September 30, 2022
Change in Net Sales from Prior Period due to:
Local price & product mix	13	%	12	%
Currency	(5)		(3)
Volume	2		(1)
Portfolio & other	—		—
Total	10	%	8	%

Water & Protection net sales were $1,534 million for the three months ended September 30, 2022, up 10 percent from $1,397 million for the three months ended September 30, 2021. Net sales increased due to a 13 percent increase in local price and a 2 percent increase in volume, partially offset by a 5 percent unfavorable currency impact. Local price & product mix gains were driven by broad-based actions across all lines of business to offset continued cost inflation, led by Shelter Solutions and Safety Solutions. Volume growth was driven by strong global demand across all technologies within Water Solutions.

Operating EBITDA was $382 million for the three months ended September 30, 2022, up 8 percent compared with $353 million for the three months ended September 30, 2021 driven by volume increases and pricing gains which together more than offset higher raw material, logistics and energy costs, changes in product mix and unfavorable currency impacts.

Water & Protection net sales were $4,460 million for the nine months ended September 30, 2022, up 8 percent from $4,137 million for the nine months ended September 30, 2021. Net sales increased due to a 12 percent increase in local price, partially offset by a 3 percent unfavorable currency impact and a 1 percent decrease in volume. Demand in Shelter Solutions residential commercial construction markets as well as increased demand for water technologies within Water Solutions were offset by volume declines in Safety Solutions. Within Water & Protection pricing actions throughout the segment were driven by Shelter Solutions and Safety Solutions.

Operating EBITDA was $1,071 million for the nine months ended September 30, 2022, up 1 percent compared with $1,060 million for the nine months ended September 30, 2021 as pricing actions were partially offset by higher raw material, logistics and energy costs, as well as product mix and unfavorable currency impacts.

49

Corporate & Other

Corporate & Other includes sales and activity of the Retained Businesses including the Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines, previously reported in the historic Mobility & Materials segment. Related to the M&M Divestitures, Corporate & Other includes Stranded Costs and Future Reimbursable Indirect Costs. The results of Corporate & Other include the sales and activity of previously divested businesses including the operations of Biomaterials, Clean Technologies, and Solamet® business units. Corporate & Other also includes certain enterprise and governance activities including non-allocated corporate overhead costs and support functions, leveraged services, non-business aligned litigation expenses and other costs not absorbed by reportable segments.

Corporate & Other	Three Months Ended				Nine Months Ended
In millions	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021
Net sales	$	272	$	335	$	879	$	1,096
Operating EBITDA	$	1	$	(11)	$	3	$	5
Equity earnings	$	—	$	2	$	5	$	6

Corporate & Other net sales were $272 million for the three months ended September 30, 2022, down from $335 million for the three months ended September 30, 2021. Net sales primarily decreased due to the divestitures of the Biomaterials business in May 2022 and the Clean Technologies business in December 2021.

Corporate & Other net sales were $879 million for the nine months ended September 30, 2022, down from $1,096 million for the nine months ended September 30, 2021. Net sales primarily decreased due to the divestitures of the Biomaterials, Clean Technologies and Solamet® businesses, partially offset by an increase in the net sales of the Retained Businesses.

50

CHANGES IN FINANCIAL CONDITION

Liquidity & Capital Resources

Information related to the Company's liquidity and capital resources can be found in the Company's 2021 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the nine months ended September 30, 2022.

The Company continually reviews its sources of liquidity and debt portfolio and may make adjustments to one or both to ensure adequate liquidity and increase the Company’s optionality and financing efficiency as it relates to financing cost and balancing terms/maturities. The Company’s primary source of incremental liquidity is cash flows from operating activities. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries' obligations as they come due.

In millions	September 30, 2022		December 31, 2021
Cash and cash equivalents	$	1,785	$	1,972
Total debt	$	11,851	$	10,782

The Company's cash and cash equivalents at September 30, 2022 and December 31, 2021 were $1.8 billion and $2.0 billion, respectively, of which $1.5 billion at September 30, 2022 and $1.4 billion at December 31, 2021 were held by subsidiaries in foreign countries, including United States territories. The increase in cash and cash equivalents held by subsidiaries in foreign countries is due to operating cash flows during the period partly offset by repatriation activities. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States.

Total debt at September 30, 2022 and December 31, 2021 was $11.9 billion and $10.8 billion, respectively. The increase was primarily due to the increase in commercial paper issuances.

As of September 30, 2022, the Company is contractually obligated to make future cash payments of $10.7 billion and $5.7 billion associated with principal and interest, respectively, on debt obligations assuming held to maturity. Related to the principal balance, all payments will be due subsequent to December 31, 2022. Related to interest, $514 million will be due in the next twelve months and the remainder will be due subsequent to September 30, 2023. On November 8, 2022, the Company announced its intent to redeem $2.5 billion of 2018 Senior Notes by the end of 2022. Refer to Note 24 - Subsequent Events for additional information.

Revolving Credit Facilities

On April 12, 2022, the Company entered into a new $2.5 billion five-year revolving credit facility (the "Five-Year Revolving Credit Facility"). As of the effectiveness of the Five-Year Revolving Credit Facility, the Company's prior $3 billion five-year revolving credit facility entered in May 2019 was terminated. All material conditions and covenants in the Five-Year Revolving Credit Facility are consistent with those of the prior, terminated credit facility. The Five-Year Revolving Credit Facility is generally expected to remain undrawn and serve as a backstop to the Company’s commercial paper and letter of credit issuance.

On April 12, 2022, the Company entered into an updated $1.0 billion 364-day revolving credit facility (the “2022 $1B Revolving Credit Facility") as the $1.0 billion 364-day revolving credit facility entered in April 2021 (the “2021 $1B Revolving Credit Facility") had an expiration date in mid-April. As of the effectiveness of the 2022 $1B Revolving Credit Facility, the 2021 $1B Revolving Credit Facility was terminated. The 2022 $1B Revolving Credit facility may be used for general corporate purposes.

In July 2022, the Company drew down $600 million under the 364-day Revolving Credit Facility in order to facilitate certain intercompany internal restructuring steps related to the M&M Divestiture. The Company repaid the borrowing in September 2022.

Special Cash Payment

In connection with and in accordance with the terms of the N&B Transaction, prior to consummation of the Exchange Offer and the N&B Merger, DuPont received a one-time cash payment of approximately $7.3 billion, (the "Special Cash Payment") pursuant to the terms of the N&B Separation and Distribution Agreement. The Company utilized the Special Cash Payment to repay the $3 billion Term Loan Facilities and used a portion of the Special Cash Payment to redeem the May 2020 Notes, as discussed below.

51

Term Loan Facilities

On February 1, 2021, the Company terminated its fully drawn $3 billion term loan facilities. The termination triggered the repayment of the aggregate outstanding principal amount of $3 billion, plus accrued and unpaid interest through and including January 31, 2021. The Company funded the repayment with proceeds from the Special Cash Payment.

May 2020 Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “May 2020 Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May 2020 Debt Offering”). Upon consummation of the N&B Transaction, the special mandatory redemption feature of the May 2020 Debt Offering was triggered, requiring the Company to redeem all of the May 2020 Notes at a redemption price equal to 100% of the aggregate principal amount of the May 2020 Notes plus accrued and unpaid interest. The Company redeemed the May 2020 Notes on May 13, 2021 and funded the redemption with proceeds from the Special Cash Payment.

Laird Performance Materials

On July 1, 2021, the Company completed the acquisition of Laird PM from Advent International for aggregate consideration of $2.4 billion, which reflects adjustments, including for acquired cash and net working capital. The acquisition is part of the Interconnect Solutions business within the Electronics & Industrial segment. The Company paid for the acquisition from existing cash balances.

Intended Rogers Acquisition

In connection with the Intended Rogers Acquisition, on November 22, 2021, the Company entered into a two-year senior unsecured committed term loan agreement in the amount of $5.2 billion. In October 2022, the facility was amended to extend the lending commitment (as amended the "Amended 2021 Term Loan Facility"). On November 1, 2022, the M&M Divestiture closed and therefore based on the terms of the Amended 2021 Term Loan Facility the commitment was terminated. Refer to Note 24 - Subsequent Events for additional information.

The Amended 2021 Term Loan Facility, the Five-Year Revolving Credit Facility, the 2022 $1B Revolving Credit Facilities and the revolving credit facilities entered into in 2022 contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2022, the Company was in compliance with this financial covenant.

Credit Ratings

The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to maintaining a strong financial position with a balanced financial policy focused on maintaining a strong investment-grade rating and driving shareholder value and remuneration. At November 4, 2022, DuPont's credit ratings were as follows:

Credit Ratings	Long-Term Rating	Short-Term Rating	Outlook
Standard & Poor’s	BBB+	A-2	Stable
Moody’s Investors Service	Baa1	P-2	Negative
Fitch Ratings	BBB+	F-2	Stable

The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subject to certain limitations. The senior unsecured notes (the "2018 Senior Notes") also contain customary default provisions. The Amended 2021 Term Loan Facility, the Five-Year Revolving Credit Facility, the 2022 $1B Revolving Credit Facilities and the revolving credit facilities entered into in 2022 contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2022, the Company was in compliance with this financial covenant.

52

Summary of Cash Flows

The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to N&B and the M&M Divestitures have not been segregated and are included in the interim Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021, as applicable.

Cash Flow Summary	Nine Months Ended
In millions	September 30, 2022		September 30, 2021
Cash provided by (used for):
Operating activities	$	714	$	1,660
Investing activities	$	(185)	$	(2,727)
Financing activities	$	(480)	$	(5,921)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	$	(191)	$	(49)

Cash Flows from Operating Activities

In the first nine months of 2022, cash provided by operating activities was $714 million, compared with $1,660 million in the same period last year. The decrease in cash provided by operating activities was primarily due to an increase in the use of cash related to net working capital and an increase in the credit for deferred income tax and other tax related items.

The table below reflects net working capital on a continuing operations basis:

Net Working Capital 1	September 30, 2022		December 31, 2021
In millions (except ratio)
Current assets	$	6,617	$	6,639
Current liabilities	4,622		3,518
Net working capital	$	1,995	$	3,121
Current ratio	1.43:1		1.89:1

1.Net working capital has been presented to exclude the assets and liabilities related to the M&M Divestitures. The assets and liabilities related to the M&M Divestitures are presented as assets of discontinued operations and liabilities of discontinued operations, respectively.

Cash Flows from Investing Activities

In the first nine months of 2022, cash used for investing activities was $185 million, compared with cash used for investing activities of $2,727 million in the first nine months of 2021.The decrease in cash usage was primarily attributable to a decrease in capital expenditures and a decrease in the acquisition of property and businesses, net of cash divested.

Cash Flows from Financing Activities

In the first nine months of 2022, cash used for financing activities was $480 million compared with cash used for financing activities of $5,921 million in the same period last year. The decrease in cash used for financing activities is primarily attributable to the absence of long-term debt reduction in the current period compared to the prior year period, which included the $2 billion redemption of the May 2020 Notes and repayment of the $3 billion term loan, as well as a decrease in repurchases of common stock versus the prior year period.

Dividends

On June 30, 2022, the Company announced that its Board declared a third quarter dividend of $0.33 per share payable on September 15, 2022, to shareholders of record on July 29, 2022.

On April 21, 2022, the Board of Directors declared a second quarter dividend of $0.33 per share, which was paid on June 15, 2022, to shareholders of record on May 31, 2022.

On February 7, 2022, the Board of Directors declared a first quarter 2022 dividend of $0.33 per share, paid on March 15, 2022, to shareholders of record on February 28, 2022.

On October 19, 2022, the Company announced that its Board declared a fourth quarter dividend of $0.33 per share payable on December 15, 2022, to shareholders of record on November 30, 2022.

53

Share Buyback Programs

In February 2022, the Company's Board of Directors authorized $1.0 billion share buyback program which expires on March 31, 2023, (the "2022 Share Buyback Program"). During the third quarter, the Company repurchased and retired 4.3 million shares for $250 million under this program. As of September 30, 2022, the Company repurchased and retired a total of 11.9 million shares for $750.0 million under the 2022 Share Buyback Program. Refer to Note 24 - Subsequent Events for additional information on the share repurchase programs.

In the first quarter of 2021, the Company's Board of Directors authorized a $1.5 billion share buyback program, which expired on June 30, 2022 ("2021 Share Buyback Program"). At the expiry of the 2021 Share Buyback Program, the Company had repurchased and retired a total of 19.6 million shares for $1.5 billion.

On June 1, 2019, the Company's Board of Directors authorized a $2.0 billion share buyback program, which expired on June 1, 2021 ("2019 Share Buyback Program"). At the expiry of the 2019 Share Buyback Program, the Company had completed the 2019 Share Buyback Program having repurchased and retired a total cost of 29.9 million shares at a cost of $2.0 billion.

See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.

Pension and Other Post-Employment Plans

DuPont expects to make additional contributions in the aggregate of approximately $35 million by year-end 2022 to pension and other post-employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.

Restructuring

In October 2021, the Company approved targeted restructuring actions to capture near term cost reductions (the "2021 Restructuring Actions"). As a result of these actions, the Company has recorded pre-tax restructuring charges of $55 million inception to date, comprised of $33 million of severance and related benefit costs and $22 million of asset related charges. At September 30, 2022, total liabilities related to the 2021 Restructuring Actions were $17 million for severance and related benefits. Actions related to the 2021 Restructuring Program are substantially complete.

In March 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company recorded pre-tax restructuring charges of $159 million inception-to-date, consisting of severance and related benefit costs of $107 million and asset related charges of $52 million. Actions associated with the 2020 Restructuring Program are considered substantially complete. Future cash payments related to the 2020 Restructuring Program are anticipated to be $2 million primarily related to the payment of severance and related benefits.

Subsequent to the period end, in October 2022, the Company approved targeted restructuring actions to capture near term cost reductions. The Company expects to incur costs of up to $125 million primarily related to the payment of severance and asset related charges, which will begin in the fourth quarter of 2022 and are expected to be substantially complete by the end of 2023.

See Note 6 to the interim Consolidated Financial Statements for more information on the Company's restructuring programs.

54

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Note 21 to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the Company's 2021 Annual Report on Form 10-K for information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of September 30, 2022, the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

55

DuPont de Nemours Inc.
PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company and its subsidiaries are subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 16 to the interim Consolidated Financial Statements.

Litigation

See Note 16 to the interim Consolidated Financial Statements.

Environmental Proceedings

The Company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The description is included per Regulation S-K, Item 103(c) of the Securities Exchange Act of 1934.

Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection

In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. EID sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. Subsequent to this inspection, the U.S. Environmental Protection Agency (“EPA”), the U.S. Department of Justice (“DOJ”), the Louisiana Department of Environmental Quality (“DEQ”), the Company (originally through EID), and Denka began discussions in the spring of 2017 relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. DuPont, Denka, EPA, DOJ and DEQ are continuing these discussions, which include potential settlement options.

New Jersey Directive PFAS

On March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Directive and Notice to Insurers to a number of companies, including Chemours, DowDuPont, EID, and certain DuPont subsidiaries. NJDEP’s allegations relate to former operations of EID involving poly- and perfluoroalkyl substances, (“PFAS”), including PFOA and PFOA- replacement products. The NJDEP seeks past and future costs of investigating, monitoring, testing, treating, and remediating New Jersey’s drinking water and waste systems, private drinking water wells and natural resources including groundwater, surface water, soil, sediments and biota. The Directive seeks certain information as to future costs and information related to the historic uses of PFAS and replacement chemicals including “information ranging from use and discharge of the chemicals through wastewater treatment plants, air emissions, and sales of products containing the chemicals to current development, manufacture, use and release of newer chemicals in the state.”

56

ITEM 1A. RISK FACTORS

Other than the risk factor set forth below, there have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s 2021 Annual Report on Form 10-K for the year ended December 31, 2021.

DuPont could incur additional tax liabilities if certain internal transactions undertaken in connection with the completed divestiture of a majority of its historic Mobility & Materials segment to Celanese, and in connection with DuPont’s pursuit of plans to divest the Delrin® acetal homopolymer business (the “Delrin® Business”), fail to qualify for their intended tax treatment.

On November 1, 2022, DuPont and certain of its subsidiaries completed the sale to Celanese of a majority of the Company’s historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Performance Resins and Advanced Solutions business lines (the “M&M Business”) for $11 billion in cash, subject to customary transaction adjustments in accordance with the Transaction Agreement (the “M&M Divestiture”).

On February 18, 2022, DuPont also announced that its Board of Directors approved the divestiture of the Delrin® Business subject to entry into a definitive agreement and satisfaction of customary closing conditions. There can be no assurance as to the outcome, timing or ability to realize expected benefits from the Delrin® Business divestiture process.

Prior to the Closing of the M&M Divestiture, DuPont engaged in certain internal reorganization activities to separate the M&M Business, and in certain cases in connection therewith, the Delrin® Business, into separate subsidiaries and to align the subsidiaries holding the M&M Business for disposition in a tax-efficient manner. DuPont has recognized a tax liability related to the M&M Divestiture. However, if certain internal transactions related to the separation of the M&M Business and/or of the Delrin® Business fail to qualify for their intended tax treatment under U.S. federal, state, local tax and/or foreign tax law, DuPont could incur additional tax liabilities.

DuPont may not realize the anticipated benefits of its share repurchase programs and any failure to repurchase the Company’s common stock after DuPont has announced its intention to do so may negatively impact the Company’s stock price.

On November 7, 2022, DuPont’s Board of Directors approved a new share repurchase program authorizing the repurchase and retirement of up to $5 billion of common stock. This new repurchase authorization is in addition to the $250 million remaining under the Company’s existing share repurchase program which was approved in February 2022. The Company intends to enter accelerated share repurchase agreements ( “ASR Agreements”) imminently, for the repurchase of an aggregate of $3.25 billion of common stock with $250 million of such repurchases under the existing program and the remaining $3 billion under the new program. new repurchase program terminates on June 30, 2024, unless extended or shortened by the Board of Directors.

Under these or any other future share repurchase programs, DuPont may make share repurchases through a variety of methods, including open share market purchases or privately negotiated transactions, including additional ASR agreements in accordance with applicable federal securities laws. The timing and amount of any repurchases, if any, will on factors such as the stock price, economic and market conditions, and corporate and regulatory requirements. Any failure to repurchase shares after the Company has announced its intention to do so may negatively impact DuPont’s reputation, investor confidence and the price of the Company’s common stock.

The existence of these share repurchase programs could cause the price of the Company’s common stock to be higher than it otherwise would be and could potentially reduce the market liquidity for DuPont stock. Although these programs are intended to enhance long-term stockholder value, there is no assurance they will do so because the market price of DuPont common stock may decline below the levels at which we repurchased shares and short-term stock price fluctuations could reduce the effectiveness of the programs.

Repurchasing common stock will reduce the amount of cash DuPont has available to fund working capital, capital expenditures, strategic acquisitions or business opportunities and other general corporate requirements, and the Company may fail to realize the anticipated benefits of these share repurchase programs.

57

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table provides information regarding purchases of the Company’s common stock by the Company during the three months ended September 30, 2022:

Issuer Purchases of Equity Securities				Total number of shares purchased as part of the Company's publicly announced share repurchase program	Approximate dollar value of shares that may yet be purchased under the Company's publicly announced share repurchase program (In millions)
Period	Total number of shares purchased	Average price paid per share
July	—	$	—	—	$	500
August	2,930,109	60.28		2,930,109	323
September	1,317,416	55.70		1,317,416	250
Third Quarter 2022	4,247,525	$	58.86	4,247,525	$	250

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

58

ITEM 6. EXHIBITS

EXHIBIT NO.	DESCRIPTION
3.1	Third Amended and Restated Certificate of Incorporation of DuPont de Nemours, Inc. incorporated by reference to Exhibit 3.1 to DuPont de Nemours, Inc.’s Current Report on Form 8-K filed April 30, 2021.
3.2	Sixth Amended and Restated Bylaws of DuPont de Nemours, Inc. incorporated by reference to Exhibit 3.1 to DuPont de Nemours, Inc.’s Current Report on Form 8-K filed October 20, 2022.
10.1	Transaction Agreement by and among DuPont de Nemours, Inc., DuPont E&I Holding, Inc. and Celanese Corporation, dated February 17, 2022**†, incorporated by reference to Exhibit 2.1 to the DuPont de Nemours, Inc. Current Report on Form 8-K filed February 22, 2022.
31.1*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

**The Company has omitted certain schedules and other similar attachments to such agreement pursuant to Item 601(a)(5) of

Regulation S-K. The Company will furnish a copy of such omitted documents to the SEC upon request.

†Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

59

DuPont de Nemours, Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DUPONT DE NEMOURS, INC.

Registrant

Date: November 8, 2022

By:	/s/ MICHAEL G. GOSS
Name:	Michael G. Goss
Title:	Vice President and Controller
City:	Wilmington
State:	Delaware

60

EX-31.1

DuPont de Nemours, Inc. EXHIBIT 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Edward D. Breen, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of DuPont de Nemours, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2022

/s/ Edward D. Breen

Edward D. Breen

Chief Executive Officer

60

EX-31.2

DuPont de Nemours, Inc. EXHIBIT 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Lori Koch, certify that:

1.I have reviewed this quarterly report on Form 10-Q of DuPont de Nemours, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2022

/s/ Lori Koch

Lori Koch

Chief Financial Officer

61

EX-32.1

DuPont de Nemours, Inc. EXHIBIT 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Edward D. Breen, Chief Executive Officer of DuPont de Nemours Inc. (the “Company”), certify that:

1.the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward D. Breen

Edward D. Breen

Chief Executive Officer

November 8, 2022

62

EX-32.2

DuPont de Nemours, Inc. EXHIBIT 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Lori Koch, Chief Financial Officer of DuPont de Nemours Inc. (the “Company”), certify that:

1.the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Lori Koch

Lori Koch

Chief Financial Officer

November 8, 2022

63

XML

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38196
Entity Registrant Name	DUPONT DE NEMOURS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1224539
Entity Address, Address Line One	974 Centre Road
Entity Address, Address Line Two	Building 730
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19805
City Area Code	302
Local Phone Number	774-3034
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	DD
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Share Outstanding		496,788,948
Entity Central Index Key	0001666700
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

XML

Consolidated Statements of Operations - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales	$ 3,317,000,000	$ 3,199,000,000	$ 9,913,000,000	$ 9,320,000,000
Cost of sales	2,095,000,000	2,032,000,000	6,354,000,000	5,852,000,000
Research and development expenses	129,000,000	137,000,000	413,000,000	409,000,000
Selling, general and administrative expenses	356,000,000	411,000,000	1,130,000,000	1,201,000,000
Amortization of intangibles	146,000,000	158,000,000	447,000,000	410,000,000
Restructuring and asset related charges - net	0	1,000,000	101,000,000	8,000,000
Acquisition, integration and separation costs	7,000,000	29,000,000	28,000,000	58,000,000
Equity in earnings of nonconsolidated affiliates	16,000,000	22,000,000	62,000,000	65,000,000
Sundry income (expense) - net	26,000,000	1,000,000	123,000,000	155,000,000
Interest expense	128,000,000	115,000,000	370,000,000	390,000,000
Income from continuing operations before income taxes	498,000,000	339,000,000	1,255,000,000	1,212,000,000
Provision for income taxes on continuing operations	139,000,000	80,000,000	299,000,000	172,000,000
Income from continuing operations, net of tax	359,000,000	259,000,000	956,000,000	1,040,000,000
Income from discontinued operations, net of tax	17,000,000	145,000,000	723,000,000	5,249,000,000
Net income	376,000,000	404,000,000	1,679,000,000	6,289,000,000
Net income attributable to noncontrolling interests	9,000,000	13,000,000	37,000,000	26,000,000
Net income available for DuPont common stockholders	$ 367,000,000	$ 391,000,000	$ 1,642,000,000	$ 6,263,000,000
Per common share data:
Earnings per common share from continuing operations - basic (in usd per share)	$ 0.69	$ 0.48	$ 1.81	$ 1.86
Earnings per common share from discontinued operations - basic (in usd per share)	0.05	0.27	1.44	9.49
Earnings per common share - basic (in usd per share)	0.73	0.75	3.25	11.35
Earnings per common share from continuing operations - diluted (in usd per share)	0.69	0.48	1.80	1.86
Earnings per common share from discontinued operations - diluted (in usd per share)	0.05	0.27	1.44	9.46
Earnings per common share - diluted (in usd per share)	$ 0.73	$ 0.75	$ 3.24	$ 11.32
Weighted-average common shares outstanding - basic (in shares)	499.4	521.5	505.6	551.7
Weighted-average common shares outstanding - diluted (in shares)	500.4	523.1	506.9	553.1

XML

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 376	$ 404	$ 1,679	$ 6,289
Other comprehensive (loss) income, net of tax
Cumulative translation adjustments	(837)	(189)	(1,802)	(554)
Pension and other post-employment benefit plans	29	12	21	23
Derivative instruments	42	20	109	38
Split-off of N&B	0	0	0	258
Total other comprehensive loss	(766)	(157)	(1,672)	(235)
Comprehensive (loss) income	(390)	247	7	6,054
Comprehensive income attributable to noncontrolling interests, net of tax	1	12	9	17
Comprehensive (loss) income attributable to DuPont	$ (391)	$ 235	$ (2)	$ 6,037

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 1,785	$ 1,972
Accounts and notes receivable - net	2,257	2,159
Inventories	2,359	2,086
Prepaid and other current assets	216	177
Assets held for sale	0	245
Assets of discontinued operations	7,733	7,664
Total current assets	14,350	14,303
Property, plant and equipment - net of accumulated depreciation (September 30, 2022 - $4,227; December 31, 2021 - $4,142)	5,477	5,753
Other Assets
Goodwill	16,302	16,981
Other intangible assets	5,550	6,222
Restricted cash and cash equivalents	103	53
Investments and noncurrent receivables	779	919
Deferred income tax assets	122	116
Deferred charges and other assets	1,416	1,360
Total other assets	24,272	25,651
Total Assets	44,099	45,707
Current Liabilities
Short-term borrowings	1,287	150
Accounts payable	2,061	2,102
Income taxes payable	284	201
Accrued and other current liabilities	990	1,040
Liabilities related to assets held for sale	0	25
Liabilities of discontinued operations	1,392	1,413
Total current liabilities	6,014	4,931
Long-Term Debt	10,564	10,632
Other Noncurrent Liabilities
Deferred income tax liabilities	464	1,459
Pension and other post-employment benefits - noncurrent	625	762
Other noncurrent obligations	929	873
Total other noncurrent liabilities	2,018	3,094
Total Liabilities	18,596	18,657
Commitments and contingent liabilities
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2022: 496,738,067 shares; 2021: 511,792,785 shares)	5	5
Additional paid-in capital	49,199	49,574
Accumulated deficit	(22,692)	(23,187)
Accumulated other comprehensive (loss) income	(1,603)	41
Total DuPont stockholders' equity	24,909	26,433
Noncontrolling interests	594	617
Total equity	25,503	27,050
Total Liabilities and Equity	$ 44,099	$ 45,707

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 4,227	$ 4,142
Shares authorized (in shares)	1,666,666,667	1,666,666,667
Par value (in usd per share)	$ 0.01	$ 0.01
Shares issued (in shares)	496,738,067	511,792,785

XML

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities
Net income	$ 1,679	$ 6,289
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	906	1,094
Credit for deferred income tax and other tax related items	(977)	(182)
Earnings of nonconsolidated affiliates less than (in excess of) dividends received	10	(41)
Net periodic benefit (credit) cost	(6)	2
Periodic benefit plan contributions	(51)	(62)
Net gain on sales and split-offs of assets, businesses and investments	(73)	(5,117)
Restructuring and asset related charges - net	101	15
Inventory step-up amortization	0	12
Other net loss	39	128
Changes in assets and liabilities, net of effects of acquired and divested companies:
Accounts and notes receivable	(342)	(399)
Inventories	(688)	(515)
Accounts payable	194	379
Other assets and liabilities, net	(78)	57
Cash provided by operating activities	714	1,660
Investing Activities
Capital expenditures	(558)	(707)
Proceeds from sales of property and businesses, net of cash divested	364	285
Acquisitions of property and businesses, net of cash acquired	5	(2,323)
Purchases of investments	(15)	(2,001)
Proceeds from sales and maturities of investments	15	2,001
Other investing activities, net	4	18
Cash used for investing activities	(185)	(2,727)
Financing Activities
Changes in short-term borrowings	1,137	0
Proceeds from credit facility	600	0
Proceeds from issuance of long-term debt transferred to IFF at split-off	0	1,250
Repayment of credit facility	(600)	0
Payments on long-term debt	0	(5,000)
Purchases of common stock	(1,125)	(1,643)
Proceeds from issuance of Company stock	83	110
Employee taxes paid for share-based payment arrangements	(25)	(26)
Distributions to noncontrolling interests	(35)	(34)
Dividends paid to stockholders	(500)	(476)
Cash transferred to IFF and subsequent adjustments	(11)	(100)
Other financing activities, net	(4)	(2)
Cash used for financing activities	(480)	(5,921)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(191)	(49)
Decrease in cash, cash equivalents and restricted cash	(142)	(7,037)
Cash, cash equivalents and restricted cash from continuing operations, beginning of period	2,037	8,733
Cash, cash equivalents and restricted cash from discontinued operations, beginning of period	39	42
Cash, cash equivalents and restricted cash at beginning of period	2,076	8,775
Cash, cash equivalents and restricted cash from continuing operations, end of period	1,896	1,700
Cash, cash equivalents and restricted cash from discontinued operations, end of period	38	38
Cash, cash equivalents and restricted cash at end of period	$ 1,934	$ 1,738

XML

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comp Loss	Treasury Stock	Non-controlling Interests
Beginning balance at Dec. 31, 2020	$ 39,070	$ 7	$ 50,039	$ (11,586)	$ 44	$ 0	$ 566
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,289			6,263			26
Other comprehensive loss	(235)				(226)		(9)
Dividends	(476)		(476)
Common stock issued/sold	110		110
Stock-based compensation	30		30
Contributions from non-controlling interests	84						84
Distributions to noncontrolling interests	(34)						(34)
Purchases of treasury stock	(1,643)					(1,643)
Retirement of treasury stock	0			(1,643)		1,643
Split-off of N&B	(15,955)	(2)		(15,926)			(27)
Other	(1)		(1)
Ending balance at Sep. 30, 2021	27,239	5	49,702	(22,892)	(182)	0	606
Beginning balance at Jun. 30, 2021	27,464	5	49,681	(22,783)	(26)	0	587
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	404			391			13
Other comprehensive loss	(157)				(156)		(1)
Common stock issued/sold	2		2
Stock-based compensation	17		17
Contributions from non-controlling interests	17						17
Distributions to noncontrolling interests	(10)						(10)
Purchases of treasury stock	(500)					(500)
Retirement of treasury stock	0			(500)		500
Other	2		2
Ending balance at Sep. 30, 2021	27,239	5	49,702	(22,892)	(182)	0	606
Beginning balance at Dec. 31, 2021	27,050	5	49,574	(23,187)	41	0	617
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,679			1,642			37
Other comprehensive loss	(1,672)				(1,644)		(28)
Dividends	(500)		(500)
Common stock issued/sold	83		83
Stock-based compensation	42		42
Contributions from non-controlling interests	2						2
Distributions to noncontrolling interests	(35)						(35)
Purchases of treasury stock	(1,125)					(1,125)
Retirement of treasury stock	0			(1,125)		1,125
Other	(21)			(22)			1
Ending balance at Sep. 30, 2022	25,503	5	49,199	(22,692)	(1,603)	0	594
Beginning balance at Jun. 30, 2022	26,137	5	49,176	(22,808)	(845)	0	609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	376			367			9
Other comprehensive loss	(766)				(758)		(8)
Stock-based compensation	23		23
Distributions to noncontrolling interests	(15)						(15)
Purchases of treasury stock	(250)					(250)
Retirement of treasury stock	0			(250)		250
Other	(2)			(1)			(1)
Ending balance at Sep. 30, 2022	$ 25,503	$ 5	$ 49,199	$ (22,692)	$ (1,603)	$ 0	$ 594

XML

Consolidated Statements of Equity (Parenthetical) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]
Dividends declared (in usd per share)	$ 0.99	$ 0.90

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

In these notes, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should also be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, collectively referred to as the "2021 Annual Report." The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Mobility & Materials

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). The Company had previously entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese") on February 17, 2022. Refer to Note 4 and Note 24 - Subsequent Events for further information. In addition, on February 18, 2022, the Company announced it is advancing the process to divest its Delrin® acetal homopolymer (H-POM) business, subject to entry into a definitive agreement and satisfaction of customary closing conditions. The Delrin® divestiture together with the M&M Divestiture discussed above (the "M&M Divestitures") represent a strategic shift that will have a major impact on DuPont's operations and results. See Note 4 for more information.

The financial position of DuPont as of September 30, 2022 and December 31, 2021 present the businesses to be divested as part of the M&M Divestiture and the divestiture of Delrin® (the "M&M Businesses") as discontinued operations. The results of operations for the three and nine months ended September 30, 2022 and 2021 present the financial results of the M&M Businesses as discontinued operations. The cash flows and comprehensive income of the M&M Businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of the M&M Businesses. See Note 4 to the interim Consolidated Financial Statements for additional information.

The Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines, previously reported within the historic Mobility & Materials segment, (the "Retained Businesses") are not included in the scope of the M&M Divestitures. Effective with the signing of the Transaction Agreement, the Retained Businesses were realigned to Corporate & Other. The reporting changes have been retrospectively applied for all periods presented.

N&B Transaction

On February 1, 2021, DuPont completed the separation and distribution of the Nutrition & Biosciences business segment (the "N&B Business"), and the merger of Nutrition & Biosciences, Inc. (“N&B”), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF"). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). See Note 4 for more information.

The results of operations of DuPont for the three and nine months ended September 30, 2021 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable periods. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B.

XML

RECENT ACCOUNTING GUIDANCE

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

RECENT ACCOUNTING GUIDANCE

RECENT ACCOUNTING GUIDANCE

Accounting Guidance Issued But Not Adopted at September 30, 2022

In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (i.e., unearned revenue) acquired in a business combination to be recognized and measured in accordance with ASC 606, Revenue from Contracts with Customers. Historically, the Company has recognized contract assets and contract liabilities at the acquisition date based on fair value estimates in accordance with ASC 805, Business Combinations. ASU 2021-08 is effective for interim and annual periods beginning after December 15, 2022 on a prospective basis, with early adoption permitted.

In September 2022, the FASB issued Accounting Standards Update No. 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50)" ("ASU 2022-04") to enhance transparency about the use of supplier finance programs. The new guidance requires that a buyer in a supplier finance program provides additional qualitative and quantitative disclosures about its program including the nature of the program, activity during the period, changes from period to period, and the potential magnitude of the program. The amendments in ASU 2022-04 are effective for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the amendment on rollforward information which is effective prospectively for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently evaluating the potential impact of ASU 2022-04 to its related disclosures.

XML

ACQUISITIONS

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

ACQUISITIONS

ACQUISITIONS

Intended Rogers Acquisition

On November 2, 2021, the Company announced that it had entered into a definitive agreement to acquire all the outstanding shares of Rogers Corporation (“Rogers”) for about $5.2 billion (the “Intended Rogers Acquisition”). On November 1, 2022, the Company announced the termination of the agreement, as DuPont and Rogers have been unable to obtain timely clearance from all the required regulators. DuPont paid Rogers a termination fee of $162.5 million in accordance with the agreement on November 2, 2022. Refer to Note 24 - Subsequent Events for additional information.

Laird Performance Materials Acquisition

On July 1, 2021, DuPont completed the acquisition (the "Laird PM Acquisition") of 100% of the ownership interest of Laird Performance Materials (“Laird PM”) from Advent International for aggregate, adjusted cash consideration of approximately $2,404 million. The cash consideration paid included a net upward adjustment of approximately $100 million for acquired cash and net working capital, amongst other items. Laird PM is reported within the Interconnect Solutions business of the Electronics & Industrial segment. The Company accounted for the acquisition in accordance with ASC 805, which requires the assets acquired and liabilities assumed to be recognized on the balance sheet at their fair values as of the acquisition date. There were no material updates to the purchase accounting and the purchase price allocation is considered final. For additional information regarding the acquisition of Laird PM, see Note 3, "Acquisitions," in the 2021 Annual Report.

Acquisition, Integration and Separation Costs

Acquisition, integration and separation costs primarily consist of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees. For the three and nine months ended September 30, 2022 these costs were primarily related to costs associated with the divestiture of the Biomaterials business unit, the prior year acquisition of Laird PM and the Intended Rogers Acquisition. Comparatively, for the three and nine months ended September 30, 2021 these costs were primarily associated with the execution of activities related to strategic initiatives including the divestiture of the Biomaterials business unit in May 2022, the prior year acquisition of Laird PM and the divestitures of the Clean Technologies and Solamet® business units.

These costs are recorded within "Acquisition, integration and separation costs" within the interim Consolidated Statements of Operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Acquisition, integration and separation costs	$	7	$	29	$	28	$	58

XML

DIVESTITURES

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

DIVESTITURES

DIVESTITURES

Mobility & Materials Divestiture

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). On February 17, 2022, the Company entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese"). Refer to Note 24 - Subsequent Events for additional information. The Company also announced on February 18, 2022 that its Board of Directors approved the divestiture of the Delrin® acetal homopolymer (H-POM) business, subject to entry into a definitive agreement and satisfaction of customary closing conditions. As of September 30, 2022, the Company anticipates a closing date for the sale of Delrin® within a year.

The Company has determined that the M&M Businesses meet the criteria to be classified as held for sale and that the sale represents a strategic shift that will have a major effect on the Company’s operations and results.

The results of operations of the M&M Businesses are presented as discontinued operations as summarized below:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Net sales	$	988	$	1,072	$	3,100	$	3,062
Cost of sales	771		746		2,357		2,093
Research and development expenses	12		15		41		47
Selling, general and administrative expenses	25		64		110		189
Amortization of intangibles	—		38		28		120
Restructuring and asset related charges - net	—		—		—		5
Acquisition, integration and separation costs	135		—		357		—
Equity in (losses) earnings of nonconsolidated affiliates	(5)		3		(7)		11
Sundry income (expense) - net	7		7		—		15
Income from discontinued operations before income taxes	47		219		200		634
Provision for (benefit from) income taxes on discontinued operations	21		45		(607)		136
Income from discontinued operations, net of tax	26		174		807		498
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	33	$	170	$	812	$	484

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the M&M Businesses:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation and amortization	$	—	$	70	$	45	$	214
Capital expenditures 1	$	22	$	17	$	64	$	41

1.Total capital expenditures are presented on a cash basis.

The following table summarizes the major classes of assets and liabilities of the M&M Businesses classified as held for sale presented as discontinued operations at September 30, 2022 and December 31, 2021:

In millions	September 30, 2022		December 31, 2021
Assets
Cash and cash equivalents	$	38	$	39
Accounts and notes receivable - net	624		552
Inventories	1,072		776
Other current assets	45		59
Property, plant and equipment - net	1,193		1,213
Goodwill	2,432		2,597
Other intangible assets	2,127		2,220
Investments and noncurrent receivables	52		62
Deferred income tax assets	21		27
Deferred charges and other assets	129		119
Total assets of discontinued operations	$	7,733	$	7,664
Liabilities
Accounts payable	$	552	$	510
Income taxes payable	41		77
Accrued and other current liabilities	137		157
Deferred income tax liabilities	537		515
Pension and other post employment benefits - noncurrent	55		90
Other noncurrent liabilities	70		64
Total liabilities of discontinued operations	$	1,392	$	1,413

N&B Transaction

On February 1, 2021, DuPont completed the separation and distribution of the N&B Business, and merger of N&B, a subsidiary DuPont formed to hold the N&B Business, with a subsidiary of IFF. The distribution was effected through an exchange offer where, on the terms and subject to the conditions of the Exchange Offer, eligible participating DuPont stockholders had the option to tender all, some or none of their shares of common stock, par value $0.01 per share, of DuPont (the “DuPont Common Stock”) for a number of shares of common stock, par value $0.01 per share, of N&B (the “N&B Common Stock”) and which resulted in all shares of N&B Common Stock being distributed to DuPont stockholders that participated in the Exchange Offer. The consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). The N&B Transaction was subject to IFF shareholder approval, customary regulatory approvals, tax authority rulings including a favorable private letter ruling from the U.S. Internal Revenue Service which confirms the N&B Transaction to be free of U.S. federal income tax, and expiration of the public exchange offer. DuPont does not have an ownership interest in IFF as a result of the N&B Transaction.

In the Exchange Offer, DuPont accepted approximately 197.4 million shares of its common stock in exchange for about 141.7 million shares of N&B Common Stock as of the date of the N&B Transaction. As a result, DuPont reduced its common stock outstanding by 197.4 million shares of DuPont Common Stock. In the N&B Merger, each share of N&B Common Stock was automatically converted into the right to receive one share of IFF common stock, par value $0.125 per share, based on the terms of the N&B Merger Agreement.

The results of operations of N&B are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2021
In millions
Net sales	$	507
Cost of sales	354
Research and development expenses	21
Selling, general and administrative expenses	47
Amortization of intangibles	38
Restructuring and asset related charges - net	1
Acquisition, integration and separation costs	172
Sundry income (expense) - net	8
Interest expense	13
Loss from discontinued operations before income taxes	(131)
Benefit from income taxes on discontinued operations	(27)
Loss from discontinued operations, net of tax	(104)
Non-taxable gain on split-off	4,940
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	4,836

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to N&B:

	Nine Months Ended September 30, 2021
In millions
Depreciation and amortization	$	63
Capital expenditures	$	27

In connection with and in accordance with the terms of the N&B Transaction, prior to consummation of the Exchange Offer and the N&B Merger, DuPont received a one-time cash payment of approximately $7.3 billion, (the "Special Cash Payment").

The Company recognized a non-taxable gain of approximately $4,940 million on the N&B Transaction. The gain is recorded in "Income from discontinued operations, net of tax" in the Company's interim Consolidated Statements of Operations for the nine months ended September 30, 2021.

N&B Transaction Agreements

In connection with the N&B Transaction, effective December 15, 2019, the Company, as previously discussed, entered into the following agreements: N&B Separation and Distribution Agreement, N&B Merger Agreement, and N&B Employee Matters Agreement. In connection with the closing of the N&B Transaction, and effective February 1, 2021, the Company entered into the following agreements: N&B IP Cross-License Agreement and N&B Tax Matters Agreement.

Discontinued Operations Activity

The Company recorded income from discontinued operations, net of tax of $17 million and $145 million for the three months ended September 30, 2022 and 2021, respectively, and $723 million and $5,249 million for the nine months ended September 30, 2022 and 2021, respectively.

Discontinued operations activity consists of the following:

Income from discontinued operations, net of tax	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
M&M Divestitures	$	26	$	174	$	807	$	498
N&B Transaction	—		(12)		—		4,836
Other 1	(9)		(17)		(84)		(85)
Income from discontinued operations, net of tax	$	17	$	145	$	723	$	5,249

1.Primarily related to the binding Memorandum of Understanding (“MOU”) between Chemours, Corteva, E. I. du Pont de Nemours and Company ("EID") and the Company. For additional information on these matters, refer to Note 16.

Biomaterials

In May 2022, the Company completed the sale of its Biomaterials business unit, which included the Company's equity method investment in DuPont Tate & Lyle Bio Products, to the Huafon Group. Total consideration received related to the sale was approximately $240 million. For the nine months ended September 30, 2022, a pre-tax gain of $26 million ($21 million net of tax) was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations. The results of operations of the Biomaterials business unit are reported in Corporate & Other.

The following table summarizes the carrying value of the major assets and liabilities of the Biomaterials business unit reflected as held for sale at December 31, 2021:

In millions	December 31, 2021
Assets
Accounts and notes receivable - net	$	27
Inventories	48
Investments and noncurrent receivables	158
Property, plant and equipment - net	12
Assets held for sale	$	245
Liabilities
Accounts payable	$	21
Accrued and other current liabilities	3
Other noncurrent obligations	1
Liabilities related to assets held for sale	$	25

XML

REVENUE

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

REVENUE

REVENUE

Revenue Recognition

Products

Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to supply manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows.

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Industrial Solutions	$	496	$	474	$	1,499	$	1,412
Interconnect Solutions	446		489		1,371		1,158
Semiconductor Technologies	569		504		1,704		1,517
Electronics & Industrial	$	1,511	$	1,467	$	4,574	$	4,087
Safety Solutions	$	684	$	646	$	2,001	$	1,933
Shelter Solutions	476		414		1,385		1,193
Water Solutions	374		337		1,074		1,011
Water & Protection	$	1,534	$	1,397	$	4,460	$	4,137
Retained Businesses 1	$	272	$	226	$	804	$	721
Other 2	—		109		75		375
Corporate & Other	$	272	$	335	$	879	$	1,096
Total	$	3,317	$	3,199	$	9,913	$	9,320

1. Retained Businesses includes the Auto Adhesives & Fluids, MultibaseTM and Tedlar® businesses.

2. Net sales reflected in Other include activity of previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
U.S. & Canada	$	1,149	$	1,011	$	3,293	$	2,875
EMEA 1	523		562		1,665		1,672
Asia Pacific	1,524		1,529		4,622		4,490
Latin America	121		97		333		283
Total	$	3,317	$	3,199	$	9,913	$	9,320

1.Europe, Middle East and Africa.

Contract Balances

From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivables when the right to consideration becomes unconditional. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue.

Revenue recognized in the first nine months of 2022 and 2021 from amounts included in contract liabilities at the beginning of the period was insignificant.

Contract Balances	September 30, 2022		December 31, 2021
In millions
Accounts and notes receivable - trade 1	$	1,712	$	1,643
Deferred revenue - current 2, 3	$	16	$	25

1.Included in "Accounts and notes receivable - net" in the Condensed Consolidated Balance Sheets.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

3.Noncurrent deferred revenue balances in the current and comparative periods were not material.

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND ASSET RELATED CHARGES - NET

RESTRUCTURING AND ASSET RELATED CHARGES - NET

Charges for restructuring programs and asset related charges, which include asset impairments and other net charges, were zero and $101 million for the three and nine months ended September 30, 2022 and $1 million and $8 million for the three and nine months ended September 30, 2021. These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $21 million at September 30, 2022 and $43 million at December 31, 2021, recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Restructuring activity consists of the following programs:

2021 Restructuring Actions

In October 2021, the Company approved targeted restructuring actions to capture near-term cost reductions (the "2021 Restructuring Actions"). The Company recorded pre-tax restructuring charges of $55 million inception-to-date, consisting of severance and related benefit costs of $33 million and asset related charges of $22 million.

Total liabilities related to the 2021 Restructuring Actions were $17 million at September 30, 2022 and $25 million at December 31, 2021 and recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Actions related to the 2021 Restructuring Program are substantially complete.

2020 Restructuring Program

In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the N&B Transaction (the "2020 Restructuring Program"). The Company recorded pre-tax restructuring charges of $159 million inception-to-date, consisting of severance and related benefit costs of $107 million and asset related charges of $52 million.

Total liabilities related to the 2020 Restructuring Program were $2 million at September 30, 2022 and $11 million at December 31, 2021 and recorded in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets. Actions related to the 2020 Restructuring Program are substantially complete.

Equity Method Investment Impairment Related Charges

In connection with the M&M Divestitures described in Note 4, in the first quarter of 2022 a portion of an equity method investment was reclassified to “Assets of discontinued operations” within the Condensed Consolidated Balance Sheet. The reclassification served as a triggering event requiring the Company to perform an impairment analysis on the retained portion of the equity method investment held within “Investments and noncurrent receivables” on the Condensed Consolidated Balance Sheet. The fair value of the retained equity method investment was estimated using a discounted cash flow model (a form of the income approach). The Company's assumptions in estimating fair value utilize Level 3 inputs and include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, and terminal growth rates. The Company determined the fair value of the retained equity method investment was below the carrying value and had no expectation the fair value would recover in the short-term due to the current economic environment. As a result, management concluded the impairment was other-than-temporary and, in March 2022, recorded an impairment charge of $94 million reflected in “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations for the nine months ended September 30, 2022 related to the Electronics & Industrial segment. No impairment was required to be recorded for the portion of the equity method investment included within “Assets of discontinued operations.”

2022 Restructuring Program

In October 2022, subsequent to quarter end, the Company approved targeted restructuring actions to capture near-term cost reductions and to further simplify certain organizational structures following the M&M Divestitures (the "2022 Restructuring Program"). The Company expects to incur costs of up to $125 million, primarily related to the payment of severance and asset related charges. Restructuring costs will begin in the fourth quarter of 2022 and are expected to be substantially complete by the end of 2023.

XML

SUPPLEMENTARY INFORMATION

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION

Sundry Income (Expense) - Net	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Non-operating pension and other post-employment benefit ("OPEB") credits	$	7	$	9	$	20	$	22
Interest income	5		1		8		10
Net gain on divestiture and sales of other assets and investments 1, 2	6		8		75		175
Foreign exchange gains (losses), net	5		(19)		9		(35)
Miscellaneous income (expenses) - net 3	3		2		11		(17)
Sundry income (expense) - net	$	26	$	1	$	123	$	155

1. The nine months ended September 30, 2022 primarily reflects income of $26 million related to the gain on sale of the Biomaterials business unit and $37 million related to the sale of a land use right within the Water & Protection segment.

2. The nine months ended September 30, 2021 primarily reflects income of $140 million related to the gain on sale of assets within Corporate & Other and income of $28 million related to the gain on sale of assets within the Electronics & Industrial segment.

3. The nine months ended September 30, 2021 includes an impairment charge of approximately $15 million related to an asset sale.

Cash, Cash Equivalents and Restricted Cash

In connection with the cost sharing arrangement entered into as part of the MOU, the Company is contractually obligated to make deposits into an escrow account to address potential future PFAS costs. At September 30, 2022 and December 31, 2021, the Company had restricted cash of $103 million and $53 million included within non-current “Restricted cash and cash equivalents” in the Condensed Consolidated Balance Sheets, the majority of which is attributable to the MOU cost sharing arrangement. Additional information regarding the MOU and the escrow account can be found in Note 16.

Accrued and Other Current Liabilities

"Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets were $990 million at September 30, 2022 and $1,040 million at December 31, 2021. Accrued payroll, which is a component of "Accrued and other current liabilities," was $326 million at September 30, 2022 and $436 million at December 31, 2021. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at September 30, 2022 and at December 31, 2021.

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.

The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the third quarter of 2022 was 27.9 percent, compared with an effective tax rate of 23.6 percent for the third quarter of 2021. The effective tax rate differential for the third quarter of 2022 was driven by the cumulative impact of currency fluctuation and the geographic mix of earnings. For the first nine months of 2022, the effective tax rate on continuing operations was 23.8 percent, compared with 14.2 percent for the first nine months of 2021. The effective tax rate for the first nine months of 2021 was principally the result of a $59 million tax benefit related to the step-up in tax basis in the goodwill of the Company's European regional headquarters legal entity.

In connection with the integration of Laird PM, the Company completed certain internal restructurings that were determined to be tax free under the applicable sections of the Internal Revenue Code. If the aforementioned transactions were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax liability.

Certain internal distributions and reorganizations that occurred during 2021 and 2020 in preparation for the N&B Transaction and the external distribution in 2021 qualified as tax-free transactions under the applicable sections of the Internal Revenue Code. If the aforementioned transactions were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax liability. Under the N&B Tax Matters Agreement, the Company would generally be allocated such liability and not be indemnified, unless certain non-qualifying actions are undertaken by N&B or IFF. To the extent that the Company is responsible for any such liability, there could be a material adverse impact on the Company's business, financial condition, results of operations and cash flows in future reporting periods.

As a result of the M&M Businesses meeting the held for sale criteria in the first quarter of 2022, the Company recorded a net tax expense of $12 million and a net tax benefit of $655 million for the three and nine months ended September 30, 2022, respectively, in connection with certain internal restructuring and some of which relied upon legal entity valuations. These restructurings involve legal entities that hold M&M Businesses and are expected to be conveyed to Celanese as part of the M&M Divestiture and legal entities that are expected to remain with DuPont. The aforementioned net tax benefit is included in “Income from discontinued operations, net of tax” in the interim Consolidated Statements of Operations. See Note 4 for additional information on the M&M Divestitures.

XML

EARNINGS PER SHARE CALCULATIONS

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

EARNINGS PER SHARE CALCULATIONS

EARNINGS PER SHARE CALCULATIONS

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2022 and 2021:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Income from continuing operations, net of tax	$	359	$	259	$	956	$	1,040
Net income from continuing operations attributable to noncontrolling interests	16		9		42		12
Income from continuing operations attributable to common stockholders	$	343	$	250	$	914	$	1,028
Income from discontinued operations, net of tax	17		145		723		5,249
Net income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to common stockholders	24		141		728		5,235
Net income attributable to common stockholders	$	367	$	391	$	1,642	$	6,263

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.81	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.49
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.25	$	11.35

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.80	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.46
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.24	$	11.32

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2022	2021	2022	2021
Weighted-average common shares - basic	499.4	521.5	505.6	551.7
Plus dilutive effect of equity compensation plans	1.0	1.6	1.3	1.4
Weighted-average common shares - diluted	500.4	523.1	506.9	553.1
Stock options, restricted stock units, and performance-based restricted stock units excluded from EPS calculations 2	4.4	2.4	3.0	2.7

1.Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

2.These outstanding options to purchase shares of common stock, restricted stock units, and performance-based restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

XML

ACCOUNTS AND NOTES RECEIVABLE - NET

9 Months Ended

Sep. 30, 2022

Receivables [Abstract]

ACCOUNTS AND NOTES RECEIVABLE - NET

ACCOUNTS AND NOTES RECEIVABLE - NET

In millions	September 30, 2022		December 31, 2021
Accounts receivable – trade 1	$	1,691	$	1,612
Other 2	566		547
Total accounts and notes receivable - net	$	2,257	$	2,159

1.Accounts receivable – trade is net of allowances of $38 million at September 30, 2022 and $28 million at December 31, 2021. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts.

2.Other includes receivables in relation to value added tax, indemnification assets, general sales tax and other taxes, and other receivables. No individual group represents more than ten percent of total receivables.

XML

INVENTORIES

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIES

In millions	September 30, 2022		December 31, 2021
Finished goods	$	1,334	$	1,201
Work in process	519		446
Raw materials	392		323
Supplies	114		116
Total inventories	$	2,359	$	2,086

XML

PROPERTY, PLANT, AND EQUIPMENT

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT, AND EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT

	Estimated Useful Lives (Years)			September 30, 2022		December 31, 2021
In millions
Land and land improvements	1	-	25	$	394	$	440
Buildings	1	-	50	1,904		1,954
Machinery, equipment, and other	1	-	25	6,462		6,467
Construction in progress				944		1,034
Total property, plant and equipment				$	9,704	$	9,895
Total accumulated depreciation				$	4,227	$	4,142
Total property, plant and equipment - net				$	5,477	$	5,753

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation expense	$	137	$	142	$	414	$	407

XML

NONCONSOLIDATED AFFILIATES

9 Months Ended

Sep. 30, 2022

Equity Method Investments and Joint Ventures [Abstract]

NONCONSOLIDATED AFFILIATES

NONCONSOLIDATED AFFILIATES

The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and noncurrent receivables" in the Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates at September 30, 2022 and December 31, 2021 is $733 million and $817 million, respectively. In the first quarter of 2022, the Company recorded an other-than-temporary impairment on an equity method investment. See Note 6 for more information.

The Company maintained an ownership interest in six nonconsolidated affiliates at September 30, 2022.

Sales to nonconsolidated affiliates represented less than 2 percent of total net sales for the three and nine months ended September 30, 2022 and 2021. Purchases from nonconsolidated affiliates represented less than 3 percent of “Cost of sales” for the three and nine months ended September 30, 2022 and less than 4 percent for the three and nine months ended September 30, 2021

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 were as follows:

In millions	Electronics & Industrial		Water & Protection		Corporate & Other		Total
Balance at December 31, 2021	$	9,583	$	6,801	$	597	$	16,981
Currency Translation Adjustment	(337)		(326)		(16)		(679)
Balance at September 30, 2022	$	9,246	$	6,475	$	581	$	16,302

The Company tests goodwill for impairment annually during the fourth quarter, or more frequently when events or changes in circumstances indicate that fair value is below carrying value.

During the first quarter of 2022, in conjunction with the announcement of the M&M Divestitures, the Company realigned the Retained Businesses, previously within the historic Mobility & Materials segment, to Corporate & Other (the "2022 Realignment"). The announcement of the M&M Divestitures and 2022 Realignment served as triggering events requiring the Company to perform impairment analyses related to goodwill carried by the impacted reporting units as of March 1, 2022. Goodwill impairment analyses were performed for reporting units impacted in the historic Mobility & Materials segment prior to the realignment, and no impairments were identified. As part of the 2022 Realignment, the Company assessed and re-defined certain reporting units effective March 1, 2022, including a reallocation of goodwill on a relative fair value basis, as applicable, to the newly identified reporting units and M&M Divestitures disposal groups. Goodwill impairment analyses were performed for the new reporting units reported within Corporate & Other and no impairments were identified. The fair value of the reporting units and the M&M Divestitures disposal groups were estimated using a combination of a discounted cash flow model and/or market approach. The Company's assumptions in estimating fair value include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, the terminal growth rates, and derived multiples from comparable market transactions.

During the first quarter of 2021, in conjunction with the closing of the N&B Transaction, the Company changed its management and reporting structure (the “2021 Segment Realignment”), which served as a triggering event requiring the Company to perform an impairment analysis related to goodwill carried by certain reporting units as of February 1, 2021, prior to the realignment. As part of the 2021 Segment Realignment, the Company assessed and re-defined certain reporting units effective February 1, 2021, including reallocation of goodwill on a relative fair value basis, as applicable, to reporting units impacted. Goodwill impairment analyses were then performed for reporting units impacted and no impairments were identified. The fair value of each reporting unit tested was estimated using a combination of a discounted cash flow model and market approach. The Company's assumptions in estimating fair value include, but are not limited to, projected revenue, gross margins, EBITDA margins, the weighted average costs of capital, the terminal growth rates, and derived multiples from comparable market transactions.

The Company's analyses used the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs. The Company’s significant assumptions in these analyses include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and tax rates. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate.

Other Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2022						December 31, 2021
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	2,331	$	(1,241)	$	1,090	$	2,374	$	(1,124)	$	1,250
Trademarks/tradenames	1,114		(542)		572		1,125		(500)		625
Customer-related	5,416		(2,366)		3,050		5,806		(2,296)		3,510
Other	105		(71)		34		113		(80)		33
Total other intangible assets with finite lives	$	8,966	$	(4,220)	$	4,746	$	9,418	$	(4,000)	$	5,418
Intangible assets with indefinite lives:
Trademarks/tradenames	804		—		804		804		—		804
Total other intangible assets with indefinite lives	804		—		804		804		—		804
Total	$	9,770	$	(4,220)	$	5,550	$	10,222	$	(4,000)	$	6,222

As part of the 2022 Realignment, the Company reallocated its intangible assets with indefinite lives to align with the new segment structure. This served as a triggering event requiring the Company to perform an impairment analysis related to intangible assets with indefinite lives carried by its historic Mobility & Materials segment as of March 1, 2022, prior to the realignment. Subsequent to the realignment, impairment analyses were then performed for the intangible assets with indefinite lives reported in Corporate & Other. No impairments were identified as a result of the analyses described above.

As part of the 2021 Segment Realignment, the Company reallocated its intangible assets with indefinite lives to align with the new segment structure. This served as a triggering event requiring the Company to perform an impairment analysis related to intangible assets with indefinite lives carried by its segments as of February 1, 2021, prior to the realignment. Subsequent to the realignment, the Company realigned intangible assets with indefinite lives as applicable to align the intangible assets with indefinite lives with the new segment structure. Impairment analyses were then performed for the intangible assets with indefinite lives carried by the segments after the realignment. No impairments were identified as a result of the analyses described above.

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2022		December 31, 2021
In millions
Electronics & Industrial	$	3,000	$	3,429
Water & Protection	2,456		2,686
Corporate & Other	94		107
Total	$	5,550	$	6,222

Total estimated amortization expense for the remainder of 2022 and the five succeeding fiscal years is as follows:

Estimated Amortization Expense
In millions
Remainder of 2022	$	139
2023	$	567
2024	$	539
2025	$	498
2026	$	471
2027	$	424

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

The Company's short-term borrowings consist of commercial paper. At September 30, 2022 and December 31, 2021, the Company's short-term borrowings were $1,287 million and $150 million, respectively. The increase in short-term borrowing is due to cash flow needs related to the M&M Divestiture as well as normal operating needs. The weighted-average interest rate on commercial paper was 3.19 percent at September 30, 2022 and 0.34 percent at December 31, 2021.

The following table summarizes the Company's long-term debt:

Long-Term Debt	September 30, 2022				December 31, 2021
In millions	Amount		Weighted Average Rate		Amount		Weighted Average Rate
Promissory notes and debentures 1
Final maturity 2023	$	2,800	4.18	%	$	2,800	3.89	%
Final maturity 2025	1,850		4.49	%	1,850		4.49	%
Final maturity 2026 and thereafter 2	5,975		5.20	%	6,050		5.13	%
Other facilities:
Finance lease obligations	2				2
Less: Unamortized debt discount and issuance costs	63				70
Total	$	10,564			$	10,632

1. Represents senior unsecured notes (the "2018 Senior Notes"), which are senior unsecured obligations of the Company. See Note 24 for additional information.

2. Includes fair value hedging adjustment of $75 million related to the Company's interest rate swap agreements. See Note 21 for additional information.

Principal Payments of long-term debt for the remainder of 2022 and the five succeeding fiscal years are as follows:

Maturities of Long-Term Debt for Next Five Years at September 30, 2022	Total
In millions
Remainder of 2022	$	—
2023	$	2,800
2024	$	—
2025	$	1,850
2026	$	—
2027	$	—

The estimated fair value of the Company's long-term borrowings was determined using Level 2 inputs within the fair value hierarchy, as described in Note 22. Based on quoted market prices for the same or similar issues, or on current rates offered to the Company for debt of the same remaining maturities, the fair value of the Company's long-term borrowings, was $10.21 billion and $12.60 billion at September 30, 2022 and December 31, 2021, respectively.

Available Committed Credit Facilities

The following table summarizes the Company's credit facilities:

Committed and Available Credit Facilities at September 30, 2022
In millions	Effective Date	Committed Credit		Credit Available		Maturity Date	Interest
Revolving Credit Facility, Five-year	April 2022	$	2,500	$	2,488	April 2027	Floating Rate
364-day Revolving Credit Facility	April 2022	1,000		1,000		April 2023	Floating Rate
Total Committed and Available Credit Facilities		$	3,500	$	3,488

In July 2022, the Company drew down $600 million under the 364-day Revolving Credit Facility in order to facilitate certain intercompany internal restructuring steps related to the M&M Divestiture. The Company repaid the borrowing in September 2022.

Intended Rogers Acquisition

In connection with the Intended Rogers Acquisition, on November 22, 2021, the Company entered into a two-year senior unsecured committed term loan agreement in the amount of $5.2 billion. In October 2022, the facility was amended to extend the lending commitments (as amended the "Amended 2021 Term Loan Facility"). On November 1, 2022, the M&M Divestiture closed and therefore based on the terms of the Amended 2021 Term Loan Facility the commitment was terminated. Refer to Note 24 - Subsequent Events for additional information on the Intended Rogers Acquisition.

May 2020 Debt Offering

On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “May 2020 Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May 2020 Debt Offering”). The consummation of the N&B Transaction triggered the special mandatory redemption feature of the May 2020 Debt Offering. The Company redeemed the May 2020 Notes on May 13, 2021 and funded the redemption with proceeds from the Special Cash Payment.

Term Loan Facilities

On February 1, 2021, the Company terminated its fully drawn $3 billion term loan facilities. The termination triggered the repayment of the aggregate outstanding principal amount of $3 billion, plus accrued and unpaid interest through and including January 31, 2021. The Company funded the repayment with proceeds from the Special Cash Payment.

Revolving Credit Facilities

On April 12, 2022, the Company entered into a new $2.5 billion five-year revolving credit facility (the "2022 Five-Year Revolving Credit Facility"). The 2022 Five-Year Revolving Credit Facility is generally expected to remain undrawn and serve as a backstop to the Company's commercial paper and letter of credit issuance. On April 12, 2022, the Company entered into an updated $1 billion 364-day revolving credit facility (the "2022 $1B Revolving Credit Facility").

Uncommitted Credit Facilities and Outstanding Letters of Credit

Unused bank credit lines on uncommitted credit facilities were approximately $810 million at September 30, 2022. These lines are available to support short-term liquidity needs and general corporate purposes including letters of credit. Outstanding letters of credit were approximately $107 million at September 30, 2022. These letters of credit support commitments made in the ordinary course of business.

Debt Covenants and Default Provisions

The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subject to certain limitations. The 2018 Senior Notes also contain customary default provisions. The 2021 Term Loan Facility, the Five-Year Revolving Credit Facility and the 2022 $1B Revolving Credit Facility contain a financial covenant requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2022, the Company was in compliance with this financial covenant. There were no material changes to the debt covenants and default provisions at September 30, 2022.

XML

COMMITMENTS AND CONTINGENT LIABILITIES

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

COMMITMENTS AND CONTINGENT LIABILITIES

Litigation, Environmental Matters, and Indemnifications

The Company and certain subsidiaries are involved in various lawsuits, claims and environmental actions that have arisen in the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, as well as possible obligations to investigate and mitigate the effects on the environment of the disposal or release of certain substances at various sites. In addition, in connection with divestitures and the related transactions, the Company from time to time has indemnified and has been indemnified by third parties against certain liabilities that may arise in connection with, among other things, business activities prior to the completion of the respective transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. The Company records liabilities for ongoing and indemnification matters when the information available indicates that it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated.

As of September 30, 2022, the Company has recorded indemnification assets of $18 million within "Accounts and notes receivable - net" and $229 million within "Deferred charges and other assets" and indemnification liabilities of $122 million within "Accrued and other current liabilities" and $221 million within "Other noncurrent obligations" within the Condensed Consolidated Balance Sheets.

The Company’s accruals discussed below for indemnification liabilities related to the binding Memorandum of Understanding (“MOU”) between Chemours, Corteva, EID and the Company and to the DowDuPont ("DWDP") Separation and Distribution Agreement and the Letter Agreement between the Company and Corteva (together the “Agreements”), are included in the balances above.

PFAS Stray Liabilities: Future Eligible PFAS Costs

On July 1, 2015, EID, a Corteva subsidiary since June 1, 2019, completed the separation of EID’s Performance Chemicals segment through the spin-off of Chemours to holders of EID common stock (the “Chemours Separation”). On June 1, 2019, the Company completed the separation of its agriculture business through the spin-off of Corteva, Inc. (“Corteva”), including Corteva’s subsidiary EID.

On January 22, 2021, the Company, Corteva, EID and Chemours entered into the MOU pursuant to which the parties have agreed to release certain claims that had been raised by Chemours including any claims arising out of or resulting from the process and manner in which EID structured or conducted the Chemours Separation, and any other claims that challenge the Chemours Separation or the assumption of Chemours Liabilities (as defined in the Chemours Separation Agreement) by Chemours and the allocation thereof, subject in each case to certain exceptions set forth in the MOU. In connection with the MOU, the confidential arbitration process regarding certain claims by Chemours was terminated in February 2021. The parties have further agreed not to bring any future, additional claims regarding the Chemours Separation Agreement or the MOU outside of arbitration.

Pursuant to the MOU, the parties have agreed to share certain costs associated with potential future liabilities related to alleged historical releases of certain PFAS out of pre-July 1, 2015 conduct (“eligible PFAS costs”) until the earlier to occur of (i) December 31, 2040, (ii) the day on which the aggregate amount of Qualified Spend, as defined in the MOU, is equal to $4 billion or (iii) a termination in accordance with the terms of the MOU. PFAS refers to per- or polyfluoroalkyl substances, which include perfluorooctanoic acids and its ammonium salts (“PFOA”).

The parties have agreed that, during the term of this sharing arrangement, Qualified Spend up to $4 billion will be borne 50 percent by Chemours and 50 percent, up to a cap of $2 billion, by the Company and Corteva. The Company and Corteva will split their 50 percent of Qualified Spend in accordance with the Agreements. After the term of this arrangement, Chemours’ indemnification obligations under the Chemours Separation Agreement would continue unchanged, subject in each case to certain exceptions set forth in the MOU.

In order to support and manage any potential future eligible PFAS costs, the parties also agreed to establish an escrow account. The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50 percent of the deposits and DuPont and Corteva together will make 50 percent of the deposits necessary to restore the balance of the escrow account to $700 million. Such payments will be made in a series of

consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU. At September 30, 2022 and December 31, 2021, DuPont's escrow deposits of $100 million and $50 million, respectively, are reflected in "Restricted cash and cash equivalents" on the Condensed Consolidated Balance Sheet.

Under the Agreements, Divested Operations and Businesses ("DDOB") liabilities of EID not allocated to or retained by Corteva or the Company are categorized as relating to either (i) PFAS Stray Liabilities, if they arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS; or (ii) Non-PFAS Stray Liabilities, (and together with PFAS Stray Liabilities, the “EID Stray Liabilities”).

The Agreements provide that the Company and Corteva will each bear specified amounts plus an additional $200 million of Indemnifiable Losses, described below, in relation to certain EID Stray Liabilities. The Agreements further provide that the Company and Corteva will each bear 50 percent, $150 million each, of the first $300 million of total Indemnifiable Losses related to PFAS Stray Liabilities. When the companies meet their respective $150 million threshold, Indemnifiable Losses related to PFAS Stray Liabilities will be borne 71 percent by DuPont and 29 percent by Corteva.

Indemnifiable Losses up to $150 million incurred for PFAS Stray Liabilities are credited against each company’s $200 million threshold. Whenever Corteva or DuPont meets its $200 million threshold, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. Thereafter, DuPont will bear 71 percent and Corteva will bear 29 percent of Indemnifiable Losses related to Non-PFAS Stray Liabilities.

Indemnifiable Losses, as defined in the DWDP Separation and Distribution Agreement, include, among other things, attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense of EID Stray Liabilities.

In connection with the MOU and the Agreements, the Company has recognized the following indemnification liabilities related to eligible PFAS costs:

Indemnified Liabilities Related to the MOU
In millions	Sept 30, 2022		Dec 31, 2021		Balance Sheet Classification
Current indemnified liabilities	$	55	$	37	Accrued and other current liabilities
Long-term indemnified liabilities	$	129	$	89	Other noncurrent obligations
Total indemnified liabilities accrued under the MOU 1, 2	$	184	$	126

1.As of September 30, 2022 and December 31, 2021, total indemnified liabilities accrued include $168 million and $112 million, respectively, related to Chemours environmental remediation activities at their site in Fayetteville, North Carolina under the Consent Order between Chemours and the North Carolina Department of Environmental Quality (the "NC DEQ").

2.In addition to the above, as of December 31, 2021, the Company had recognized a liability of $12.5 million related to the settlement agreement between Chemours, Corteva and DuPont and Delaware's Attorney General, discussed below.

Future charges associated with the MOU would be recognized over the term of the agreement as a component of income from discontinued operations to the extent liabilities become probable and estimable.

In 2004, EID settled a West Virginia state court class action, Leach v. E. I. du Pont de Nemours and Company, which alleged that PFOA from EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Members of the Leach class have standing to pursue personal injury claims for six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. Since the 2017 settlement about 100 additional cases alleging personal injury, including kidney and testicular cancer claims, were filed or noticed and pending in the Ohio MDL.

On January 21, 2021, EID and Chemours entered into settlement agreements with plaintiffs’ counsel representing the Ohio MDL plaintiffs providing for a settlement of cases and claims in the Ohio MDL, except as noted below (the “Settlement”). The total settlement amount was $83 million in cash with each of the Company and EID contributing $27 million and Chemours contributing $29 million. At June 30, 2021 the Company had paid in full its $27 million contribution. The Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by the Company, Corteva, EID or Chemours. In connection with the Settlement, in April 2021 the plaintiffs filed a motion to terminate

the Ohio MDL. The case captioned “Abbott v. E. I. du Pont de Nemours and Company” is a personal injury action that is not included in the Settlement of the Ohio MDL. DuPont was not named party in the Leach case or the Ohio MDL and is not a named party in the Abbott case.

As of September 30, 2022, there are various cases alleging damages due to PFAS which are discussed below. Such actions often include additional claims based on allegations that the transfer by EID of certain PFAS liabilities to Chemours resulted in a fraudulent conveyance or voidable transaction. With the exception of the fraudulent conveyance claims, which are excluded from the MOU, legal fees, expenses, costs, and any potential liabilities for eligible PFAS costs presented by the following matters will be shared as defined in the MOU between Chemours, EID, Corteva and DuPont.

Beginning in April 2019, several dozen lawsuits alleging water contamination from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against EID and Chemours, in addition to 3M and other AFFF manufacturers. The majority of these lawsuits were consolidated in a multi-district litigation docket in federal court in South Carolina (the “SC MDL”). Since then, the SC MDL has grown and contains approximately 3,130 cases. Most of the actions in the SC MDL name DuPont as a defendant due to the fraudulent transfer claims related to the Chemours Separation and the DowDuPont separations. Generally, the SC MDL contains multiple types of lawsuits including, but not limited to, approximately 2,840 personal injury cases, state attorneys general natural resource damages cases, and water provider contamination cases. Three of the water provider contamination cases have been selected by the court as bellwether cases. The court has encouraged all parties to discuss resolution of the water provider category of cases. Consistent with the court’s instruction and under the mutual obligations of the MOU, Chemours, Corteva/EID and DuPont, together, are engaged with plaintiffs’ counsel on these cases. DuPont has never made or sold AFFF, perfluorooctanesulfonic acid ("PFOS") or PFOS containing products.

There are also state attorneys general lawsuits against DuPont, outside of the SC MDL. These also claim environmental contamination by certain PFAS compounds but distinct from AFFF. Generally, the states raise common law tort claims and seek economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup contamination from certain PFAS compounds, and to abate the alleged nuisance. Most of these actions include fraudulent transfer claims related to the Chemours Separation and the DowDuPont separations.

In July 2021, Chemours, Corteva (for itself and EID) and DuPont reached a resolution with the State of Delaware that avoids litigation and addresses potential natural resources damages from known historical and current releases by the companies in or affecting Delaware. The resolution releases these potential state claims arising from the environmental impacts of various chemicals, including PFAS, across all current and historical locations. Consistent with the MOU, Chemours will bear 50 percent or $25 million of the $50 million settlement and Corteva and DuPont will each bear $12.5 million. The Company paid its portion of the settlement in January 2022. The settlement also calls for a potential Supplemental Payment to Delaware up to a total of $25 million funded 50 percent by Chemours and 50 percent by Corteva and DuPont, jointly, under certain circumstances which are not deemed probable.

In April 2021, DuPont de Nemours (Nederland) B.V., and the Dutch entities of Chemours and Corteva, received a civil summons filed before the Court of Rotterdam, the Netherlands, on behalf of four municipalities neighboring the Chemours Dordrecht facility. The municipalities are seeking liability declarations relating to the Dordrecht site’s current and historical PFAS operations and emissions.

In addition to the above matters, the Company is a named party in various other legal matters that make claims related to PFAS, for which the costs of litigation and future liabilities, if any, are eligible PFAS costs under the MOU and Indemnification Losses under the Agreements. These matters include lawsuits filed by water districts and private water companies in New Jersey and California generally alleging contamination of water systems.

There are pending cases that make claims related to PFAS that have been filed against Chemours and Corteva/EID in which the Company is not a named party, but for which the costs of litigation and future liabilities, if any, are or may be eligible PFAS costs under the MOU and Indemnification Losses under the Agreements.

While Management believes it has appropriately estimated the liability associated with eligible PFAS matters and Indemnifiable Losses as of the date of this report, it is reasonably possible that the Company could incur additional eligible PFAS costs and Indemnifiable Losses in excess of the amounts accrued. These additional costs could have a significant effect on the Company’s financial condition and/or cash flows in the period in which they occur; however, costs qualifying as Qualified Spend are limited by the terms of the MOU.

Other Litigation Matters

In addition to the matters described above, the Company is party to claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. As of September 30, 2022, the Company has liabilities of $23 million associated with these other litigation matters. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company. In accordance with its accounting policy for litigation matters, the Company will expense litigation defense costs as incurred, which could be significant to the Company’s financial condition and/or cash flows in the period.

Environmental Matters

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At September 30, 2022, the Company had accrued obligations of $260 million for probable environmental remediation and restoration costs. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the Condensed Consolidated Balance Sheets. It is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

In June of 2022, the EPA announced updated health advisories for various PFAS compounds in drinking water. Chemours received notice from the NC DEQ that its obligations under the Consent Order could be enlarged as a result of EPA’s announcement. In the second quarter of 2022, the Company recorded an incremental liability related to its indemnification obligations under the MOU. The increase primarily relates to incremental costs associated with activities at Chemours' site in Fayetteville, North Carolina under the Consent Order with the NC DEQ.

The accrued environmental obligations include the following:

Environmental Accrued Obligations
In millions	Sept 30, 2022		Dec 31, 2021		Potential exposure above the amount accrued 1
Environmental remediation liabilities not subject to indemnity	$	39	$	43	$	105
Environmental remediation indemnified liabilities:
Indemnifications related to Dow and Corteva 2	48		46		63
MOU related obligations (discussed above) 3	172		116		84
Other Environmental Indemnifications	1		—		2
Total environmental related liabilities	$	260	$	205	$	254

1.The environmental accrual represents management’s best estimate of the costs for remediation and restoration with respect to environmental matters, although it is reasonably possible that the ultimate cost with respect to these particular matters could range above the amount accrued.

2.Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify Dow and Corteva for certain Non-PFAS clean-up responsibilities and associated remediation costs.

3.The MOU related obligations include the Company's estimate of its liability under the MOU for remediation activities based on the current regulatory environment.

XML

LEASES

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

LEASES

LEASES

The lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Operating lease costs	$	27	$	27	$	82	$	80

Operating cash flows from operating leases, excluding those related to the M&M Divestitures, were $82 million and $80 million for the nine months ended September 30, 2022 and 2021, respectively.

New operating lease assets and liabilities entered into during the nine months ended September 30, 2022 and 2021 were $75 million and $64 million, respectively. Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2022		December 31, 2021
Operating Leases
Operating lease right-of-use assets 1	$	386	$	422
Current operating lease liabilities 2	84		92
Noncurrent operating lease liabilities 3	301		337
Total operating lease liabilities	$	385	$	429

1.Included in "Deferred charges and other assets" in the Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the Condensed Consolidated Balance Sheet.

Operating lease right-of-use ("ROU") assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide the lessor’s implicit rate, the Company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments.

Lease Term and Discount Rate for Operating Leases	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (years)	8.07		8.50
Weighted average discount rate	2.33	%	2.01	%

Maturities of lease liabilities were as follows:

Maturity of Lease Liabilities at September 30, 2022	Operating Leases
In millions
Remainder of 2022	$	25
2023	89
2024	75
2025	53
2026	36
2027 and thereafter	153
Total lease payments	$	431
Less: Interest	46
Present value of lease liabilities	$	385

The Company has leases in which it is the lessor, with the largest being a result of the N&B transaction. In connection with the N&B Transaction, DuPont entered into leasing agreements with IFF, whereby DuPont is leasing certain properties, including office spaces and R&D laboratories to IFF. These leases are classified as operating leases and lessor income and related expenses are not significant to the Company's Condensed Consolidated Balance Sheet or interim Consolidated Statement of Operations. Lease agreements where the Company is the lessor have final expirations through 2036.

XML

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

Share Repurchase Program

In February 2022, the Company's Board of Directors authorized a $1.0 billion share buyback program which expires on March 31, 2023, (the "2022 Share Buyback Program"). During the third quarter, the Company repurchased and retired 4.3 million shares for $250 million under this program. As of September 30, 2022, the Company repurchased and retired a total of 11.9 million shares for $750 million under the 2022 Share Buyback Program. Refer to Note 24 - Subsequent Events for additional information on the share repurchase programs.

In the first quarter of 2021, the Company's Board of Directors authorized a $1.5 billion share buyback program, which expired on June 30, 2022 ("2021 Share Buyback Program"). At the expiry of the 2021 Share Buyback Program, the Company had repurchased and retired a total of 19.6 million shares for $1.5 billion.

On June 1, 2019, the Company's Board of Directors approved a $2 billion share buyback program ("2019 Share Buyback Program"), which expired on June 1, 2021. At the expiry of the 2019 Share Buyback Program, the Company had repurchased and retired a total of 29.9 million shares at a cost of $2 billion.

Accumulated Other Comprehensive Loss

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2022 and 2021:

Accumulated Other Comprehensive Loss	Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2021
Balance at January 1, 2021	$	470	$	(425)	$	(1)	$	44
Other comprehensive (loss) income before reclassifications	(545)		20		38		(487)
Amounts reclassified from accumulated other comprehensive loss	—		3		—		3
Split-off of N&B reclassification adjustment	184		73		1		258
Net other comprehensive (loss) income	$	(361)	$	96	$	39	$	(226)
Balance at September 30, 2021	$	109	$	(329)	$	38	$	(182)
2022
Balance at January 1, 2022	$	(88)	$	73	$	56	$	41
Other comprehensive (loss) income before reclassifications	(1,774)		24		109		(1,641)
Amounts reclassified from accumulated other comprehensive loss	—		(3)		—		(3)
Net other comprehensive (loss) income	$	(1,774)	$	21	$	109	$	(1,644)
Balance at September 30, 2022	$	(1,862)	$	94	$	165	$	(1,603)

The tax effects on the net activity related to each component of other comprehensive (loss) income were not significant for the three and nine months ended September 30, 2022 and 2021.

A summary of the reclassifications out of AOCL for the three and nine months ended September 30, 2022 and 2021 is provided as follows:

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2022		2021		2022		2021
Cumulative translation adjustments	$	—	$	—	$	—	$	184	See (1) below
Pension and other post-employment benefit plans	$	(2)	$	2	$	(4)	$	110	See (1) below
Tax expense (benefit)	—		(5)		1		(34)		See (1) below
After tax	$	(2)	$	(3)	$	(3)	$	76
Derivative instruments	$	—	$	—	$	—	$	1	See (1) below
Total reclassifications for the period, after tax	$	(2)	$	(3)	$	(3)	$	261

1. The activity for the three and nine months ended September 30, 2022 is classified within the "Sundry income (expense) - net". The activity for the three and nine months ended September 30, 2021 is classified almost entirely within "Income from discontinued operations, net of tax" as part of the N&B Transaction, with a portion classified within "Sundry income (expense) - net" and "(Benefit from) provision for income taxes on continuing operations" as part of continuing operations.

XML

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS

9 Months Ended

Sep. 30, 2022

Retirement Benefits [Abstract]

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS

A summary of the Company's pension plans and other post-employment benefits can be found in Note 19 to the Consolidated Financial Statements included in the Company’s 2021 Annual Report.

The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post-employment benefits:

Net Periodic Benefit (Credit) Cost for All Plans	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Service cost 1	$	9	$	13	$	32	$	42
Interest cost 2	14		11		41		32
Expected return on plan assets 3	(24)		(26)		(76)		(80)
Amortization of prior service credit 4	(1)		(2)		(4)		(4)
Amortization of unrecognized net loss 5	1		3		2		10
Curtailment/settlement 6	(2)		(1)		(1)		2
Net periodic benefit (credit) cost - total	$	(3)	$	(2)	$	(6)	$	2
Less: Net periodic benefit credit - discontinued operations	(2)		(2)		(7)		(4)
Net periodic benefit cost - continuing operations	$	(1)	$	—	$	1	$	6

1. The service cost from continuing operations was $6 million and $21 million for the three and nine months ended September 30, 2022, respectively, compared with $9 million and $28 million for the three and nine months ended September 30, 2021, respectively.

2. The interest cost from continuing operations was $13 million and $37 million for the three and nine months ended September 30, 2022, respectively, compared with $10 million and $29 million for the three and nine months ended September 30, 2021, respectively.

3. The expected return on plan assets from continuing operations was $19 million and $57 million for the three and nine months ended September 30, 2022, respectively, compared with $19 million and $59 million for the three and nine months ended September 30, 2021.

4. The amortization of prior service credit from continuing operations was zero and $2 million for the three and nine months ended September 30, 2022, respectively, compared with a gain of $2 million and $4 million for the three and nine months ended September 30, 2021, respectively.

5. The amortization of unrecognized net loss from continuing operations was $1 million and $3 million or the three and nine months ended September 30, 2022, respectively, compared with a net loss of $3 million and $10 million for the three and nine months ended September 30, 2021, respectively.

6. The curtailment and settlement gain from continuing operations was $2 million and $1 million for the three and nine months ended September 30, 2022, respectively, a gain of $1 million for the three months ended September 30, 2021, and a loss of $2 million for the nine months ended September 30, 2021.

The continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations.

DuPont expects to make additional contributions in the aggregate of approximately $35 million by year-end 2022.

XML

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

A summary of the Company's stock-based compensation plans can be found in Note 20 to the Consolidated Financial Statements included in the Company's 2021 Annual Report. In the second quarter of 2020, the stockholders of DuPont approved the DuPont 2020 Equity and Incentive Plan (the "2020 Plan") which allows the Company to grant options, share appreciation rights, restricted shares, restricted stock units ("RSUs"), share bonuses, other share-based awards, cash awards, or any combination of the foregoing. Under the 2020 Plan, a maximum of 17 million shares of common stock are available for award as of September 30, 2022.

DuPont recognized share-based compensation expense of $20 million and $15 million for the three months ended September 30, 2022 and 2021, respectively, and $58 million and $49 million for the nine months ended September 30, 2022 and 2021, respectively. The income tax benefits related to stock-based compensation arrangements were $4 million and $3 million for the three months ended September 30, 2022 and 2021, respectively, and $12 million and $10 million for the nine months ended September 30, 2022 and 2021, respectively.

In the first quarter of 2022, the Company granted 0.7 million RSUs, 0.5 million stock options and 0.3 million performance-based stock units ("PSUs"). The weighted-average fair values per share associated with the grants were $75.12 per RSU, $17.41 per stock option and $81.55 per PSU. The stock options had a weighted-average exercise price per share of $75.05. There was minimal activity in the second and third quarters of 2022.

XML

FINANCIAL INSTRUMENTS

9 Months Ended

Sep. 30, 2022

Investments, All Other Investments [Abstract]

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS

The following table summarizes the fair value of financial instruments at September 30, 2022 and December 31, 2021:

Fair Value of Financial Instruments	September 30, 2022								December 31, 2021
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	427	$	—	$	—	$	427	$	841	$	—	$	—	$	841
Restricted cash equivalents 1	$	111	$	—	$	—	$	111	$	65	$	—	$	—	$	65
Total cash and restricted cash equivalents	$	538	$	—	$	—	$	538	$	906	$	—	$	—	$	906
Long-term debt including debt due within one year	$	(10,639)	$	497	$	(64)	$	(10,206)	$	(10,632)	$	—	$	(1,963)	$	(12,595)
Derivatives relating to:
Net investment hedge 2	—		211		—		211		—		74		—		74
Foreign currency 3, 4	—		39		(50)		(11)		—		5		(10)		(5)
Interest rate swap agreements 5	—		—		(75)		(75)		—		—		—		—
Total derivatives	$	—	$	250	$	(125)	$	125	$	—	$	79	$	(10)	$	69

1.At September 30, 2022 there was $8 million of restricted cash classified as "Prepaid and other current assets" and $103 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheets. At December 31, 2021 there was $12 million of restricted cash classified as "Prepaid and other current assets" and $53 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheet. See Note 7 for more information on restricted cash.

2.Classified as "Deferred charges and other assets" in the Condensed Consolidated Balance Sheets.

3.Classified as "Prepaid and other current assets" and "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

4.Presented net of cash collateral where master netting arrangements allow.

5.Classified as "Other noncurrent obligations" in the Condensed Consolidated Balance Sheets.

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps.

The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly monitored and reported to management.

The notional amounts of the Company's derivative instruments were as follows:

Notional Amounts	September 30, 2022		December 31, 2021
In millions
Derivatives designated as hedging instruments:
Net investment hedge	$	1,000	$	1,000
Interest rate swap agreements	$	1,000	$	—
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(407)	$	(625)

1.Presented net of contracts bought and sold.

Derivatives Designated in Hedging Relationships

Net Foreign Investment Hedge

In the second quarter of 2021, the Company entered into fixed-for-fixed cross currency swaps with an aggregate notional amount totaling $1 billion to hedge the variability of exchange rate impacts between the U.S. dollar and euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged $1 billion at an interest rate of 4.73% for €819 million at a weighted average interest rate of 3.26%. The cross-currency swap is designated as a net investment hedge and expires on November 15, 2028.

The Company has made an accounting policy election to account for the net investment hedge using the spot method. The Company has also elected to amortize the excluded components in interest expense in the related quarterly accounting period that such interest is accrued. The cross-currency swap is marked to market at each reporting date and any unrealized gains or losses are included in unrealized currency translation adjustments within AOCL, net of amounts associated with excluded components which are recognized in interest expense in the interim Consolidated Statements of Operations.

Interest Rate Swap Agreements

In the second quarter of 2022, the Company entered into fixed-to-floating interest rate swap agreements with an aggregate notional principal amount totaling $1 billion to hedge changes in the fair value of the Company’s long-term debt due to interest rate change movements. These swaps converted $1 billion of the Company’s $1.65 billion principal amount of fixed rate notes due 2038 into floating rate debt for the portion of their terms through 2032 with an interest rate based on the Secured Overnight Financing Rate ("SOFR"). Under the terms of the agreements, the Company agrees to exchange, at specified intervals, fixed for floating interest amounts based on the agreed upon notional principal amount. The interest rate swaps are designated as fair value hedges and expire on November 15, 2032.

The interest rate swaps are carried at fair value. Fair value hedge accounting has been applied and thus, changes in the fair value of these swaps and changes in the fair value of the related hedged portion of long-term debt will be presented and will net to zero in Sundry income (expense) – net in the interim Consolidated Statements of Operations.

Derivatives not Designated in Hedging Relationships

Foreign Currency Contracts

The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues.

Effect of Derivative Instruments

Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a loss of $24 million and $11 million for the three months ended September 30, 2022 and 2021, respectively. There was a loss of $73 million and $38 million for the nine months ended September 30, 2022 and 2021, respectively. The income statement effects of other derivatives were immaterial.

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair Value Measurements on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2022	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	538
Derivatives relating to: 2
Net investment hedge	211
Foreign currency contracts 3	80
Total assets at fair value	$	829
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	10,206
Derivatives relating to: 2
Interest rate swap agreements	75
Foreign currency contracts 3	91
Total liabilities at fair value	$	10,372

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts for foreign currency contracts were $41 million for both assets and liabilities as of September 30, 2022.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Fair value includes fair value hedging adjustments related to the Company's interest rate swap agreements.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2021	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	906
Derivatives relating to: 2
Net investment hedge	74
Foreign currency contracts 3	11
Total assets at fair value	$	991
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	12,595
Derivatives relating to: 2
Foreign currency contracts 3	16
Total liabilities at fair value	$	12,611

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $6 million for both assets and liabilities as of December 31, 2021.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

Fair Value Measurements on a Nonrecurring Basis

In the first quarter of 2022, the Company recorded an other-than-temporary impairment, classified as Level 3 measurements, on an equity method investment. See Note 6 for further discussion of these fair value measurements.

XML

SEGMENTS AND GEOGRAPHIC REGIONS

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SEGMENTS AND GEOGRAPHIC REGIONS

SEGMENTS AND GEOGRAPHIC REGIONS

Effective February 2022, the revenues and certain expenses of the M&M Businesses are classified as discontinued operations in the current and historical periods. In addition, the Retained Businesses previously reported in the historic Mobility & Materials segment are reported in Corporate & Other. These reporting changes have been retrospectively applied for all periods presented.

The historic Mobility & Material segment costs that are classified as discontinued operations include only direct operating expenses incurred by the M&M Businesses which the Company will cease to incur upon the close of the M&M Divestitures. Indirect costs, such as those related to corporate and shared service functions previously allocated to the M&M Businesses, do not meet the criteria for discontinued operations and remain reported within continuing operations. A portion of these indirect costs include costs related to activities the Company will continue to undertake post-closing of the M&M Divestiture, and for which it will be reimbursed (“Future Reimbursable Indirect Costs”). Future Reimbursable Indirect Costs are reported within continuing operations but are excluded from operating EBITDA as defined below. The remaining portion of these indirect costs is not subject to future reimbursement (“Stranded Costs”). Stranded Costs are reported within continuing operations in Corporate & Other and are included within Operating EBITDA.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

The reporting changes have been retrospectively reflected in the segment results for all periods presented.

Segment Information	Electronics. & Industrial		Water & Protection		Corporate & Other 1		Total
In millions
Three Months Ended September 30, 2022
Net sales	$	1,511	$	1,534	$	272	$	3,317
Operating EBITDA 2	$	473	$	382	$	1	$	856
Equity in earnings of nonconsolidated affiliates	$	7	$	9	$	—	$	16
Three Months Ended September 30, 2021
Net sales	$	1,467	$	1,397	$	335	$	3,199
Operating EBITDA 2	$	475	$	353	$	(11)	$	817
Equity in earnings of nonconsolidated affiliates	$	13	$	7	$	2	$	22
Nine Months Ended September 30, 2022
Net sales	$	4,574	$	4,460	$	879	$	9,913
Operating EBITDA 2	$	1,429	$	1,071	$	3	$	2,503
Equity in earnings of nonconsolidated affiliates	$	26	$	31	$	5	$	62
Nine Months Ended September 30, 2021
Net sales	$	4,087	$	4,137	$	1,096	$	9,320
Operating EBITDA 2	$	1,335	$	1,060	$	5	$	2,400
Equity in earnings of nonconsolidated affiliates	$	32	$	27	$	6	$	65

1.Corporate & Other includes activities of the Retained Businesses and previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

2.A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA is provided below.

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2022 and 2021		Three Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	359	$	259
+	Provision for income taxes on continuing operations	139		80
Income from continuing operations before income taxes		$	498	$	339
+	Depreciation and amortization	283		300
-	Interest income 1	5		1
+	Interest expense	127		115
-	Non-operating pension/OPEB benefit 1	7		9
-	Foreign exchange gains (losses), net 1	5		(19)
+	Future reimbursable indirect costs	14		15
-	Significant items	49		(39)
Operating EBITDA		$	856	$	817

1.Included in "Sundry income (expense) - net."

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2022 and 2021		Nine Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	956	$	1,040
+	Provision for income taxes on continuing operations	299		172
Income from continuing operations before income taxes		$	1,255	$	1,212
+	Depreciation and amortization	861		817
-	Interest income 1	8		10
+	Interest expense	365		390
-	Non-operating pension/OPEB benefit 1	20		22
-	Foreign exchange gains (losses), net 1	9		(35)
+	Future reimbursable indirect costs	45		46
-	Significant items	(14)		68
Operating EBITDA		$	2,503	$	2,400

1.Included in "Sundry income (expense) - net."

The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(7)	$	(7)
Gain on divestiture 2	—		—		5		5
Intended Rogers Acquisition financing fees 3	—		—		(1)		(1)
Employee Retention Credit 4	20		20		12		52
Total	$	20	$	20	$	9	$	49

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Reflected in "Sundry income (expense) - net."

3. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

4. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

Significant Items by Segment for the Three Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(29)	$	(29)
Restructuring and asset related charges - net 2	—		—		(1)		(1)
Gain on divestiture 3	—		—		3		3
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	(27)	$	(39)

1. Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

Significant Items by Segment for the Nine Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(28)	$	(28)
Restructuring and asset related charges - net 2	(1)		(3)		(3)		(7)
Asset impairment charges 3	(94)		—		—		(94)
Gain on divestiture 4	—		37		31		68
Intended Rogers Acquisition financing fees 5	—		—		(5)		(5)
Employee Retention Credit 6	20		20		12		52
Total	$	(75)	$	54	$	7	$	(14)

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Includes restructuring actions and asset related charges. See Note 6 for additional information.

3. Relates to an impairment of an equity method investment. See Note 6 for additional information.

4. Reflected in "Sundry income (expense) - net."

5. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

6. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

Significant Items by Segment for the Nine Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(58)	$	(58)
Restructuring and asset related charges - net 2	(2)		—		(6)		(8)
Gain on divestiture 3	2		—		144		146
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	80	$	68

1.Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

Closing of the M&M Divestiture and the Use of Proceeds

On November 1, 2022, DuPont completed the divestiture of the majority of its historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Business”), to Celanese for a purchase price of $11.0 billion in cash. Preliminary cash received, as adjusted for preliminary and other adjustments, was $11.0 billion including approximately $0.5 billion of cash transferred with the M&M Business for which DuPont was reimbursed.

Use of Net Proceeds

On November 7, 2022, DuPont’s Board of Directors approved a new share repurchase program authorizing the repurchase and retirement of up to $5 billion of common stock. The new repurchase authorization of up to $5 billion is in addition to the $250 million remaining under the Company’s existing share repurchase program which was approved in February 2022. The Company intends to enter accelerated share repurchase agreements (the “ASR Agreements”) imminently, for the repurchase of an aggregate of approximately $3.25 billion of common stock with $250 million of such repurchases under the existing program and the remaining $3 billion under the new program. Any additional repurchases under the new share repurchase program will be made from time to time on the open market at prevailing market prices or in privately negotiated transactions off the market, which may include additional accelerated share repurchase agreements. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The new repurchase program terminates on June 30, 2024, unless extended or shortened by the Board of Directors.

The Company is in the process of notifying holders of the 2018 Senior Notes of the Company's intent to exercise its right to redeem fixed-rate long term debt of $2.5 billion due 2023 in full together with unpaid interest. The Company expects to complete the redemption by the end of 2022 with proceeds from the M&M Transaction.

Intended Rogers Acquisition

On November 1, 2022, the Company announced the termination of the previously announced agreement to acquire the outstanding shares of Rogers Corporation, as DuPont and Rogers have been unable to obtain timely clearance from all the required regulators. DuPont paid Rogers a termination fee of $162.5 million in accordance with the agreement on November 2, 2022, which will be recognized as a charge in the fourth quarter of 2022.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

In these notes, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should also be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, collectively referred to as the "2021 Annual Report." The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.

Mobility & Materials

On November 1, 2022 DuPont completed the previously announced divestiture of the majority of the historic Mobility & Materials segment, including the Engineering Polymers business line and select product lines within the Advanced Solutions and Performance Resins business lines (the “M&M Divestiture”). The Company had previously entered into a Transaction Agreement (the "Transaction Agreement") with Celanese Corporation ("Celanese") on February 17, 2022. Refer to Note 4 and Note 24 - Subsequent Events for further information. In addition, on February 18, 2022, the Company announced it is advancing the process to divest its Delrin® acetal homopolymer (H-POM) business, subject to entry into a definitive agreement and satisfaction of customary closing conditions. The Delrin® divestiture together with the M&M Divestiture discussed above (the "M&M Divestitures") represent a strategic shift that will have a major impact on DuPont's operations and results. See Note 4 for more information.

The financial position of DuPont as of September 30, 2022 and December 31, 2021 present the businesses to be divested as part of the M&M Divestiture and the divestiture of Delrin® (the "M&M Businesses") as discontinued operations. The results of operations for the three and nine months ended September 30, 2022 and 2021 present the financial results of the M&M Businesses as discontinued operations. The cash flows and comprehensive income of the M&M Businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of the M&M Businesses. See Note 4 to the interim Consolidated Financial Statements for additional information.

The Auto Adhesives & Fluids, MultibaseTM and Tedlar® product lines, previously reported within the historic Mobility & Materials segment, (the "Retained Businesses") are not included in the scope of the M&M Divestitures. Effective with the signing of the Transaction Agreement, the Retained Businesses were realigned to Corporate & Other. The reporting changes have been retrospectively applied for all periods presented.

N&B Transaction

On February 1, 2021, DuPont completed the separation and distribution of the Nutrition & Biosciences business segment (the "N&B Business"), and the merger of Nutrition & Biosciences, Inc. (“N&B”), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF"). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). See Note 4 for more information.

The results of operations of DuPont for the three and nine months ended September 30, 2021 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable periods. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B.

Accounting Guidance Issued But Not Adopted at September 30, 2022

Accounting Guidance Issued But Not Adopted at September 30, 2022

In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (i.e., unearned revenue) acquired in a business combination to be recognized and measured in accordance with ASC 606, Revenue from Contracts with Customers. Historically, the Company has recognized contract assets and contract liabilities at the acquisition date based on fair value estimates in accordance with ASC 805, Business Combinations. ASU 2021-08 is effective for interim and annual periods beginning after December 15, 2022 on a prospective basis, with early adoption permitted.

In September 2022, the FASB issued Accounting Standards Update No. 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50)" ("ASU 2022-04") to enhance transparency about the use of supplier finance programs. The new guidance requires that a buyer in a supplier finance program provides additional qualitative and quantitative disclosures about its program including the nature of the program, activity during the period, changes from period to period, and the potential magnitude of the program. The amendments in ASU 2022-04 are effective for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the amendment on rollforward information which is effective prospectively for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently evaluating the potential impact of ASU 2022-04 to its related disclosures.

XML

ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Integration and Separation Costs

These costs are recorded within "Acquisition, integration and separation costs" within the interim Consolidated Statements of Operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Acquisition, integration and separation costs	$	7	$	29	$	28	$	58

XML

DIVESTITURES (Tables)

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations

The results of operations of the M&M Businesses are presented as discontinued operations as summarized below:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Net sales	$	988	$	1,072	$	3,100	$	3,062
Cost of sales	771		746		2,357		2,093
Research and development expenses	12		15		41		47
Selling, general and administrative expenses	25		64		110		189
Amortization of intangibles	—		38		28		120
Restructuring and asset related charges - net	—		—		—		5
Acquisition, integration and separation costs	135		—		357		—
Equity in (losses) earnings of nonconsolidated affiliates	(5)		3		(7)		11
Sundry income (expense) - net	7		7		—		15
Income from discontinued operations before income taxes	47		219		200		634
Provision for (benefit from) income taxes on discontinued operations	21		45		(607)		136
Income from discontinued operations, net of tax	26		174		807		498
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	33	$	170	$	812	$	484

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the M&M Businesses:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation and amortization	$	—	$	70	$	45	$	214
Capital expenditures 1	$	22	$	17	$	64	$	41

1.Total capital expenditures are presented on a cash basis.

The following table summarizes the major classes of assets and liabilities of the M&M Businesses classified as held for sale presented as discontinued operations at September 30, 2022 and December 31, 2021:

In millions	September 30, 2022		December 31, 2021
Assets
Cash and cash equivalents	$	38	$	39
Accounts and notes receivable - net	624		552
Inventories	1,072		776
Other current assets	45		59
Property, plant and equipment - net	1,193		1,213
Goodwill	2,432		2,597
Other intangible assets	2,127		2,220
Investments and noncurrent receivables	52		62
Deferred income tax assets	21		27
Deferred charges and other assets	129		119
Total assets of discontinued operations	$	7,733	$	7,664
Liabilities
Accounts payable	$	552	$	510
Income taxes payable	41		77
Accrued and other current liabilities	137		157
Deferred income tax liabilities	537		515
Pension and other post employment benefits - noncurrent	55		90
Other noncurrent liabilities	70		64
Total liabilities of discontinued operations	$	1,392	$	1,413

The results of operations of N&B are presented as discontinued operations as summarized below:

	Nine Months Ended September 30, 2021
In millions
Net sales	$	507
Cost of sales	354
Research and development expenses	21
Selling, general and administrative expenses	47
Amortization of intangibles	38
Restructuring and asset related charges - net	1
Acquisition, integration and separation costs	172
Sundry income (expense) - net	8
Interest expense	13
Loss from discontinued operations before income taxes	(131)
Benefit from income taxes on discontinued operations	(27)
Loss from discontinued operations, net of tax	(104)
Non-taxable gain on split-off	4,940
Income from discontinued operations attributable to DuPont stockholders, net of tax	$	4,836

The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to N&B:

	Nine Months Ended September 30, 2021
In millions
Depreciation and amortization	$	63
Capital expenditures	$	27

Discontinued operations activity consists of the following:

Income from discontinued operations, net of tax	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
M&M Divestitures	$	26	$	174	$	807	$	498
N&B Transaction	—		(12)		—		4,836
Other 1	(9)		(17)		(84)		(85)
Income from discontinued operations, net of tax	$	17	$	145	$	723	$	5,249

1.Primarily related to the binding Memorandum of Understanding (“MOU”) between Chemours, Corteva, E. I. du Pont de Nemours and Company ("EID") and the Company. For additional information on these matters, refer to Note 16.

The following table summarizes the carrying value of the major assets and liabilities of the Biomaterials business unit reflected as held for sale at December 31, 2021:

In millions	December 31, 2021
Assets
Accounts and notes receivable - net	$	27
Inventories	48
Investments and noncurrent receivables	158
Property, plant and equipment - net	12
Assets held for sale	$	245
Liabilities
Accounts payable	$	21
Accrued and other current liabilities	3
Other noncurrent obligations	1
Liabilities related to assets held for sale	$	25

XML

REVENUE (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Trade Revenue

Net Trade Revenue by Segment and Business or Major Product Line	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Industrial Solutions	$	496	$	474	$	1,499	$	1,412
Interconnect Solutions	446		489		1,371		1,158
Semiconductor Technologies	569		504		1,704		1,517
Electronics & Industrial	$	1,511	$	1,467	$	4,574	$	4,087
Safety Solutions	$	684	$	646	$	2,001	$	1,933
Shelter Solutions	476		414		1,385		1,193
Water Solutions	374		337		1,074		1,011
Water & Protection	$	1,534	$	1,397	$	4,460	$	4,137
Retained Businesses 1	$	272	$	226	$	804	$	721
Other 2	—		109		75		375
Corporate & Other	$	272	$	335	$	879	$	1,096
Total	$	3,317	$	3,199	$	9,913	$	9,320

1. Retained Businesses includes the Auto Adhesives & Fluids, MultibaseTM and Tedlar® businesses.

2. Net sales reflected in Other include activity of previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

Net Trade Revenue by Geographic Region	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
U.S. & Canada	$	1,149	$	1,011	$	3,293	$	2,875
EMEA 1	523		562		1,665		1,672
Asia Pacific	1,524		1,529		4,622		4,490
Latin America	121		97		333		283
Total	$	3,317	$	3,199	$	9,913	$	9,320

1.Europe, Middle East and Africa.

Schedule of Contract Balances

Contract Balances	September 30, 2022		December 31, 2021
In millions
Accounts and notes receivable - trade 1	$	1,712	$	1,643
Deferred revenue - current 2, 3	$	16	$	25

1.Included in "Accounts and notes receivable - net" in the Condensed Consolidated Balance Sheets.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

3.Noncurrent deferred revenue balances in the current and comparative periods were not material.

XML

SUPPLEMENTARY INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Sundry Income (Expense), Net

Sundry Income (Expense) - Net	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Non-operating pension and other post-employment benefit ("OPEB") credits	$	7	$	9	$	20	$	22
Interest income	5		1		8		10
Net gain on divestiture and sales of other assets and investments 1, 2	6		8		75		175
Foreign exchange gains (losses), net	5		(19)		9		(35)
Miscellaneous income (expenses) - net 3	3		2		11		(17)
Sundry income (expense) - net	$	26	$	1	$	123	$	155

1. The nine months ended September 30, 2022 primarily reflects income of $26 million related to the gain on sale of the Biomaterials business unit and $37 million related to the sale of a land use right within the Water & Protection segment.

2. The nine months ended September 30, 2021 primarily reflects income of $140 million related to the gain on sale of assets within Corporate & Other and income of $28 million related to the gain on sale of assets within the Electronics & Industrial segment.

3. The nine months ended September 30, 2021 includes an impairment charge of approximately $15 million related to an asset sale.

XML

EARNINGS PER SHARE CALCULATIONS (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following tables provide earnings per share calculations for the three and nine months ended September 30, 2022 and 2021:

Net Income for Earnings Per Share Calculations - Basic & Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Income from continuing operations, net of tax	$	359	$	259	$	956	$	1,040
Net income from continuing operations attributable to noncontrolling interests	16		9		42		12
Income from continuing operations attributable to common stockholders	$	343	$	250	$	914	$	1,028
Income from discontinued operations, net of tax	17		145		723		5,249
Net income from discontinued operations attributable to noncontrolling interests	(7)		4		(5)		14
Income from discontinued operations attributable to common stockholders	24		141		728		5,235
Net income attributable to common stockholders	$	367	$	391	$	1,642	$	6,263

Earnings Per Share Calculations - Basic	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.81	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.49
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.25	$	11.35

Earnings Per Share Calculations - Diluted	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars per share	2022		2021		2022		2021
Earnings from continuing operations attributable to common stockholders	$	0.69	$	0.48	$	1.80	$	1.86
Earnings from discontinued operations, net of tax	0.05		0.27		1.44		9.46
Earnings attributable to common stockholders 1	$	0.73	$	0.75	$	3.24	$	11.32

Share Count Information	Three Months Ended September 30,		Nine Months Ended September 30,
Shares in millions	2022	2021	2022	2021
Weighted-average common shares - basic	499.4	521.5	505.6	551.7
Plus dilutive effect of equity compensation plans	1.0	1.6	1.3	1.4
Weighted-average common shares - diluted	500.4	523.1	506.9	553.1
Stock options, restricted stock units, and performance-based restricted stock units excluded from EPS calculations 2	4.4	2.4	3.0	2.7

1.Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

2.These outstanding options to purchase shares of common stock, restricted stock units, and performance-based restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

XML

ACCOUNTS AND NOTES RECEIVABLE - NET (Tables)

9 Months Ended

Sep. 30, 2022

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable

In millions	September 30, 2022		December 31, 2021
Accounts receivable – trade 1	$	1,691	$	1,612
Other 2	566		547
Total accounts and notes receivable - net	$	2,257	$	2,159

1.Accounts receivable – trade is net of allowances of $38 million at September 30, 2022 and $28 million at December 31, 2021. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts.

2.Other includes receivables in relation to value added tax, indemnification assets, general sales tax and other taxes, and other receivables. No individual group represents more than ten percent of total receivables.

XML

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Current Inventory

In millions	September 30, 2022		December 31, 2021
Finished goods	$	1,334	$	1,201
Work in process	519		446
Raw materials	392		323
Supplies	114		116
Total inventories	$	2,359	$	2,086

XML

PROPERTY, PLANT, AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2022

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

	Estimated Useful Lives (Years)			September 30, 2022		December 31, 2021
In millions
Land and land improvements	1	-	25	$	394	$	440
Buildings	1	-	50	1,904		1,954
Machinery, equipment, and other	1	-	25	6,462		6,467
Construction in progress				944		1,034
Total property, plant and equipment				$	9,704	$	9,895
Total accumulated depreciation				$	4,227	$	4,142
Total property, plant and equipment - net				$	5,477	$	5,753

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Depreciation expense	$	137	$	142	$	414	$	407

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 were as follows:

In millions	Electronics & Industrial		Water & Protection		Corporate & Other		Total
Balance at December 31, 2021	$	9,583	$	6,801	$	597	$	16,981
Currency Translation Adjustment	(337)		(326)		(16)		(679)
Balance at September 30, 2022	$	9,246	$	6,475	$	581	$	16,302

Schedule of Other Finite Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2022						December 31, 2021
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	2,331	$	(1,241)	$	1,090	$	2,374	$	(1,124)	$	1,250
Trademarks/tradenames	1,114		(542)		572		1,125		(500)		625
Customer-related	5,416		(2,366)		3,050		5,806		(2,296)		3,510
Other	105		(71)		34		113		(80)		33
Total other intangible assets with finite lives	$	8,966	$	(4,220)	$	4,746	$	9,418	$	(4,000)	$	5,418
Intangible assets with indefinite lives:
Trademarks/tradenames	804		—		804		804		—		804
Total other intangible assets with indefinite lives	804		—		804		804		—		804
Total	$	9,770	$	(4,220)	$	5,550	$	10,222	$	(4,000)	$	6,222

Schedule of Other Indefinite Intangible Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

	September 30, 2022						December 31, 2021
In millions	Gross Carrying Amount		Accum Amort		Net		Gross Carrying Amount		Accum Amort		Net
Intangible assets with finite lives:
Developed technology	$	2,331	$	(1,241)	$	1,090	$	2,374	$	(1,124)	$	1,250
Trademarks/tradenames	1,114		(542)		572		1,125		(500)		625
Customer-related	5,416		(2,366)		3,050		5,806		(2,296)		3,510
Other	105		(71)		34		113		(80)		33
Total other intangible assets with finite lives	$	8,966	$	(4,220)	$	4,746	$	9,418	$	(4,000)	$	5,418
Intangible assets with indefinite lives:
Trademarks/tradenames	804		—		804		804		—		804
Total other intangible assets with indefinite lives	804		—		804		804		—		804
Total	$	9,770	$	(4,220)	$	5,550	$	10,222	$	(4,000)	$	6,222

Schedule of Net Intangibles by Segment

The following table provides the net carrying value of other intangible assets by segment:

Net Intangibles by Segment	September 30, 2022		December 31, 2021
In millions
Electronics & Industrial	$	3,000	$	3,429
Water & Protection	2,456		2,686
Corporate & Other	94		107
Total	$	5,550	$	6,222

Schedule of Estimated Amortization Expense

Total estimated amortization expense for the remainder of 2022 and the five succeeding fiscal years is as follows:

Estimated Amortization Expense
In millions
Remainder of 2022	$	139
2023	$	567
2024	$	539
2025	$	498
2026	$	471
2027	$	424

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

The following table summarizes the Company's long-term debt:

Long-Term Debt	September 30, 2022				December 31, 2021
In millions	Amount		Weighted Average Rate		Amount		Weighted Average Rate
Promissory notes and debentures 1
Final maturity 2023	$	2,800	4.18	%	$	2,800	3.89	%
Final maturity 2025	1,850		4.49	%	1,850		4.49	%
Final maturity 2026 and thereafter 2	5,975		5.20	%	6,050		5.13	%
Other facilities:
Finance lease obligations	2				2
Less: Unamortized debt discount and issuance costs	63				70
Total	$	10,564			$	10,632

1. Represents senior unsecured notes (the "2018 Senior Notes"), which are senior unsecured obligations of the Company. See Note 24 for additional information.

2. Includes fair value hedging adjustment of $75 million related to the Company's interest rate swap agreements. See Note 21 for additional information.

Schedule of Maturities of Long-term Debt

Principal Payments of long-term debt for the remainder of 2022 and the five succeeding fiscal years are as follows:

Maturities of Long-Term Debt for Next Five Years at September 30, 2022	Total
In millions
Remainder of 2022	$	—
2023	$	2,800
2024	$	—
2025	$	1,850
2026	$	—
2027	$	—

Schedule of Line of Credit Facilities

The following table summarizes the Company's credit facilities:

Committed and Available Credit Facilities at September 30, 2022
In millions	Effective Date	Committed Credit		Credit Available		Maturity Date	Interest
Revolving Credit Facility, Five-year	April 2022	$	2,500	$	2,488	April 2027	Floating Rate
364-day Revolving Credit Facility	April 2022	1,000		1,000		April 2023	Floating Rate
Total Committed and Available Credit Facilities		$	3,500	$	3,488

XML

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of Loss Contingencies by Contingency

In connection with the MOU and the Agreements, the Company has recognized the following indemnification liabilities related to eligible PFAS costs:

Indemnified Liabilities Related to the MOU
In millions	Sept 30, 2022		Dec 31, 2021		Balance Sheet Classification
Current indemnified liabilities	$	55	$	37	Accrued and other current liabilities
Long-term indemnified liabilities	$	129	$	89	Other noncurrent obligations
Total indemnified liabilities accrued under the MOU 1, 2	$	184	$	126

1.As of September 30, 2022 and December 31, 2021, total indemnified liabilities accrued include $168 million and $112 million, respectively, related to Chemours environmental remediation activities at their site in Fayetteville, North Carolina under the Consent Order between Chemours and the North Carolina Department of Environmental Quality (the "NC DEQ").

2.In addition to the above, as of December 31, 2021, the Company had recognized a liability of $12.5 million related to the settlement agreement between Chemours, Corteva and DuPont and Delaware's Attorney General, discussed below.

Schedule of Environmental Obligation

The accrued environmental obligations include the following:

Environmental Accrued Obligations
In millions	Sept 30, 2022		Dec 31, 2021		Potential exposure above the amount accrued 1
Environmental remediation liabilities not subject to indemnity	$	39	$	43	$	105
Environmental remediation indemnified liabilities:
Indemnifications related to Dow and Corteva 2	48		46		63
MOU related obligations (discussed above) 3	172		116		84
Other Environmental Indemnifications	1		—		2
Total environmental related liabilities	$	260	$	205	$	254

1.The environmental accrual represents management’s best estimate of the costs for remediation and restoration with respect to environmental matters, although it is reasonably possible that the ultimate cost with respect to these particular matters could range above the amount accrued.

2.Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify Dow and Corteva for certain Non-PFAS clean-up responsibilities and associated remediation costs.

3.The MOU related obligations include the Company's estimate of its liability under the MOU for remediation activities based on the current regulatory environment.

XML

LEASES (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Lease Term and Discount Rates

The lease cost for operating leases were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Operating lease costs	$	27	$	27	$	82	$	80

Lease Term and Discount Rate for Operating Leases	September 30, 2022		December 31, 2021
Weighted-average remaining lease term (years)	8.07		8.50
Weighted average discount rate	2.33	%	2.01	%

Schedule of Operating Lease Assets and Liabilities

Supplemental balance sheet information related to leases was as follows:

In millions	September 30, 2022		December 31, 2021
Operating Leases
Operating lease right-of-use assets 1	$	386	$	422
Current operating lease liabilities 2	84		92
Noncurrent operating lease liabilities 3	301		337
Total operating lease liabilities	$	385	$	429

1.Included in "Deferred charges and other assets" in the Condensed Consolidated Balance Sheet.

2.Included in "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheet.

3.Included in "Other noncurrent obligations" in the Condensed Consolidated Balance Sheet.

Schedule of Maturity of Lease Liabilities

Maturities of lease liabilities were as follows:

Maturity of Lease Liabilities at September 30, 2022	Operating Leases
In millions
Remainder of 2022	$	25
2023	89
2024	75
2025	53
2026	36
2027 and thereafter	153
Total lease payments	$	431
Less: Interest	46
Present value of lease liabilities	$	385

XML

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the nine months ended September 30, 2022 and 2021:

Accumulated Other Comprehensive Loss	Cumulative Translation Adj		Pension and OPEB		Derivative Instruments		Total
In millions
2021
Balance at January 1, 2021	$	470	$	(425)	$	(1)	$	44
Other comprehensive (loss) income before reclassifications	(545)		20		38		(487)
Amounts reclassified from accumulated other comprehensive loss	—		3		—		3
Split-off of N&B reclassification adjustment	184		73		1		258
Net other comprehensive (loss) income	$	(361)	$	96	$	39	$	(226)
Balance at September 30, 2021	$	109	$	(329)	$	38	$	(182)
2022
Balance at January 1, 2022	$	(88)	$	73	$	56	$	41
Other comprehensive (loss) income before reclassifications	(1,774)		24		109		(1,641)
Amounts reclassified from accumulated other comprehensive loss	—		(3)		—		(3)
Net other comprehensive (loss) income	$	(1,774)	$	21	$	109	$	(1,644)
Balance at September 30, 2022	$	(1,862)	$	94	$	165	$	(1,603)

Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss

A summary of the reclassifications out of AOCL for the three and nine months ended September 30, 2022 and 2021 is provided as follows:

Reclassifications Out of Accumulated Other Comprehensive Loss	Three Months Ended September 30,				Nine Months Ended September 30,				Income Classification
In millions	2022		2021		2022		2021
Cumulative translation adjustments	$	—	$	—	$	—	$	184	See (1) below
Pension and other post-employment benefit plans	$	(2)	$	2	$	(4)	$	110	See (1) below
Tax expense (benefit)	—		(5)		1		(34)		See (1) below
After tax	$	(2)	$	(3)	$	(3)	$	76
Derivative instruments	$	—	$	—	$	—	$	1	See (1) below
Total reclassifications for the period, after tax	$	(2)	$	(3)	$	(3)	$	261

1. The activity for the three and nine months ended September 30, 2022 is classified within the "Sundry income (expense) - net". The activity for the three and nine months ended September 30, 2021 is classified almost entirely within "Income from discontinued operations, net of tax" as part of the N&B Transaction, with a portion classified within "Sundry income (expense) - net" and "(Benefit from) provision for income taxes on continuing operations" as part of continuing operations.

XML

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS (Tables)

9 Months Ended

Sep. 30, 2022

Retirement Benefits [Abstract]

Schedule of Net Periodic Benefit (Credit)

The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post-employment benefits:

Net Periodic Benefit (Credit) Cost for All Plans	Three Months Ended September 30,				Nine Months Ended September 30,
In millions	2022		2021		2022		2021
Service cost 1	$	9	$	13	$	32	$	42
Interest cost 2	14		11		41		32
Expected return on plan assets 3	(24)		(26)		(76)		(80)
Amortization of prior service credit 4	(1)		(2)		(4)		(4)
Amortization of unrecognized net loss 5	1		3		2		10
Curtailment/settlement 6	(2)		(1)		(1)		2
Net periodic benefit (credit) cost - total	$	(3)	$	(2)	$	(6)	$	2
Less: Net periodic benefit credit - discontinued operations	(2)		(2)		(7)		(4)
Net periodic benefit cost - continuing operations	$	(1)	$	—	$	1	$	6

1. The service cost from continuing operations was $6 million and $21 million for the three and nine months ended September 30, 2022, respectively, compared with $9 million and $28 million for the three and nine months ended September 30, 2021, respectively.

2. The interest cost from continuing operations was $13 million and $37 million for the three and nine months ended September 30, 2022, respectively, compared with $10 million and $29 million for the three and nine months ended September 30, 2021, respectively.

3. The expected return on plan assets from continuing operations was $19 million and $57 million for the three and nine months ended September 30, 2022, respectively, compared with $19 million and $59 million for the three and nine months ended September 30, 2021.

4. The amortization of prior service credit from continuing operations was zero and $2 million for the three and nine months ended September 30, 2022, respectively, compared with a gain of $2 million and $4 million for the three and nine months ended September 30, 2021, respectively.

5. The amortization of unrecognized net loss from continuing operations was $1 million and $3 million or the three and nine months ended September 30, 2022, respectively, compared with a net loss of $3 million and $10 million for the three and nine months ended September 30, 2021, respectively.

6. The curtailment and settlement gain from continuing operations was $2 million and $1 million for the three and nine months ended September 30, 2022, respectively, a gain of $1 million for the three months ended September 30, 2021, and a loss of $2 million for the nine months ended September 30, 2021.

XML

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2022

Investments, All Other Investments [Abstract]

Schedule of the Fair Value of Financial Instruments

The following table summarizes the fair value of financial instruments at September 30, 2022 and December 31, 2021:

Fair Value of Financial Instruments	September 30, 2022								December 31, 2021
In millions	Cost		Gain		Loss		Fair Value		Cost		Gain		Loss		Fair Value
Cash equivalents	$	427	$	—	$	—	$	427	$	841	$	—	$	—	$	841
Restricted cash equivalents 1	$	111	$	—	$	—	$	111	$	65	$	—	$	—	$	65
Total cash and restricted cash equivalents	$	538	$	—	$	—	$	538	$	906	$	—	$	—	$	906
Long-term debt including debt due within one year	$	(10,639)	$	497	$	(64)	$	(10,206)	$	(10,632)	$	—	$	(1,963)	$	(12,595)
Derivatives relating to:
Net investment hedge 2	—		211		—		211		—		74		—		74
Foreign currency 3, 4	—		39		(50)		(11)		—		5		(10)		(5)
Interest rate swap agreements 5	—		—		(75)		(75)		—		—		—		—
Total derivatives	$	—	$	250	$	(125)	$	125	$	—	$	79	$	(10)	$	69

1.At September 30, 2022 there was $8 million of restricted cash classified as "Prepaid and other current assets" and $103 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheets. At December 31, 2021 there was $12 million of restricted cash classified as "Prepaid and other current assets" and $53 million classified as "Restricted cash and cash equivalents" in the Condensed Consolidated Balance Sheet. See Note 7 for more information on restricted cash.

2.Classified as "Deferred charges and other assets" in the Condensed Consolidated Balance Sheets.

3.Classified as "Prepaid and other current assets" and "Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets.

4.Presented net of cash collateral where master netting arrangements allow.

5.Classified as "Other noncurrent obligations" in the Condensed Consolidated Balance Sheets.

Schedule of Notional Amounts

The notional amounts of the Company's derivative instruments were as follows:

Notional Amounts	September 30, 2022		December 31, 2021
In millions
Derivatives designated as hedging instruments:
Net investment hedge	$	1,000	$	1,000
Interest rate swap agreements	$	1,000	$	—
Derivatives not designated as hedging instruments:
Foreign currency contracts 1	$	(407)	$	(625)

1.Presented net of contracts bought and sold.

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of the Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

Basis of Fair Value Measurements on a Recurring Basis at September 30, 2022	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	538
Derivatives relating to: 2
Net investment hedge	211
Foreign currency contracts 3	80
Total assets at fair value	$	829
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	10,206
Derivatives relating to: 2
Interest rate swap agreements	75
Foreign currency contracts 3	91
Total liabilities at fair value	$	10,372

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts for foreign currency contracts were $41 million for both assets and liabilities as of September 30, 2022.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Fair value includes fair value hedging adjustments related to the Company's interest rate swap agreements.

Basis of Fair Value Measurements on a Recurring Basis at December 31, 2021	Significant Other Observable Inputs (Level 2)
In millions
Assets at fair value:
Cash equivalents and restricted cash equivalents 1	$	906
Derivatives relating to: 2
Net investment hedge	74
Foreign currency contracts 3	11
Total assets at fair value	$	991
Liabilities at fair value:
Long-term debt including debt due within one year 4	$	12,595
Derivatives relating to: 2
Foreign currency contracts 3	16
Total liabilities at fair value	$	12,611

1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Prepaid and other current assets" in the Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.

2. See Note 21 for the classification of derivatives in the Condensed Consolidated Balance Sheets.

3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Condensed Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $6 million for both assets and liabilities as of December 31, 2021.

4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

XML

SEGMENTS AND GEOGRAPHIC REGIONS (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Operating Segment Information

The reporting changes have been retrospectively reflected in the segment results for all periods presented.

Segment Information	Electronics. & Industrial		Water & Protection		Corporate & Other 1		Total
In millions
Three Months Ended September 30, 2022
Net sales	$	1,511	$	1,534	$	272	$	3,317
Operating EBITDA 2	$	473	$	382	$	1	$	856
Equity in earnings of nonconsolidated affiliates	$	7	$	9	$	—	$	16
Three Months Ended September 30, 2021
Net sales	$	1,467	$	1,397	$	335	$	3,199
Operating EBITDA 2	$	475	$	353	$	(11)	$	817
Equity in earnings of nonconsolidated affiliates	$	13	$	7	$	2	$	22
Nine Months Ended September 30, 2022
Net sales	$	4,574	$	4,460	$	879	$	9,913
Operating EBITDA 2	$	1,429	$	1,071	$	3	$	2,503
Equity in earnings of nonconsolidated affiliates	$	26	$	31	$	5	$	62
Nine Months Ended September 30, 2021
Net sales	$	4,087	$	4,137	$	1,096	$	9,320
Operating EBITDA 2	$	1,335	$	1,060	$	5	$	2,400
Equity in earnings of nonconsolidated affiliates	$	32	$	27	$	6	$	65

1.Corporate & Other includes activities of the Retained Businesses and previously divested businesses including Biomaterials, Clean Technologies and Solamet®.

2.A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA is provided below.

Schedule of Reconciliation of Income (Loss) from Continuing Operations

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2022 and 2021		Three Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	359	$	259
+	Provision for income taxes on continuing operations	139		80
Income from continuing operations before income taxes		$	498	$	339
+	Depreciation and amortization	283		300
-	Interest income 1	5		1
+	Interest expense	127		115
-	Non-operating pension/OPEB benefit 1	7		9
-	Foreign exchange gains (losses), net 1	5		(19)
+	Future reimbursable indirect costs	14		15
-	Significant items	49		(39)
Operating EBITDA		$	856	$	817

1.Included in "Sundry income (expense) - net."

Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2022 and 2021		Nine Months Ended September 30,
In millions		2022		2021
Income from continuing operations, net of tax		$	956	$	1,040
+	Provision for income taxes on continuing operations	299		172
Income from continuing operations before income taxes		$	1,255	$	1,212
+	Depreciation and amortization	861		817
-	Interest income 1	8		10
+	Interest expense	365		390
-	Non-operating pension/OPEB benefit 1	20		22
-	Foreign exchange gains (losses), net 1	9		(35)
+	Future reimbursable indirect costs	45		46
-	Significant items	(14)		68
Operating EBITDA		$	2,503	$	2,400

1.Included in "Sundry income (expense) - net."

Schedule of Certain Items by Segment

The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above:

Significant Items by Segment for the Three Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(7)	$	(7)
Gain on divestiture 2	—		—		5		5
Intended Rogers Acquisition financing fees 3	—		—		(1)		(1)
Employee Retention Credit 4	20		20		12		52
Total	$	20	$	20	$	9	$	49

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Reflected in "Sundry income (expense) - net."

3. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

4. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

Significant Items by Segment for the Three Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(29)	$	(29)
Restructuring and asset related charges - net 2	—		—		(1)		(1)
Gain on divestiture 3	—		—		3		3
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	(27)	$	(39)

1. Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

Significant Items by Segment for the Nine Months Ended September 30, 2022	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(28)	$	(28)
Restructuring and asset related charges - net 2	(1)		(3)		(3)		(7)
Asset impairment charges 3	(94)		—		—		(94)
Gain on divestiture 4	—		37		31		68
Intended Rogers Acquisition financing fees 5	—		—		(5)		(5)
Employee Retention Credit 6	20		20		12		52
Total	$	(75)	$	54	$	7	$	(14)

1. Acquisition, integration and separation costs related to strategic initiatives including the sale of the Biomaterials business unit, the acquisition of Laird PM and the Intended Rogers Acquisition.

2. Includes restructuring actions and asset related charges. See Note 6 for additional information.

3. Relates to an impairment of an equity method investment. See Note 6 for additional information.

4. Reflected in "Sundry income (expense) - net."

5. Includes acquisition costs associated with the Intended Rogers Acquisition related to the financing agreements, specifically the structuring fees and the amortization of the commitment fees reflected in "Interest Expense."

6. Employee Retention Credit pursuant to the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act as enhanced by the Consolidated Appropriations Act (“CAA”) and American Rescue Plan Act (“ARPA”) reflected in "Cost of sales," "Research and development expenses" and "Selling, general and administrative expenses."

Significant Items by Segment for the Nine Months Ended September 30, 2021	Electronics & Industrial		Water & Protection		Corporate & Other		Total
In millions
Acquisition, integration and separation costs 1	$	—	$	—	$	(58)	$	(58)
Restructuring and asset related charges - net 2	(2)		—		(6)		(8)
Gain on divestiture 3	2		—		144		146
Inventory step-up amortization 4	(12)		—		—		(12)
Total	$	(12)	$	—	$	80	$	68

1.Acquisition, integration and separation costs related to strategic initiatives, which primarily includes the acquisition of Laird PM and the sale of the Solamet®, Biomaterials, and Clean Technologies business units.

2. Includes Board approved restructuring plans and asset related charges. See Note 6 for additional information.

3. Reflected in "Sundry income (expense) - net."

4. Includes the amortization of the fair value step-up in Laird PM's inventories as a result of the acquisition.

XML

ACQUISITIONS - Narrative (Details) - USD ($) $ in Millions	Nov. 02, 2022	Nov. 02, 2021	Jul. 01, 2021
Rogers Corporation
Business Acquisition [Line Items]
Business combination, consideration transferred		$ 5,200.0
Rogers Corporation | Subsequent Event
Business Acquisition [Line Items]
Payment of termination fee	$ 162.5
Laird Performance Materials
Business Acquisition [Line Items]
Business combination, consideration transferred			$ 2,404.0
Ownership interest acquired (percentage)			100.00%
Net upward adjustments			$ 100.0

XML

ACQUISITIONS - Acquisition, Integration, and Separation Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisition, integration and separation costs	$ 7	$ 29	$ 28	$ 58

XML

DIVESTITURES - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		9 Months Ended
	Feb. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)		$ 0.01		$ 0.01		$ 0.01
Income from discontinued operations, net of tax		$ 17	$ 145	$ 723	$ 5,249
Pre-tax gain		5	3	68	146
DuPont
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.01
Mobility & Materials Businesses | Discontinued Operations, Held for sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax		$ 26	$ 174	807	498
Nutrition & Biosciences Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	$ 7,300
Nutrition & Biosciences Business | Nutrition & Biosciences Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.01
Nutrition & Biosciences Business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares accepted and retired in exchange offer (in shares)	197,400,000
Shares exchanged in exchange offer (in shares)	141,700,000
Gain (loss) from discontinued operation, net of tax					4,940
Income from discontinued operations, net of tax					$ (104)
Nutrition & Biosciences Business | Discontinued Operations | International Flavors & Fragrances Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.125
Convertible common stock, merger trigger, shares right to receive upon conversion (in shares)	1
Biomaterials Business Unit | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses				240
Pre-tax gain				26
Gain (loss) on disposition of business, net of tax				$ 21

XML

DIVESTITURES - Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations, net of tax	$ 17	$ 145	$ 723	$ 5,249
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)	4	(5)	14
Mobility & Materials Businesses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Provision for (benefit from) income taxes on discontinued operations	12		(655)
Mobility & Materials Businesses | Discontinued Operations, Held for sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	988	1,072	3,100	3,062
Cost of sales	771	746	2,357	2,093
Research and development expenses	12	15	41	47
Selling, general and administrative expenses	25	64	110	189
Amortization of intangibles	0	38	28	120
Restructuring and asset related charges - net	0	0	0	5
Acquisition, integration and separation costs	135	0	357	0
Equity in (losses) earnings of nonconsolidated affiliates	(5)	3	(7)	11
Sundry income (expense) - net	7	7	0	15
Income (loss) from discontinued operations before income taxes	47	219	200	634
Provision for (benefit from) income taxes on discontinued operations	21	45	(607)	136
(Loss) income from discontinued operations, net of tax	26	174	807	498
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)	4	(5)	14
Income from discontinued operations attributable to DuPont stockholders, net of tax	33	170	812	484
Nutrition & Biosciences Business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales				507
Cost of sales				354
Research and development expenses				21
Selling, general and administrative expenses				47
Amortization of intangibles				38
Restructuring and asset related charges - net				1
Acquisition, integration and separation costs				172
Sundry income (expense) - net				8
Interest expense				13
Income (loss) from discontinued operations before income taxes				(131)
Provision for (benefit from) income taxes on discontinued operations				(27)
(Loss) income from discontinued operations, net of tax				(104)
Non-taxable gain on split-off				4,940
Income from discontinued operations attributable to DuPont stockholders, net of tax	$ 0	$ (12)	$ 0	$ 4,836

XML

DIVESTITURES - Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Mobility & Materials Businesses | Discontinued Operations, Held for sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 0	$ 70	$ 45	$ 214
Capital expenditures	$ 22	$ 17	$ 64	41
Nutrition & Biosciences Business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization				63
Capital expenditures				$ 27

XML

DIVESTITURES - Carrying Amount of Assets and Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Discontinued Operations, Held for sale | Mobility & Materials Businesses
Assets
Cash and cash equivalents	$ 38	$ 39
Accounts and notes receivable - net	624	552
Inventories	1,072	776
Other current assets	45	59
Property, plant and equipment - net	1,193	1,213
Goodwill	2,432	2,597
Other intangible assets	2,127	2,220
Investments and noncurrent receivables	52	62
Deferred income tax assets	21	27
Deferred charges and other assets	129	119
Assets held for sale	7,733	7,664
Liabilities
Accounts payable	552	510
Income taxes payable	41	77
Accrued and other current liabilities	137	157
Deferred income tax liabilities	537	515
Pension and other post employment benefits - noncurrent	55	90
Other noncurrent liabilities	70	64
Liabilities related to assets held for sale	$ 1,392	1,413
Disposal Group, Held-for-sale, Not Discontinued Operations | Biomaterials Business Unit
Assets
Accounts and notes receivable - net		27
Inventories		48
Property, plant and equipment - net		12
Investments and noncurrent receivables		158
Assets held for sale		245
Liabilities
Accounts payable		21
Accrued and other current liabilities		3
Other noncurrent liabilities		1
Liabilities related to assets held for sale		$ 25

XML

DIVESTITURES - Income (loss) from Discontinued Operations, net of tax (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 17	$ 145	$ 723	$ 5,249
Discontinued Operations, Held for sale | M&M Divestitures
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	26	174	807	498
Income from discontinued operations attributable to DuPont stockholders, net of tax	33	170	812	484
Discontinued Operations | N&B Transaction
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax				(104)
Income from discontinued operations attributable to DuPont stockholders, net of tax	0	(12)	0	4,836
Discontinued Operations | Other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations attributable to DuPont stockholders, net of tax	$ (9)	$ (17)	$ (84)	$ (85)

XML

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 3,317	$ 3,199	$ 9,913	$ 9,320
Accounts and notes receivable - trade	1,712		1,712		$ 1,643
Deferred revenue - current	16		16		$ 25
Corporate & Other
Disaggregation of Revenue [Line Items]
Net sales	272	335	879	1,096
U.S. & Canada
Disaggregation of Revenue [Line Items]
Net sales	1,149	1,011	3,293	2,875
EMEA
Disaggregation of Revenue [Line Items]
Net sales	523	562	1,665	1,672
Asia Pacific
Disaggregation of Revenue [Line Items]
Net sales	1,524	1,529	4,622	4,490
Latin America
Disaggregation of Revenue [Line Items]
Net sales	121	97	333	283
Retained Businesses | Corporate & Other
Disaggregation of Revenue [Line Items]
Net sales	272	226	804	721
Other | Corporate & Other
Disaggregation of Revenue [Line Items]
Net sales	0	109	75	375
Electronics & Industrial
Disaggregation of Revenue [Line Items]
Net sales	1,511	1,467	4,574	4,087
Electronics & Industrial | Industrial Solutions
Disaggregation of Revenue [Line Items]
Net sales	496	474	1,499	1,412
Electronics & Industrial | Interconnect Solutions
Disaggregation of Revenue [Line Items]
Net sales	446	489	1,371	1,158
Electronics & Industrial | Semiconductor Technologies
Disaggregation of Revenue [Line Items]
Net sales	569	504	1,704	1,517
Water & Protection
Disaggregation of Revenue [Line Items]
Net sales	1,534	1,397	4,460	4,137
Water & Protection | Safety Solutions
Disaggregation of Revenue [Line Items]
Net sales	684	646	2,001	1,933
Water & Protection | Shelter Solutions
Disaggregation of Revenue [Line Items]
Net sales	476	414	1,385	1,193
Water & Protection | Water Solutions
Disaggregation of Revenue [Line Items]
Net sales	$ 374	$ 337	$ 1,074	$ 1,011

XML

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Oct. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Charges for restructuring programs and asset impairments	$ 0	$ 1,000,000	$ 101,000,000	$ 8,000,000
Restructuring reserve	21,000,000		21,000,000			$ 43,000,000
Equity method investment, other than temporary impairment			94,000,000
2021 Restructuring Actions
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	55,000,000		55,000,000
Liabilities recorded in "Accrued and other current liabilities"	17,000,000		17,000,000			25,000,000
2020 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	159,000,000		159,000,000
Liabilities recorded in "Accrued and other current liabilities"	2,000,000		2,000,000			$ 11,000,000
2022 Restructuring Program | Subsequent Event
Restructuring Cost and Reserve [Line Items]
Expected restructuring costs					$ 125,000,000
Severance and related benefit costs | 2021 Restructuring Actions
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	33,000,000		33,000,000
Severance and related benefit costs | 2020 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	107,000,000		107,000,000
Asset related charges | 2021 Restructuring Actions
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	22,000,000		22,000,000
Asset related charges | 2020 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	$ 52,000,000		$ 52,000,000

XML

SUPPLEMENTARY INFORMATION - Summary of Sundry Income (Expense) - Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule Of Sundry Income (Expense) [Line Items]
Non-operating pension and other post-employment benefit ("OPEB") credits	$ 7	$ 9	$ 20	$ 22
Interest income	5	1	8	10
Net gain on divestiture and sales of other assets and investments	6	8	75	175
Foreign exchange gains (losses), net	5	(19)	9	(35)
Miscellaneous income (expenses) - net	3	2	11	(17)
Sundry income (expense) - net	26	1	123	155
Pre-tax gain	$ 5	$ 3	68	146
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Biomaterials Business Unit
Schedule Of Sundry Income (Expense) [Line Items]
Pre-tax gain			26
Disposal Group, Held-for-sale, Not Discontinued Operations | Chestnut Run
Schedule Of Sundry Income (Expense) [Line Items]
Impairment related to an asset sale				15
Water & Protection
Schedule Of Sundry Income (Expense) [Line Items]
Net gain on divestiture and sales of other assets and investments			$ 37
Corporate and Other
Schedule Of Sundry Income (Expense) [Line Items]
Net gain on divestiture and sales of other assets and investments				140
Electronics & Imaging
Schedule Of Sundry Income (Expense) [Line Items]
Net gain on divestiture and sales of other assets and investments				$ 28

XML

SUPPLEMENTARY INFORMATION - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Supplementary Information
Restricted cash, noncurrent	$ 103	$ 53
Accrued and other current liabilities	990	1,040
Accrued payroll	326	436
Payments due annually beginning September 2023 | DuPont and Corteva
Supplementary Information
Restricted cash, noncurrent	$ 103	$ 53

XML

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Examination [Line Items]
Effective tax rate, percent	27.90%	23.60%	23.80%	14.20%
Tax expense (benefit) related to step-up in tax basis in goodwill				$ (59)
Mobility & Materials Businesses
Income Tax Examination [Line Items]
Tax expense (benefit)	$ 12		$ (655)

XML

EARNINGS PER SHARE CALCULATIONS - Summary of Net Income for EPS Calculations, Basic (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Income from continuing operations, net of tax	$ 359	$ 259	$ 956	$ 1,040
Net income from continuing operations attributable to noncontrolling interests	16	9	42	12
Income from continuing operations attributable to common stockholders	343	250	914	1,028
Income from discontinued operations, net of tax	17	145	723	5,249
Net (loss) income from discontinued operations attributable to noncontrolling interests	(7)	4	(5)	14
Income from discontinued operations attributable to common stockholders	24	141	728	5,235
Net income attributable to common stockholders	$ 367	$ 391	$ 1,642	$ 6,263

XML

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Basic (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings from continuing operations attributable to common stockholders (in usd per share)	$ 0.69	$ 0.48	$ 1.81	$ 1.86
Earnings from discontinued operations, net of tax (in usd per share)	0.05	0.27	1.44	9.49
Earnings per common share - basic (in usd per share)	$ 0.73	$ 0.75	$ 3.25	$ 11.35

XML

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Diluted (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings from continuing operations attributable to common stockholders (in usd per share)	$ 0.69	$ 0.48	$ 1.80	$ 1.86
Earnings from discontinued operations, net of tax (in usd per share)	0.05	0.27	1.44	9.46
Earnings per common share - diluted (in usd per share)	$ 0.73	$ 0.75	$ 3.24	$ 11.32

XML

EARNINGS PER SHARE CALCULATIONS - Summary of Count Information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Weighted-average common shares - basic (in shares)	499.4	521.5	505.6	551.7
Plus dilutive effect of equity compensation plans (in shares)	1.0	1.6	1.3	1.4
Weighted-average common shares - diluted (in shares)	500.4	523.1	506.9	553.1
Stock options and restricted stock units excluded from EPS calculations (in shares)	4.4	2.4	3.0	2.7

XML

ACCOUNTS AND NOTES RECEIVABLE - NET (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Accounts Receivable - trade	$ 1,691	$ 1,612
Other	566	547
Total accounts and notes receivable - net	2,257	2,159
Accounts and notes receivables - trade, allowance	$ 38	$ 28

XML

INVENTORIES (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 1,334	$ 1,201
Work in process	519	446
Raw materials	392	323
Supplies	114	116
Total inventories	$ 2,359	$ 2,086

XML

PROPERTY, PLANT, AND EQUIPMENT - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 9,704	$ 9,895
Total accumulated depreciation	4,227	4,142
Total property, plant and equipment - net	5,477	5,753
Land and land improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	394	440
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	1,904	1,954
Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	6,462	6,467
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 944	$ 1,034
Minimum | Land and land improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Minimum | Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Minimum | Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Maximum | Land and land improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	25 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	50 years
Maximum | Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	25 years

XML

PROPERTY, PLANT, AND EQUIPMENT - Schedule of Depreciation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 137	$ 142	$ 414	$ 407

XML

NONCONSOLIDATED AFFILIATES (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) affiliate	Sep. 30, 2021	Sep. 30, 2022 USD ($) affiliate	Sep. 30, 2021	Dec. 31, 2021 USD ($)
Investments in and Advances to Affiliates [Line Items]
Net investment in nonconsolidated affiliates | $	$ 733		$ 733		$ 817
Ownership interest affiliates | affiliate	6		6
Customer Concentration Risk | Revenue Benchmark | Equity Method Investee
Investments in and Advances to Affiliates [Line Items]
Concentration risk, percentage (less than)	2.00%	2.00%	2.00%	2.00%
Supplier Concentration Risk | Cost of Goods and Service Benchmark | Equity Method Investee
Investments in and Advances to Affiliates [Line Items]
Concentration risk, percentage (less than)	3.00%	4.00%	3.00%	4.00%

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Roll Forward]
Net goodwill, beginning of period	$ 16,981
Currency Translation Adjustment	(679)
Net goodwill, end of period	16,302
Corporate & Other
Goodwill [Roll Forward]
Net goodwill, beginning of period	597
Currency Translation Adjustment	(16)
Net goodwill, end of period	581
Electronics & Industrial | Operating Segments
Goodwill [Roll Forward]
Net goodwill, beginning of period	9,583
Currency Translation Adjustment	(337)
Net goodwill, end of period	9,246
Water & Protection | Operating Segments
Goodwill [Roll Forward]
Net goodwill, beginning of period	6,801
Currency Translation Adjustment	(326)
Net goodwill, end of period	$ 6,475

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 8,966	$ 9,418
Accum Amort	(4,220)	(4,000)
Net	4,746	5,418
Indefinite-lived Intangible Assets [Line Items]
Total other intangible assets with indefinite lives	804	804
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Gross Carrying Amount	9,770	10,222
Net	5,550	6,222
Trademarks/tradenames
Indefinite-lived Intangible Assets [Line Items]
Total other intangible assets with indefinite lives	804	804
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,331	2,374
Accum Amort	(1,241)	(1,124)
Net	1,090	1,250
Trademarks/tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,114	1,125
Accum Amort	(542)	(500)
Net	572	625
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,416	5,806
Accum Amort	(2,366)	(2,296)
Net	3,050	3,510
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	105	113
Accum Amort	(71)	(80)
Net	$ 34	$ 33

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangibles by Segment (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 5,550	$ 6,222
Corporate & Other
Schedule of Intangible Assets [Line Items]
Other intangible assets	94	107
Electronics & Industrial | Operating Segments
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,000	3,429
Water & Protection | Operating Segments
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 2,456	$ 2,686

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details) $ in Millions	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 139
2023	567
2024	539
2025	498
2026	471
2027	$ 424

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES - Narrative (Details) - USD ($)			1 Months Ended	9 Months Ended
	Apr. 12, 2022	Nov. 22, 2021	Jul. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Feb. 01, 2021	May 01, 2020
Line of Credit Facility [Line Items]
Short-term borrowings				$ 1,287,000,000	$ 150,000,000
Maximum borrowing capacity				3,500,000,000
Remaining borrowing capacity, uncommitted				810,000,000
Letters of credit outstanding				$ 107,000,000
Ratio of indebtedness to net capital (not exceed)				0.60
2021 Term Loan Facility | Unsecured Debt | Rogers Corporation
Line of Credit Facility [Line Items]
Term		2 years
Face amount of debt		$ 5,200,000,000
Senior Unsecured Notes due 2023 | Senior Notes
Line of Credit Facility [Line Items]
Face amount of debt							$ 2,000,000,000
Interest rate, percentage							2.169%
Term Loan Facilities
Line of Credit Facility [Line Items]
Face amount of debt						$ 3,000,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Term		5 years
Revolving Credit Facility | 364-day Revolving Credit Facility
Line of Credit Facility [Line Items]
Proceeds from credit facility			$ 600,000,000
Term				364 days
Maximum borrowing capacity				$ 1,000,000,000
Revolving Credit Facility | 364-day Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Term	364 days
Maximum borrowing capacity	$ 1,000,000,000
Revolving Credit Facility | 2022 Five-Year Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Term	5 years
Maximum borrowing capacity	$ 2,500,000,000
Level 2 | Recurring
Line of Credit Facility [Line Items]
Long-term debt				10,210,000,000	12,600,000,000
Commercial paper
Line of Credit Facility [Line Items]
Short-term borrowings				$ 1,287,000,000	$ 150,000,000
Short-term borrowing, weighted average interest rate				3.19%	0.34%

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES - Long-Term Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Finance lease obligations	$ 2	$ 2
Less: Unamortized debt discount and issuance costs	63	70
Long-Term Debt	10,564	10,632
Interest rate swap agreements | Designated as Hedging Instrument
Debt Instrument [Line Items]
Fair value hedging adjustment	75
Promissory Notes And Debentures, Final Maturity, 2023 | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross amount	$ 2,800	$ 2,800
Weighted Average Rate	4.18%	3.89%
Promissory Notes And Debentures, Final Maturity, 2025 | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross amount	$ 1,850	$ 1,850
Weighted Average Rate	4.49%	4.49%
Promissory Notes And Debentures, Final Maturity, 2026 and thereafter | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross amount	$ 5,975	$ 6,050
Weighted Average Rate	5.20%	5.13%

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES - Maturities of Long-Term Debt for Next Five Years (Details) $ in Millions	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Remainder of 2022	$ 0
2023	2,800,000
2024	0
2025	1,850,000
2026	0
2027	$ 0

XML

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES - Committed and Available Credit Facilities (Details) - USD ($) $ in Millions		9 Months Ended
	Nov. 22, 2021	Sep. 30, 2022
Line of Credit Facility [Line Items]
Committed Credit		$ 3,500
Credit Available		$ 3,488
Revolving Credit Facility
Line of Credit Facility [Line Items]
Term	5 years
Revolving Credit Facility, Five-year | Revolving Credit Facility
Line of Credit Facility [Line Items]
Term		5 years
Committed Credit		$ 2,500
Credit Available		$ 2,488
364-day Revolving Credit Facility | Revolving Credit Facility
Line of Credit Facility [Line Items]
Term		364 days
Committed Credit		$ 1,000
Credit Available		$ 1,000

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Narrative (Details) $ in Millions			1 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Jan. 21, 2021 USD ($)	Jul. 31, 2021 USD ($)	Apr. 30, 2021 municipality	Dec. 31, 2017 USD ($) plaintiff case	Sep. 30, 2022 USD ($) case
Loss Contingencies [Line Items]
Qualified spend - eligible PFAS costs, maximum						$ 4,000.0
Escrow account balance - required minimum						700.0
Non-PFAS stray liabilities threshold						200.0
Indemnifiable losses threshold related to PFAS stray liabilities - per party						150.0
Indemnifiable losses threshold related to PFAS stray liabilities - total						300.0
Estimated litigation liability						23.0
Total environmental related liabilities	$ 205.0					$ 260.0
PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of lawsuits | case					100
State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party	12.5
DuPont and Corteva
Loss Contingencies [Line Items]
Percentage split of PFAS liabilities under the separation agreement						50.00%
PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party		$ 83.0
Supplemental Settlement | State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party			$ 25.0
Chemours
Loss Contingencies [Line Items]
Qualified spend - eligible PFAS costs percentage split						50.00%
Future escrow deposit, percentage split						50.00%
Chemours | State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party			$ 25.0
Percentage of settlement			50.00%
Chemours | Payments due September 2021, September 2022
Loss Contingencies [Line Items]
Future escrow deposit						$ 100.0
Chemours | Payments due annually beginning September 2023
Loss Contingencies [Line Items]
Future escrow deposit						50.0
Chemours | PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party		29.0
Chemours | Supplemental Settlement | State of Delaware
Loss Contingencies [Line Items]
Percentage of settlement			50.00%
DuPont and Corteva
Loss Contingencies [Line Items]
Qualified spend - eligible PFAS costs, maximum						$ 2,000.0
Qualified spend - eligible PFAS costs percentage split						50.00%
Future escrow deposit, percentage split						50.00%
DuPont and Corteva | Payments due September 2021, September 2022
Loss Contingencies [Line Items]
Future escrow deposit						$ 100.0
DuPont and Corteva | Payments due annually beginning September 2023
Loss Contingencies [Line Items]
Future escrow deposit						$ 50.0
DuPont and Corteva | Supplemental Settlement | State of Delaware
Loss Contingencies [Line Items]
Percentage of settlement			50.00%
DuPont
Loss Contingencies [Line Items]
Non-PFAS stray liabilities percent split after threshold						71.00%
DuPont | State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party			$ 12.5
DuPont | PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party		27.0
Corteva
Loss Contingencies [Line Items]
Non-PFAS stray liabilities percent split after threshold						29.00%
Corteva | State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party			12.5
Historical EID And Chemours | Firefighter Foam Cases
Loss Contingencies [Line Items]
Number of lawsuits | case						3,130
Historical EID And Chemours | Firefighter Foam Cases - Personal Injury
Loss Contingencies [Line Items]
Number of lawsuits | case						2,840
Historical EID And Chemours | Water Contamination
Loss Contingencies [Line Items]
Number of lawsuits | case						3
Historical EID And Chemours | PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party					$ 335.0
Historical EID | PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff					3,550
EID | PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party		$ 27.0
Chemours, Corteva and DuPont
Loss Contingencies [Line Items]
Number of accuser | municipality				4
Chemours, Corteva and DuPont | State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party			$ 50.0
Accounts And Notes Receivable, Other
Loss Contingencies [Line Items]
Indemnification asset						$ 18.0
Deferred Charges And Other Assets
Loss Contingencies [Line Items]
Indemnification asset						229.0
Accrued and other current liabilities
Loss Contingencies [Line Items]
Indemnification liabilities						122.0
Other noncurrent obligations
Loss Contingencies [Line Items]
Indemnification liabilities						221.0
Restricted cash equivalents | DuPont
Loss Contingencies [Line Items]
Escrow deposit	$ 50.0					$ 100.0

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Indemnified Liabilities Related to the MOU (Details) - USD ($) $ in Millions	Dec. 31, 2021	Sep. 30, 2022
Loss Contingencies [Line Items]
Total environmental related liabilities	$ 205.0	$ 260.0
State of Delaware
Loss Contingencies [Line Items]
Amount awarded to other party	12.5
Accrued and other current liabilities
Loss Contingencies [Line Items]
Total indemnified liabilities accrued under the MOU		122.0
Other noncurrent obligations
Loss Contingencies [Line Items]
Total indemnified liabilities accrued under the MOU		221.0
MOU Agreement
Loss Contingencies [Line Items]
Total indemnified liabilities accrued under the MOU	126.0	184.0
MOU Agreement | Accrued and other current liabilities
Loss Contingencies [Line Items]
Current indemnified liabilities	37.0	55.0
MOU Agreement | Other noncurrent obligations
Loss Contingencies [Line Items]
Long-term indemnified liabilities	89.0	129.0
MOU Agreement | Chemours
Loss Contingencies [Line Items]
Total environmental related liabilities	116.0	172.0
MOU Agreement | Chemours | Fayetteville
Loss Contingencies [Line Items]
Total environmental related liabilities	$ 112.0	$ 168.0

XML

COMMITMENTS AND CONTINGENT LIABILITIES - Environmental Accrued Obligations (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Total environmental related liabilities	$ 260	$ 205
Potential exposure above the amount accrued	254
Environmental remediation liabilities not subject to indemnity
Loss Contingencies [Line Items]
Total environmental related liabilities	39	43
Potential exposure above the amount accrued	105
Indemnification Agreement | Dow & Corteva
Loss Contingencies [Line Items]
Total environmental related liabilities	48	46
Potential exposure above the amount accrued	63
MOU Agreement | Chemours
Loss Contingencies [Line Items]
Total environmental related liabilities	172	116
Potential exposure above the amount accrued	84
Other Environmental Indemnifications
Loss Contingencies [Line Items]
Total environmental related liabilities	1	$ 0
Potential exposure above the amount accrued	$ 2

XML

LEASES - Lease Cost and Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 27	$ 27	$ 82	$ 80
Operating lease payments			82	80
Operating lease assets and liabilities			$ 75	$ 64

XML

LEASES - Schedule of Leases (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 386	$ 422
Current operating lease liabilities	84	92
Noncurrent operating lease liabilities	301	337
Present value of lease liabilities	$ 385	$ 429
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued and other current liabilities	Accrued and other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent

XML

LEASES - Lease Term and Discount Rate (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (years)	8 years 25 days	8 years 6 months
Weighted average discount rate	2.33%	2.01%

XML

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 25
2023	89
2024	75
2025	53
2026	36
2027 and thereafter	153
Total lease payments	431
Less: Interest	46
Present value of lease liabilities	$ 385	$ 429

XML

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended		18 Months Ended	24 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jun. 01, 2021	Feb. 28, 2022	Mar. 31, 2021	Jun. 01, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Retirement of treasury stock	$ 0	$ 0	$ 0	$ 0
Payments for repurchase of common stock			$ 1,125	$ 1,643
2022 Share Buyback Program
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock repurchase amount							$ 1,000
Stock repurchased and retired (in shares)	4.3		11.9
Retirement of treasury stock	$ 250		$ 750
2021 Share Buyback Program
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock repurchase amount								$ 1,500
Stock repurchased and retired (in shares)					19.6
Payments for repurchase of common stock					$ 1,500
2019 Share Buyback Program
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock repurchase amount									$ 2,000
Stock repurchased and retired (in shares)						29.9
Payments for repurchase of common stock						$ 2,000

XML

STOCKHOLDERS' EQUITY - Summary of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 25,503	$ 27,239	$ 25,503	$ 27,239	$ 26,137	$ 27,050	$ 27,464	$ 39,070
Total other comprehensive loss	(766)	(157)	(1,672)	(235)
Ending balance	25,503	27,239	25,503	27,239
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,603)	(182)	(1,603)	(182)	$ (845)	41	$ (26)	44
Other comprehensive (loss) income before reclassifications			(1,641)	(487)
Amounts reclassified from accumulated other comprehensive loss			(3)	3
Split-off of N&B reclassification adjustment				258
Total other comprehensive loss	(758)	(156)	(1,644)	(226)
Ending balance	(1,603)	(182)	(1,603)	(182)
Cumulative translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,862)	109	(1,862)	109		(88)		470
Other comprehensive (loss) income before reclassifications			(1,774)	(545)
Amounts reclassified from accumulated other comprehensive loss			0	0
Split-off of N&B reclassification adjustment				184
Total other comprehensive loss			(1,774)	(361)
Ending balance	(1,862)	109	(1,862)	109
Pension and OPEB
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	94	(329)	94	(329)		73		(425)
Other comprehensive (loss) income before reclassifications			24	20
Amounts reclassified from accumulated other comprehensive loss			(3)	3
Split-off of N&B reclassification adjustment				73
Total other comprehensive loss			21	96
Ending balance	94	(329)	94	(329)
Derivative Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	165	38	165	38		$ 56		$ (1)
Other comprehensive (loss) income before reclassifications			109	38
Amounts reclassified from accumulated other comprehensive loss			0	0
Split-off of N&B reclassification adjustment				1
Total other comprehensive loss			109	39
Ending balance	$ 165	$ 38	$ 165	$ 38

XML

STOCKHOLDERS' EQUITY - Summary of Reclassifications Out of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax	$ (2)	$ (3)	$ (3)	$ 261
Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax	0	0	0	184
Pension and other post-employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Pension and other post-employment benefit plans	(2)	2	(4)	110
Tax expense (benefit)	0	(5)	1	(34)
After tax	(2)	(3)	(3)	76
Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax	$ 0	$ 0	$ 0	$ 1

XML

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 9	$ 13	$ 32	$ 42
Interest cost	14	11	41	32
Expected return on plan assets	(24)	(26)	(76)	(80)
Amortization of prior service credit	(1)	(2)	(4)	(4)
Amortization of unrecognized net loss	1	3	2	10
Curtailment/settlement	(2)	(1)	(1)	2
Net periodic benefit (credit) cost - total	(3)	(2)	(6)	2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	9	13	32	42
Interest cost	14	11	41	32
Expected return on plan assets	24	26	76	80
Amortization of prior service credit	(1)	(2)	(4)	(4)
Amortization of unrecognized net loss	(1)	(3)	(2)	(10)
Curtailment/settlement, gain (loss)	2	1	1	(2)
Additional contributions	35		35
Discontinued Operations
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (credit) cost - total	(2)	(2)	(7)	(4)
Continuing Operations
Defined Benefit Plan Disclosure [Line Items]
Service cost	6	9	21	28
Interest cost	13	10	37	29
Expected return on plan assets	(19)	(19)	(57)	(59)
Amortization of prior service credit	0	(2)	(2)	(4)
Amortization of unrecognized net loss	1	3	3	10
Curtailment/settlement	(2)	(1)	(1)	2
Net periodic benefit (credit) cost - total	(1)	0	1	6
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	6	9	21	28
Interest cost	13	10	37	29
Expected return on plan assets	19	19	57	59
Amortization of prior service credit	0	(2)	(2)	(4)
Amortization of unrecognized net loss	(1)	(3)	(3)	(10)
Curtailment/settlement, gain (loss)	$ 2	$ 1	$ 1	$ (2)

XML

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Compensation expense	$ 20		$ 15	$ 58	$ 49
Income tax benefits	$ 4		$ 3	$ 12	$ 10
Stock options granted (in shares)		0.5
Weighted-average stock option price (in usd per share)		$ 17.41
Weighted-average stock options exercise price (in usd per share)		$ 75.05
Restricted Stock Units (RSUs)
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares granted (in shares)		0.7
Weighted-average share price (in usd per share)		$ 75.12
Performance Shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares granted (in shares)		0.3
Weighted-average share price (in usd per share)		$ 81.55
DuPont 2020 Equity and Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Capital shares reserved for future issuance (in shares)	17.0			17.0

XML

FINANCIAL INSTRUMENTS - Summary of Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Cash equivalents	$ 427	$ 841
Restricted Cash Equivalents	111	65
Total cash and restricted cash equivalents	538	906
Long-term debt including debt due within one year, Cost	(10,639)	(10,632)
Long term debt including debt due within one year, Gain	497	0
Long term debt including debt due within one year, Loss	(64)	(1,963)
Long term debt including debt due within one year, Fair Value	(10,206)	(12,595)
Derivatives relating to:
Derivative assets (liabilities), Cost	0	0
Derivative assets (liabilities), Gain	250	79
Derivative assets (liabilities), Loss	(125)	(10)
Derivative assets (liabilities), Fair Value	125	69
Restricted cash, current	8	12
Restricted cash, noncurrent	103	53
Net investment hedge
Derivatives relating to:
Derivative assets (liabilities), Cost	0	0
Derivative assets (liabilities), Gain	211	74
Derivative assets (liabilities), Loss	0	0
Derivative assets (liabilities), Fair Value	211	74
Foreign currency
Derivatives relating to:
Derivative assets (liabilities), Cost	0	0
Derivative assets (liabilities), Gain	39	5
Derivative assets (liabilities), Loss	(50)	(10)
Derivative assets (liabilities), Fair Value	(11)	(5)
Interest rate swap agreements
Derivatives relating to:
Derivative assets (liabilities), Cost	0	0
Derivative assets (liabilities), Gain	0	0
Derivative assets (liabilities), Loss	(75)	0
Derivative assets (liabilities), Fair Value	$ (75)	$ 0

XML

FINANCIAL INSTRUMENTS - Notional Amounts (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Derivatives designated as hedging instruments: | Net investment hedge
Derivative [Line Items]
Derivative, notional amount, net	$ 1,000	$ 1,000
Derivatives designated as hedging instruments: | Interest rate swap agreements
Derivative [Line Items]
Derivative, notional amount, net	1,000	0
Derivatives not designated as hedging instruments: | Foreign Exchange Contract
Derivative [Line Items]
Derivative, notional amount, net	$ (407)	$ (625)

XML

FINANCIAL INSTRUMENTS - Derivatives (Details) € in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 EUR (€)
Floating Rate Note Due 2038
Derivatives, Fair Value [Line Items]
Face amount of debt					$ 1,000
Fixed Rate Notes due 2038
Derivatives, Fair Value [Line Items]
Face amount of debt					1,650
Designated as Hedging Instrument | Net investment hedge
Derivatives, Fair Value [Line Items]
Derivative, notional amount						$ 1,000	€ 819
Derivative, fixed interest rate						4.73%	4.73%
Derivative, average fixed interest rate						3.26%	3.26%
Designated as Hedging Instrument | Interest rate swap agreements
Derivatives, Fair Value [Line Items]
Derivative, notional amount					$ 1,000
Not Designated as Hedging Instrument | Foreign Exchange Contract | Other Nonoperating Income (Expense)
Derivatives, Fair Value [Line Items]
Foreign currency contracts loss	$ 24	$ 11	$ 73	$ 38

XML

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Liabilities at fair value:
Long term debt including debt due within one year	$ 10,206	$ 12,595
Offsetting counterparty and cash collateral netting amount for assets	41	6
Offsetting counterparty and cash collateral netting amount for liabilities	41	6
Recurring | Level 2
Assets at fair value:
Cash equivalents and restricted cash equivalents	538	906
Total assets at fair value	829	991
Liabilities at fair value:
Long term debt including debt due within one year	10,206	12,595
Total liabilities at fair value	10,372	12,611
Recurring | Level 2 | Net investment hedge
Assets at fair value:
Derivatives relating to	211	74
Recurring | Level 2 | Interest rate swap agreements
Liabilities at fair value:
Derivatives relating to	75
Recurring | Level 2 | Foreign currency contracts
Assets at fair value:
Derivatives relating to	80	11
Liabilities at fair value:
Derivatives relating to	$ 91	$ 16

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Operating Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net sales	$ 3,317	$ 3,199	$ 9,913	$ 9,320
Operating EBITDA	856	817	2,503	2,400
Equity in earnings of nonconsolidated affiliates	16	22	62	65
Corporate & Other
Segment Reporting Information [Line Items]
Net sales	272	335	879	1,096
Operating EBITDA	1	(11)	3	5
Equity in earnings of nonconsolidated affiliates	0	2	5	6
Electronics & Industrial
Segment Reporting Information [Line Items]
Net sales	1,511	1,467	4,574	4,087
Water & Protection
Segment Reporting Information [Line Items]
Net sales	1,534	1,397	4,460	4,137
Water & Protection | Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,534	1,397	4,460	4,137
Operating EBITDA	382	353	1,071	1,060
Equity in earnings of nonconsolidated affiliates	9	7	31	27
Electronics & Industrial | Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,511	1,467	4,574	4,087
Operating EBITDA	473	475	1,429	1,335
Equity in earnings of nonconsolidated affiliates	$ 7	$ 13	$ 26	$ 32

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Reconciliation of Operating EBITDA (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Income from continuing operations, net of tax	$ 359	$ 259	$ 956	$ 1,040
Provision for income taxes on continuing operations	139	80	299	172
Income from continuing operations before income taxes	498	339	1,255	1,212
Depreciation and amortization			906	1,094
Interest income	5	1	8	10
Interest expense	128	115	370	390
Non-operating pension/OPEB benefit	7	9	20	22
Significant items	49	(39)	(14)	68
Operating EBITDA	856	817	2,503	2,400
Continuing Operations
Segment Reporting Information [Line Items]
Income from continuing operations, net of tax	359	259	956	1,040
Provision for income taxes on continuing operations	139	80	299	172
Income from continuing operations before income taxes	498	339	1,255	1,212
Depreciation and amortization	283	300	861	817
Interest income	5	1	8	10
Interest expense	127	115	365	390
Non-operating pension/OPEB benefit	7	9	20	22
Foreign exchange gain (losses), net	5	(19)	9	(35)
Future reimbursable indirect costs	14	15	45	46
Significant items	49	(39)	(14)	68
Operating EBITDA	$ 856	$ 817	$ 2,503	$ 2,400

XML

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Certain Items by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Acquisition, integration and separation costs	$ (7)	$ (29)	$ (28)	$ (58)
Restructuring and asset related charges - net		(1)	(7)	(8)
Asset impairment charges			(94)
Gain on divestiture	5	3	68	146
Inventory step-up amortization		(12)		(12)
Intended Rogers Acquisition financing fees	(1)		(5)
Employee Retention Credit	52		52
Significant items	49	(39)	(14)	68
Corporate & Other
Segment Reporting Information [Line Items]
Acquisition, integration and separation costs	(7)	(29)	(28)	(58)
Restructuring and asset related charges - net		(1)	(3)	(6)
Asset impairment charges			0
Gain on divestiture	5	3	31	144
Inventory step-up amortization		0		0
Intended Rogers Acquisition financing fees	(1)		(5)
Employee Retention Credit	12		12
Significant items	9	(27)	7	80
Electronics & Industrial | Operating Segments
Segment Reporting Information [Line Items]
Acquisition, integration and separation costs	0	0	0	0
Restructuring and asset related charges - net		0	(1)	(2)
Asset impairment charges			(94)
Gain on divestiture	0	0	0	2
Inventory step-up amortization		(12)		(12)
Intended Rogers Acquisition financing fees	0		0
Employee Retention Credit	20		20
Significant items	20	(12)	(75)	(12)
Water & Protection | Operating Segments
Segment Reporting Information [Line Items]
Acquisition, integration and separation costs	0	0	0	0
Restructuring and asset related charges - net		0	(3)	0
Asset impairment charges			0
Gain on divestiture	0	0	37	0
Inventory step-up amortization		0		0
Intended Rogers Acquisition financing fees	0		0
Employee Retention Credit	20		20
Significant items	$ 20	$ 0	$ 54	$ 0

XML

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions			2 Months Ended
	Nov. 02, 2022	Nov. 01, 2022	Dec. 31, 2022	Nov. 07, 2022	Feb. 28, 2022
2018 Senior Note Due 2023 | Senior Notes | Forecast
Subsequent Event [Line Items]
Redemption of debt			$ 2,500.0
2022 Share Buyback Program
Subsequent Event [Line Items]
Stock repurchase amount					$ 1,000.0
Accelerated Share Repurchase agreement | Forecast
Subsequent Event [Line Items]
Stock repurchase amount				$ 3,250.0
New Accelerate Share Repurchase Program | Forecast
Subsequent Event [Line Items]
Stock repurchase amount				3,000.0
Subsequent Event | Rogers Corporation
Subsequent Event [Line Items]
Payment of termination fee	$ 162.5
Subsequent Event | Discontinued Operations, Disposed of by Sale | Mobility & Materials Businesses
Subsequent Event [Line Items]
Consideration for sale of business unit		$ 11,000.0
Proceeds from divestiture of businesses		11,000.0
Cash divested adjustments		$ 500.0
Subsequent Event | November 2022 Repurchase Program
Subsequent Event [Line Items]
Stock repurchase amount				5,000.0
Subsequent Event | 2022 Share Buyback Program
Subsequent Event [Line Items]
Remaining authorized repurchase amount from previous program				$ 250.0